US20210030770A1 - Lithium cholesterol compositions, including, but not limited to lithium cholesterol sulfate compositions, and methods of treatment for alzheimer's disease and neurological disorders - Google Patents
Lithium cholesterol compositions, including, but not limited to lithium cholesterol sulfate compositions, and methods of treatment for alzheimer's disease and neurological disorders Download PDFInfo
- Publication number
- US20210030770A1 US20210030770A1 US17/076,081 US202017076081A US2021030770A1 US 20210030770 A1 US20210030770 A1 US 20210030770A1 US 202017076081 A US202017076081 A US 202017076081A US 2021030770 A1 US2021030770 A1 US 2021030770A1
- Authority
- US
- United States
- Prior art keywords
- lithium
- cholesterol
- disorder
- compositions
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 229910052744 lithium Inorganic materials 0.000 title claims abstract description 204
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 title claims abstract description 191
- 239000000203 mixture Substances 0.000 title claims abstract description 166
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 title claims abstract description 159
- 238000000034 method Methods 0.000 title claims abstract description 112
- 235000012000 cholesterol Nutrition 0.000 title claims abstract description 81
- 208000024827 Alzheimer disease Diseases 0.000 title claims abstract description 64
- 238000011282 treatment Methods 0.000 title claims description 95
- 208000012902 Nervous system disease Diseases 0.000 title claims description 30
- BHYOQNUELFTYRT-UHFFFAOYSA-N Cholesterol sulfate Natural products C1C=C2CC(OS(O)(=O)=O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 BHYOQNUELFTYRT-UHFFFAOYSA-N 0.000 title abstract description 81
- BHYOQNUELFTYRT-DPAQBDIFSA-N cholesterol sulfate Chemical compound C1C=C2C[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 BHYOQNUELFTYRT-DPAQBDIFSA-N 0.000 title abstract description 78
- 208000025966 Neurological disease Diseases 0.000 title description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 85
- 239000003814 drug Substances 0.000 claims abstract description 64
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 63
- 208000029560 autism spectrum disease Diseases 0.000 claims abstract description 46
- 208000020925 Bipolar disease Diseases 0.000 claims abstract description 22
- 229940124597 therapeutic agent Drugs 0.000 claims abstract description 20
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 claims description 135
- 150000001875 compounds Chemical class 0.000 claims description 110
- 230000000694 effects Effects 0.000 claims description 45
- 230000026731 phosphorylation Effects 0.000 claims description 33
- 238000006366 phosphorylation reaction Methods 0.000 claims description 33
- 239000003937 drug carrier Substances 0.000 claims description 32
- 230000001965 increasing effect Effects 0.000 claims description 29
- 239000003795 chemical substances by application Substances 0.000 claims description 26
- 102000019058 Glycogen Synthase Kinase 3 beta Human genes 0.000 claims description 22
- 108010051975 Glycogen Synthase Kinase 3 beta Proteins 0.000 claims description 22
- 210000004556 brain Anatomy 0.000 claims description 22
- 238000009472 formulation Methods 0.000 claims description 19
- 230000003247 decreasing effect Effects 0.000 claims description 18
- 230000002401 inhibitory effect Effects 0.000 claims description 18
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 17
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 17
- 210000004369 blood Anatomy 0.000 claims description 16
- 239000008280 blood Substances 0.000 claims description 16
- 210000003734 kidney Anatomy 0.000 claims description 15
- 239000007787 solid Substances 0.000 claims description 15
- 208000029028 brain injury Diseases 0.000 claims description 13
- 208000018737 Parkinson disease Diseases 0.000 claims description 12
- 239000003085 diluting agent Substances 0.000 claims description 11
- 210000004185 liver Anatomy 0.000 claims description 11
- 239000006186 oral dosage form Substances 0.000 claims description 11
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 11
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 claims description 10
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 claims description 10
- 230000000626 neurodegenerative effect Effects 0.000 claims description 10
- 208000019022 Mood disease Diseases 0.000 claims description 9
- 230000005855 radiation Effects 0.000 claims description 9
- 239000002904 solvent Substances 0.000 claims description 9
- 208000029726 Neurodevelopmental disease Diseases 0.000 claims description 8
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 8
- 230000009529 traumatic brain injury Effects 0.000 claims description 8
- 208000028017 Psychotic disease Diseases 0.000 claims description 7
- 206010042458 Suicidal ideation Diseases 0.000 claims description 7
- 239000003755 preservative agent Substances 0.000 claims description 7
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 6
- 208000034189 Sclerosis Diseases 0.000 claims description 6
- 239000002671 adjuvant Substances 0.000 claims description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 6
- 239000003995 emulsifying agent Substances 0.000 claims description 6
- 239000000796 flavoring agent Substances 0.000 claims description 6
- 229940127237 mood stabilizer Drugs 0.000 claims description 6
- 239000004050 mood stabilizer Substances 0.000 claims description 6
- 208000022610 schizoaffective disease Diseases 0.000 claims description 6
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 claims description 6
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 claims description 6
- 208000016686 tic disease Diseases 0.000 claims description 6
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 claims description 5
- 239000001961 anticonvulsive agent Substances 0.000 claims description 5
- 239000011248 coating agent Substances 0.000 claims description 5
- 239000003086 colorant Substances 0.000 claims description 5
- 229960003530 donepezil Drugs 0.000 claims description 5
- 229960003980 galantamine Drugs 0.000 claims description 5
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 claims description 5
- 239000003112 inhibitor Substances 0.000 claims description 5
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 claims description 5
- 229960004640 memantine Drugs 0.000 claims description 5
- 229960004136 rivastigmine Drugs 0.000 claims description 5
- 239000003765 sweetening agent Substances 0.000 claims description 5
- 239000000935 antidepressant agent Substances 0.000 claims description 4
- 229960003965 antiepileptics Drugs 0.000 claims description 4
- 239000003963 antioxidant agent Substances 0.000 claims description 4
- 235000006708 antioxidants Nutrition 0.000 claims description 4
- 235000013355 food flavoring agent Nutrition 0.000 claims description 4
- 235000003599 food sweetener Nutrition 0.000 claims description 4
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 claims description 3
- 229940122041 Cholinesterase inhibitor Drugs 0.000 claims description 3
- 229940087098 Oxidase inhibitor Drugs 0.000 claims description 3
- 101710171573 Primary amine oxidase Proteins 0.000 claims description 3
- 229930003427 Vitamin E Natural products 0.000 claims description 3
- 230000001773 anti-convulsant effect Effects 0.000 claims description 3
- 230000001430 anti-depressive effect Effects 0.000 claims description 3
- 239000003420 antiserotonin agent Substances 0.000 claims description 3
- 239000000544 cholinesterase inhibitor Substances 0.000 claims description 3
- 150000002231 fructose derivatives Chemical class 0.000 claims description 3
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 3
- 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 claims description 3
- 239000003772 serotonin uptake inhibitor Substances 0.000 claims description 3
- 235000019165 vitamin E Nutrition 0.000 claims description 3
- 229940046009 vitamin E Drugs 0.000 claims description 3
- 239000011709 vitamin E Substances 0.000 claims description 3
- 239000004606 Fillers/Extenders Substances 0.000 claims description 2
- 239000002304 perfume Substances 0.000 claims description 2
- 229910006145 SO3Li Inorganic materials 0.000 claims 1
- 125000003917 carbamoyl group Chemical class [H]N([H])C(*)=O 0.000 claims 1
- 230000007472 neurodevelopment Effects 0.000 claims 1
- 230000000926 neurological effect Effects 0.000 abstract description 5
- 229960001078 lithium Drugs 0.000 description 191
- 210000004027 cell Anatomy 0.000 description 51
- 201000010099 disease Diseases 0.000 description 38
- -1 lithium cholesterol compounds Chemical class 0.000 description 35
- 229940079593 drug Drugs 0.000 description 31
- 239000007788 liquid Substances 0.000 description 29
- 229910003002 lithium salt Inorganic materials 0.000 description 28
- 159000000002 lithium salts Chemical class 0.000 description 27
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 25
- 238000006243 chemical reaction Methods 0.000 description 25
- 239000000463 material Substances 0.000 description 24
- 239000004480 active ingredient Substances 0.000 description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 23
- 208000035475 disorder Diseases 0.000 description 22
- 239000002552 dosage form Substances 0.000 description 21
- 238000002360 preparation method Methods 0.000 description 21
- 230000001225 therapeutic effect Effects 0.000 description 21
- 239000002158 endotoxin Substances 0.000 description 20
- 235000019441 ethanol Nutrition 0.000 description 20
- 229920006008 lipopolysaccharide Polymers 0.000 description 20
- 238000004519 manufacturing process Methods 0.000 description 19
- 239000000047 product Substances 0.000 description 19
- 239000000126 substance Substances 0.000 description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 17
- 239000000969 carrier Substances 0.000 description 17
- 239000003921 oil Substances 0.000 description 17
- 239000000243 solution Substances 0.000 description 17
- 239000000725 suspension Substances 0.000 description 17
- 239000003826 tablet Substances 0.000 description 17
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 16
- 230000003993 interaction Effects 0.000 description 16
- 235000002639 sodium chloride Nutrition 0.000 description 16
- 208000015122 neurodegenerative disease Diseases 0.000 description 15
- 230000004770 neurodegeneration Effects 0.000 description 14
- 235000019198 oils Nutrition 0.000 description 14
- 239000000839 emulsion Substances 0.000 description 13
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 239000013543 active substance Substances 0.000 description 12
- 239000012528 membrane Substances 0.000 description 12
- 210000004379 membrane Anatomy 0.000 description 12
- 229920001223 polyethylene glycol Polymers 0.000 description 12
- 210000002381 plasma Anatomy 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- 239000012071 phase Substances 0.000 description 10
- 150000003839 salts Chemical class 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 9
- 239000000853 adhesive Substances 0.000 description 9
- 150000001298 alcohols Chemical class 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 239000000470 constituent Substances 0.000 description 9
- 150000002148 esters Chemical class 0.000 description 9
- 235000011187 glycerol Nutrition 0.000 description 9
- 238000001990 intravenous administration Methods 0.000 description 9
- 230000002025 microglial effect Effects 0.000 description 9
- 239000000843 powder Substances 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 230000004044 response Effects 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 9
- 230000000699 topical effect Effects 0.000 description 9
- 238000002965 ELISA Methods 0.000 description 8
- 239000007864 aqueous solution Substances 0.000 description 8
- 238000003556 assay Methods 0.000 description 8
- 230000008499 blood brain barrier function Effects 0.000 description 8
- 239000002775 capsule Substances 0.000 description 8
- 125000004432 carbon atom Chemical group C* 0.000 description 8
- 230000002209 hydrophobic effect Effects 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 239000008297 liquid dosage form Substances 0.000 description 8
- 239000006210 lotion Substances 0.000 description 8
- 235000010981 methylcellulose Nutrition 0.000 description 8
- 239000001923 methylcellulose Substances 0.000 description 8
- 239000003883 ointment base Substances 0.000 description 8
- 230000000144 pharmacologic effect Effects 0.000 description 8
- 239000000651 prodrug Substances 0.000 description 8
- 229940002612 prodrug Drugs 0.000 description 8
- 239000012453 solvate Substances 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 7
- 239000002202 Polyethylene glycol Substances 0.000 description 7
- 241000700159 Rattus Species 0.000 description 7
- 229920002472 Starch Polymers 0.000 description 7
- 230000001070 adhesive effect Effects 0.000 description 7
- 230000009286 beneficial effect Effects 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 238000004113 cell culture Methods 0.000 description 7
- 239000006071 cream Substances 0.000 description 7
- 239000006260 foam Substances 0.000 description 7
- 239000000499 gel Substances 0.000 description 7
- 230000000670 limiting effect Effects 0.000 description 7
- 229920000609 methyl cellulose Polymers 0.000 description 7
- 239000006072 paste Substances 0.000 description 7
- 230000003389 potentiating effect Effects 0.000 description 7
- 230000002265 prevention Effects 0.000 description 7
- 235000019698 starch Nutrition 0.000 description 7
- 230000001988 toxicity Effects 0.000 description 7
- 231100000419 toxicity Toxicity 0.000 description 7
- 206010012289 Dementia Diseases 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 239000000654 additive Substances 0.000 description 6
- 210000001218 blood-brain barrier Anatomy 0.000 description 6
- 235000010980 cellulose Nutrition 0.000 description 6
- 229920002678 cellulose Polymers 0.000 description 6
- 239000001913 cellulose Substances 0.000 description 6
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 230000014509 gene expression Effects 0.000 description 6
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 6
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 239000002674 ointment Substances 0.000 description 6
- 239000004006 olive oil Substances 0.000 description 6
- 235000008390 olive oil Nutrition 0.000 description 6
- 229960004063 propylene glycol Drugs 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 238000001262 western blot Methods 0.000 description 6
- 206010003805 Autism Diseases 0.000 description 5
- 208000020706 Autistic disease Diseases 0.000 description 5
- 208000020401 Depressive disease Diseases 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 5
- 108010010803 Gelatin Proteins 0.000 description 5
- 108010065920 Insulin Lispro Proteins 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 239000004264 Petrolatum Substances 0.000 description 5
- 239000011230 binding agent Substances 0.000 description 5
- 238000004166 bioassay Methods 0.000 description 5
- 239000001768 carboxy methyl cellulose Substances 0.000 description 5
- 239000004359 castor oil Substances 0.000 description 5
- 235000019438 castor oil Nutrition 0.000 description 5
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 5
- 229920001577 copolymer Polymers 0.000 description 5
- 239000013078 crystal Substances 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 239000006185 dispersion Substances 0.000 description 5
- 238000009505 enteric coating Methods 0.000 description 5
- 239000002702 enteric coating Substances 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 239000008273 gelatin Substances 0.000 description 5
- 229920000159 gelatin Polymers 0.000 description 5
- 235000019322 gelatine Nutrition 0.000 description 5
- 235000011852 gelatine desserts Nutrition 0.000 description 5
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 5
- WNRQPCUGRUFHED-DETKDSODSA-N humalog Chemical compound C([C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CS)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CS)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(O)=O)C1=CC=C(O)C=C1.C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 WNRQPCUGRUFHED-DETKDSODSA-N 0.000 description 5
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 229960002068 insulin lispro Drugs 0.000 description 5
- 238000007918 intramuscular administration Methods 0.000 description 5
- 239000010410 layer Substances 0.000 description 5
- XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 description 5
- 229910052808 lithium carbonate Inorganic materials 0.000 description 5
- 230000007774 longterm Effects 0.000 description 5
- 239000000314 lubricant Substances 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 238000007911 parenteral administration Methods 0.000 description 5
- 229940066842 petrolatum Drugs 0.000 description 5
- 235000019271 petrolatum Nutrition 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 238000012552 review Methods 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 229910052708 sodium Inorganic materials 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- 238000007920 subcutaneous administration Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 230000006433 tumor necrosis factor production Effects 0.000 description 5
- 0 *O[C@H]1CC[C@@]2(C)C(=CC[C@]3([H])[C@]2([H])CC[C@]2(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@@]32[H])C1 Chemical compound *O[C@H]1CC[C@@]2(C)C(=CC[C@]3([H])[C@]2([H])CC[C@]2(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@@]32[H])C1 0.000 description 4
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 4
- 229920000858 Cyclodextrin Polymers 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 4
- 240000007472 Leucaena leucocephala Species 0.000 description 4
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 4
- 229930195725 Mannitol Natural products 0.000 description 4
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 235000019483 Peanut oil Nutrition 0.000 description 4
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 235000021355 Stearic acid Nutrition 0.000 description 4
- 208000000323 Tourette Syndrome Diseases 0.000 description 4
- 208000016620 Tourette disease Diseases 0.000 description 4
- 108091000117 Tyrosine 3-Monooxygenase Proteins 0.000 description 4
- 102000048218 Tyrosine 3-monooxygenases Human genes 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 150000001408 amides Chemical class 0.000 description 4
- 230000006399 behavior Effects 0.000 description 4
- 239000000090 biomarker Substances 0.000 description 4
- 210000000170 cell membrane Anatomy 0.000 description 4
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 238000013270 controlled release Methods 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 150000002191 fatty alcohols Chemical class 0.000 description 4
- 238000003304 gavage Methods 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 4
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 4
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 210000005027 intestinal barrier Anatomy 0.000 description 4
- 230000007358 intestinal barrier function Effects 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- PSBOOKLOXQFNPZ-UHFFFAOYSA-M lithium;2-hydroxybenzoate Chemical compound [Li+].OC1=CC=CC=C1C([O-])=O PSBOOKLOXQFNPZ-UHFFFAOYSA-M 0.000 description 4
- 239000000594 mannitol Substances 0.000 description 4
- 235000010355 mannitol Nutrition 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 238000012544 monitoring process Methods 0.000 description 4
- 210000002569 neuron Anatomy 0.000 description 4
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 4
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 4
- 239000000312 peanut oil Substances 0.000 description 4
- 229940100467 polyvinyl acetate phthalate Drugs 0.000 description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
- 239000008159 sesame oil Substances 0.000 description 4
- 235000011803 sesame oil Nutrition 0.000 description 4
- 235000010356 sorbitol Nutrition 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 239000008117 stearic acid Substances 0.000 description 4
- 229960004274 stearic acid Drugs 0.000 description 4
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 235000015112 vegetable and seed oil Nutrition 0.000 description 4
- 239000008158 vegetable oil Substances 0.000 description 4
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 241000416162 Astragalus gummifer Species 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 3
- 239000001856 Ethyl cellulose Substances 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 206010019196 Head injury Diseases 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 208000032382 Ischaemic stroke Diseases 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 239000004166 Lanolin Substances 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 206010026749 Mania Diseases 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- 229920001615 Tragacanth Polymers 0.000 description 3
- WJDLZSIDYWMNGA-RTFZCPRASA-M [H][C@@]12C/C=C3/C[C@@H](OS(=O)(=O)[Li]O)CC[C@]3(C)[C@@]1([H])CC[C@]1(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@@]21[H] Chemical compound [H][C@@]12C/C=C3/C[C@@H](OS(=O)(=O)[Li]O)CC[C@]3(C)[C@@]1([H])CC[C@]1(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@@]21[H] WJDLZSIDYWMNGA-RTFZCPRASA-M 0.000 description 3
- AHDLGGDGRWBHHO-BKCBCWJJSA-J [H][C@@]12CC=C3C[C@@H](OC(=O)CCC(=O)[Li]O)CC[C@]3(C)[C@@]1([H])CC[C@]1(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@@]21[H].[H][C@@]12CC=C3C[C@@H](OCC(=O)[Li]O)CC[C@]3(C)[C@@]1([H])CC[C@]1(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@@]21[H].[H][C@@]12CC=C3C[C@@H](OP(=O)([Li]O)O[Li])CC[C@]3(C)[C@@]1([H])CC[C@]1(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@@]21[H].[H][C@@]12CC=C3C[C@@H](OS(=O)(=O)[Li]O)CC[C@]3(C)[C@@]1([H])CC[C@]1(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@@]21[H] Chemical compound [H][C@@]12CC=C3C[C@@H](OC(=O)CCC(=O)[Li]O)CC[C@]3(C)[C@@]1([H])CC[C@]1(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@@]21[H].[H][C@@]12CC=C3C[C@@H](OCC(=O)[Li]O)CC[C@]3(C)[C@@]1([H])CC[C@]1(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@@]21[H].[H][C@@]12CC=C3C[C@@H](OP(=O)([Li]O)O[Li])CC[C@]3(C)[C@@]1([H])CC[C@]1(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@@]21[H].[H][C@@]12CC=C3C[C@@H](OS(=O)(=O)[Li]O)CC[C@]3(C)[C@@]1([H])CC[C@]1(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@@]21[H] AHDLGGDGRWBHHO-BKCBCWJJSA-J 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 125000001931 aliphatic group Chemical group 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 239000012298 atmosphere Substances 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000001506 calcium phosphate Substances 0.000 description 3
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 3
- 150000003857 carboxamides Chemical class 0.000 description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 3
- 229940105329 carboxymethylcellulose Drugs 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 150000003972 cyclic carboxylic anhydrides Chemical class 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 239000008121 dextrose Substances 0.000 description 3
- 235000019325 ethyl cellulose Nutrition 0.000 description 3
- 229920001249 ethyl cellulose Polymers 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000003925 fat Substances 0.000 description 3
- 235000019197 fats Nutrition 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 238000009093 first-line therapy Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 150000002334 glycols Chemical class 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 230000006951 hyperphosphorylation Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 238000007913 intrathecal administration Methods 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 229940039717 lanolin Drugs 0.000 description 3
- 235000019388 lanolin Nutrition 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 238000011866 long-term treatment Methods 0.000 description 3
- 229920002521 macromolecule Polymers 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 230000000116 mitigating effect Effects 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 239000010695 polyglycol Substances 0.000 description 3
- 229920000151 polyglycol Polymers 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 229920002744 polyvinyl acetate phthalate Polymers 0.000 description 3
- 230000000750 progressive effect Effects 0.000 description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- 238000005670 sulfation reaction Methods 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000010487 tragacanth Nutrition 0.000 description 3
- 229940116362 tragacanth Drugs 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 2
- 229920003067 (meth)acrylic acid ester copolymer Polymers 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- SVTBMSDMJJWYQN-UHFFFAOYSA-N 2-methylpentane-2,4-diol Chemical compound CC(O)CC(C)(C)O SVTBMSDMJJWYQN-UHFFFAOYSA-N 0.000 description 2
- RWHRFHQRVDUPIK-UHFFFAOYSA-N 50867-57-7 Chemical compound CC(=C)C(O)=O.CC(=C)C(O)=O RWHRFHQRVDUPIK-UHFFFAOYSA-N 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 2
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 2
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 2
- 102000001776 Matrix metalloproteinase-9 Human genes 0.000 description 2
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
- 108010025020 Nerve Growth Factor Proteins 0.000 description 2
- 102000007072 Nerve Growth Factors Human genes 0.000 description 2
- 208000036110 Neuroinflammatory disease Diseases 0.000 description 2
- 208000037273 Pathologic Processes Diseases 0.000 description 2
- 229920000954 Polyglycolide Polymers 0.000 description 2
- 108010009736 Protein Hydrolysates Proteins 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 229930182558 Sterol Natural products 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- UYXTWWCETRIEDR-UHFFFAOYSA-N Tributyrin Chemical compound CCCC(=O)OCC(OC(=O)CCC)COC(=O)CCC UYXTWWCETRIEDR-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- IYKJEILNJZQJPU-UHFFFAOYSA-N acetic acid;butanedioic acid Chemical compound CC(O)=O.OC(=O)CCC(O)=O IYKJEILNJZQJPU-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 239000012790 adhesive layer Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 230000007792 alzheimer disease pathology Effects 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 230000003288 anthiarrhythmic effect Effects 0.000 description 2
- 239000002220 antihypertensive agent Substances 0.000 description 2
- 229940030600 antihypertensive agent Drugs 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 239000000010 aprotic solvent Substances 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 210000001772 blood platelet Anatomy 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 206010007776 catatonia Diseases 0.000 description 2
- 229960000541 cetyl alcohol Drugs 0.000 description 2
- 208000020832 chronic kidney disease Diseases 0.000 description 2
- 230000006854 communication Effects 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- 238000013329 compounding Methods 0.000 description 2
- 239000003636 conditioned culture medium Substances 0.000 description 2
- 235000005687 corn oil Nutrition 0.000 description 2
- 239000002285 corn oil Substances 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 235000012343 cottonseed oil Nutrition 0.000 description 2
- 239000002385 cottonseed oil Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 230000002939 deleterious effect Effects 0.000 description 2
- 238000000326 densiometry Methods 0.000 description 2
- 239000007933 dermal patch Substances 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- MQHNKCZKNAJROC-UHFFFAOYSA-N dipropyl phthalate Chemical compound CCCOC(=O)C1=CC=CC=C1C(=O)OCCC MQHNKCZKNAJROC-UHFFFAOYSA-N 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 230000009429 distress Effects 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 230000002996 emotional effect Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- 229940052303 ethers for general anesthesia Drugs 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000011888 foil Substances 0.000 description 2
- 239000003349 gelling agent Substances 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 229960002989 glutamic acid Drugs 0.000 description 2
- 150000002314 glycerols Chemical class 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 239000000017 hydrogel Substances 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 239000005414 inactive ingredient Substances 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000003701 inert diluent Substances 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000007917 intracranial administration Methods 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 229940073577 lithium chloride Drugs 0.000 description 2
- 229940071264 lithium citrate Drugs 0.000 description 2
- WJSIUCDMWSDDCE-UHFFFAOYSA-K lithium citrate (anhydrous) Chemical compound [Li+].[Li+].[Li+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O WJSIUCDMWSDDCE-UHFFFAOYSA-K 0.000 description 2
- IZJGDPULXXNWJP-UHFFFAOYSA-M lithium orotate Chemical compound [Li+].[O-]C(=O)C1=CC(=O)NC(=O)N1 IZJGDPULXXNWJP-UHFFFAOYSA-M 0.000 description 2
- 229940087762 lithium orotate Drugs 0.000 description 2
- INHCSSUBVCNVSK-UHFFFAOYSA-L lithium sulfate Inorganic materials [Li+].[Li+].[O-]S([O-])(=O)=O INHCSSUBVCNVSK-UHFFFAOYSA-L 0.000 description 2
- 229940087748 lithium sulfate Drugs 0.000 description 2
- 238000009136 lithium therapy Methods 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 239000011976 maleic acid Substances 0.000 description 2
- 125000005397 methacrylic acid ester group Chemical group 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 229940029985 mineral supplement Drugs 0.000 description 2
- 235000020786 mineral supplement Nutrition 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 210000000282 nail Anatomy 0.000 description 2
- 230000004766 neurogenesis Effects 0.000 description 2
- 230000003959 neuroinflammation Effects 0.000 description 2
- 231100000878 neurological injury Toxicity 0.000 description 2
- 230000000324 neuroprotective effect Effects 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000009054 pathological process Effects 0.000 description 2
- 229920001277 pectin Polymers 0.000 description 2
- 235000010987 pectin Nutrition 0.000 description 2
- 239000001814 pectin Substances 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 239000002831 pharmacologic agent Substances 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920000747 poly(lactic acid) Polymers 0.000 description 2
- 239000004633 polyglycolic acid Substances 0.000 description 2
- 239000004626 polylactic acid Substances 0.000 description 2
- 229920002689 polyvinyl acetate Polymers 0.000 description 2
- 239000011118 polyvinyl acetate Substances 0.000 description 2
- 239000000955 prescription drug Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 229960002429 proline Drugs 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 239000003531 protein hydrolysate Substances 0.000 description 2
- 230000003252 repetitive effect Effects 0.000 description 2
- 235000003441 saturated fatty acids Nutrition 0.000 description 2
- 239000000932 sedative agent Substances 0.000 description 2
- 229940125723 sedative agent Drugs 0.000 description 2
- 230000003997 social interaction Effects 0.000 description 2
- 235000010413 sodium alginate Nutrition 0.000 description 2
- 239000000661 sodium alginate Substances 0.000 description 2
- 229940005550 sodium alginate Drugs 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical class [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 239000007962 solid dispersion Substances 0.000 description 2
- 235000011069 sorbitan monooleate Nutrition 0.000 description 2
- 239000001593 sorbitan monooleate Substances 0.000 description 2
- 229940035049 sorbitan monooleate Drugs 0.000 description 2
- 208000020431 spinal cord injury Diseases 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 235000003702 sterols Nutrition 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 230000019635 sulfation Effects 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- XTHPWXDJESJLNJ-UHFFFAOYSA-N sulfurochloridic acid Chemical compound OS(Cl)(=O)=O XTHPWXDJESJLNJ-UHFFFAOYSA-N 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- RBTVSNLYYIMMKS-UHFFFAOYSA-N tert-butyl 3-aminoazetidine-1-carboxylate;hydrochloride Chemical compound Cl.CC(C)(C)OC(=O)N1CC(N)C1 RBTVSNLYYIMMKS-UHFFFAOYSA-N 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 231100000027 toxicology Toxicity 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- 239000002691 unilamellar liposome Substances 0.000 description 2
- 230000002485 urinary effect Effects 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- 239000000230 xanthan gum Substances 0.000 description 2
- 235000010493 xanthan gum Nutrition 0.000 description 2
- 229940082509 xanthan gum Drugs 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- YMMVCTFOVNOGFQ-UHFFFAOYSA-N 2-(2-propanoyloxyethoxy)ethyl propanoate Chemical compound CCC(=O)OCCOCCOC(=O)CC YMMVCTFOVNOGFQ-UHFFFAOYSA-N 0.000 description 1
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 1
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- JTXMVXSTHSMVQF-UHFFFAOYSA-N 2-acetyloxyethyl acetate Chemical compound CC(=O)OCCOC(C)=O JTXMVXSTHSMVQF-UHFFFAOYSA-N 0.000 description 1
- UOQDKQOXSLQEOJ-UHFFFAOYSA-N 2-methylprop-2-enoate;trimethylazanium Chemical compound C[NH+](C)C.CC(=C)C([O-])=O UOQDKQOXSLQEOJ-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- XUGISPSHIFXEHZ-UHFFFAOYSA-N 3beta-acetoxy-cholest-5-ene Natural products C1C=C2CC(OC(C)=O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 XUGISPSHIFXEHZ-UHFFFAOYSA-N 0.000 description 1
- NBDTZVVEDLDLSG-UHFFFAOYSA-N 4,6,6-trimethylheptan-2-yl acetate Chemical compound CC(C)(C)CC(C)CC(C)OC(C)=O NBDTZVVEDLDLSG-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- BGBIRJIRPKZAJD-UHFFFAOYSA-N 4-ethyl-2-methylideneoctanoic acid;furan-2,5-dione Chemical compound O=C1OC(=O)C=C1.CCCCC(CC)CC(=C)C(O)=O BGBIRJIRPKZAJD-UHFFFAOYSA-N 0.000 description 1
- PXRKCOCTEMYUEG-UHFFFAOYSA-N 5-aminoisoindole-1,3-dione Chemical compound NC1=CC=C2C(=O)NC(=O)C2=C1 PXRKCOCTEMYUEG-UHFFFAOYSA-N 0.000 description 1
- NWPRCRWQMGIBOT-UHFFFAOYSA-N 7-(2-hydroxyethyl)-1,3-dimethylpurine-2,6-dione Chemical compound O=C1N(C)C(=O)N(C)C2=C1N(CCO)C=N2 NWPRCRWQMGIBOT-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 208000017194 Affective disease Diseases 0.000 description 1
- 201000010000 Agranulocytosis Diseases 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 description 1
- 238000010173 Alzheimer-disease mouse model Methods 0.000 description 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
- 208000037259 Amyloid Plaque Diseases 0.000 description 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 description 1
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 description 1
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 102000013918 Apolipoproteins E Human genes 0.000 description 1
- 108010025628 Apolipoproteins E Proteins 0.000 description 1
- 235000003911 Arachis Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 230000007324 Aβ metabolism Effects 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 1
- 229940078581 Bone resorption inhibitor Drugs 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- XOPGPLTYNMQOIT-KTSVDMKYSA-L C.C.C.C.CC(=O)OC(C)=O.[H][C@@]12CC=C3C[C@@H](O)CC[C@]3(C)[C@@]1([H])CC[C@]1(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@@]21[H].[H][C@@]12CC=C3C[C@@H](OC(=O)CC(=O)O)CC[C@]3(C)[C@@]1([H])CC[C@]1(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@@]21[H].[H][C@@]12CC=C3C[C@@H](OC(=O)CC(=O)[Li]O)CC[C@]3(C)[C@@]1([H])CC[C@]1(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@@]21[H].[Li]O Chemical compound C.C.C.C.CC(=O)OC(C)=O.[H][C@@]12CC=C3C[C@@H](O)CC[C@]3(C)[C@@]1([H])CC[C@]1(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@@]21[H].[H][C@@]12CC=C3C[C@@H](OC(=O)CC(=O)O)CC[C@]3(C)[C@@]1([H])CC[C@]1(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@@]21[H].[H][C@@]12CC=C3C[C@@H](OC(=O)CC(=O)[Li]O)CC[C@]3(C)[C@@]1([H])CC[C@]1(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@@]21[H].[Li]O XOPGPLTYNMQOIT-KTSVDMKYSA-L 0.000 description 1
- XZGBFRZPFGEGNG-UBONRPAQSA-L COS(=O)(=O)Cl.[H][C@@]12CC=C3C[C@@H](O)CC[C@]3(C)[C@@]1([H])CC[C@]1(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@@]21[H].[H][C@@]12CC=C3C[C@@H](OS(=O)(=O)O)CC[C@]3(C)[C@@]1([H])CC[C@]1(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@@]21[H].[H][C@@]12CC=C3C[C@@H](OS(=O)(=O)OC)CC[C@]3(C)[C@@]1([H])CC[C@]1(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@@]21[H].[H][C@@]12CC=C3C[C@@H](OS(=O)(=O)[Li]O)CC[C@]3(C)[C@@]1([H])CC[C@]1(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@@]21[H].[Li]O Chemical compound COS(=O)(=O)Cl.[H][C@@]12CC=C3C[C@@H](O)CC[C@]3(C)[C@@]1([H])CC[C@]1(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@@]21[H].[H][C@@]12CC=C3C[C@@H](OS(=O)(=O)O)CC[C@]3(C)[C@@]1([H])CC[C@]1(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@@]21[H].[H][C@@]12CC=C3C[C@@H](OS(=O)(=O)OC)CC[C@]3(C)[C@@]1([H])CC[C@]1(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@@]21[H].[H][C@@]12CC=C3C[C@@H](OS(=O)(=O)[Li]O)CC[C@]3(C)[C@@]1([H])CC[C@]1(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@@]21[H].[Li]O XZGBFRZPFGEGNG-UBONRPAQSA-L 0.000 description 1
- 101100298998 Caenorhabditis elegans pbs-3 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- VZQQCJXTVVEVPI-JLWBAGDESA-K ClC(Cl)Cl.[H][C@@]12CC=C3C[C@@H](O)CC[C@]3(C)[C@@]1([H])CC[C@]1(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@@]21[H].[H][C@@]12CC=C3C[C@@H](OP(=O)(O)O)CC[C@]3(C)[C@@]1([H])CC[C@]1(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@@]21[H].[H][C@@]12CC=C3C[C@@H](OP(=O)([Li]O)[Li]O)CC[C@]3(C)[C@@]1([H])CC[C@]1(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@@]21[H].[Li]O Chemical compound ClC(Cl)Cl.[H][C@@]12CC=C3C[C@@H](O)CC[C@]3(C)[C@@]1([H])CC[C@]1(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@@]21[H].[H][C@@]12CC=C3C[C@@H](OP(=O)(O)O)CC[C@]3(C)[C@@]1([H])CC[C@]1(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@@]21[H].[H][C@@]12CC=C3C[C@@H](OP(=O)([Li]O)[Li]O)CC[C@]3(C)[C@@]1([H])CC[C@]1(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@@]21[H].[Li]O VZQQCJXTVVEVPI-JLWBAGDESA-K 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 208000012239 Developmental disease Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- YUXIBTJKHLUKBD-UHFFFAOYSA-N Dibutyl succinate Chemical compound CCCCOC(=O)CCC(=O)OCCCC YUXIBTJKHLUKBD-UHFFFAOYSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- VIZORQUEIQEFRT-UHFFFAOYSA-N Diethyl adipate Chemical compound CCOC(=O)CCCCC(=O)OCC VIZORQUEIQEFRT-UHFFFAOYSA-N 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 208000033618 Elevated mood Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 241001539473 Euphoria Species 0.000 description 1
- 206010015535 Euphoric mood Diseases 0.000 description 1
- 206010070246 Executive dysfunction Diseases 0.000 description 1
- 206010072063 Exposure to lead Diseases 0.000 description 1
- 239000001116 FEMA 4028 Substances 0.000 description 1
- 201000011240 Frontotemporal dementia Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 108010068370 Glutens Proteins 0.000 description 1
- UXDDRFCJKNROTO-UHFFFAOYSA-N Glycerol 1,2-diacetate Chemical compound CC(=O)OCC(CO)OC(C)=O UXDDRFCJKNROTO-UHFFFAOYSA-N 0.000 description 1
- 239000004348 Glyceryl diacetate Substances 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 206010018687 Granulocytopenia Diseases 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 108050003558 Interleukin-17 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 229930182821 L-proline Natural products 0.000 description 1
- 241000195947 Lycopodium Species 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- 101000648740 Mus musculus Tumor necrosis factor Proteins 0.000 description 1
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 1
- OHLUUHNLEMFGTQ-UHFFFAOYSA-N N-methylacetamide Chemical compound CNC(C)=O OHLUUHNLEMFGTQ-UHFFFAOYSA-N 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- 201000005118 Nephrogenic diabetes insipidus Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 206010033864 Paranoia Diseases 0.000 description 1
- 208000027099 Paranoid disease Diseases 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- ORNBQBCIOKFOEO-YQUGOWONSA-N Pregnenolone Natural products O=C(C)[C@@H]1[C@@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC3)C[C@@H](O)CC4)CC2)CC1 ORNBQBCIOKFOEO-YQUGOWONSA-N 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 102000003923 Protein Kinase C Human genes 0.000 description 1
- 108090000315 Protein Kinase C Proteins 0.000 description 1
- 206010061481 Renal injury Diseases 0.000 description 1
- 241000220010 Rhode Species 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 102100030681 SH3 and multiple ankyrin repeat domains protein 3 Human genes 0.000 description 1
- 101710101741 SH3 and multiple ankyrin repeat domains protein 3 Proteins 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
- 239000004147 Sorbitan trioleate Substances 0.000 description 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
- MKRNVBXERAPZOP-UHFFFAOYSA-N Starch acetate Chemical compound O1C(CO)C(OC)C(O)C(O)C1OCC1C(OC2C(C(O)C(OC)C(CO)O2)OC(C)=O)C(O)C(O)C(OC2C(OC(C)C(O)C2O)CO)O1 MKRNVBXERAPZOP-UHFFFAOYSA-N 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 208000034799 Tauopathies Diseases 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 1
- 102100026383 Vasopressin-neurophysin 2-copeptin Human genes 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 229920002494 Zein Polymers 0.000 description 1
- 239000001089 [(2R)-oxolan-2-yl]methanol Substances 0.000 description 1
- AVTXVDFKYBVTKR-DPAQBDIFSA-N [(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] dihydrogen phosphate Chemical compound C1C=C2C[C@@H](OP(O)(O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 AVTXVDFKYBVTKR-DPAQBDIFSA-N 0.000 description 1
- UYKMGKOXOSVHIO-OHZOQVCSSA-L [2H]CF.[H][C@@]12CC=C3C[C@@H](O)CC[C@]3(C)[C@@]1([H])CC[C@]1(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@@]21[H].[H][C@@]12CC=C3C[C@@H](OS(=O)(=O)O)CC[C@]3(C)[C@@]1([H])CC[C@]1(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@@]21[H].[H][C@@]12CC=C3C[C@@H](OS(=O)(=O)[Li]O)CC[C@]3(C)[C@@]1([H])CC[C@]1(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@@]21[H].[Li]O Chemical compound [2H]CF.[H][C@@]12CC=C3C[C@@H](O)CC[C@]3(C)[C@@]1([H])CC[C@]1(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@@]21[H].[H][C@@]12CC=C3C[C@@H](OS(=O)(=O)O)CC[C@]3(C)[C@@]1([H])CC[C@]1(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@@]21[H].[H][C@@]12CC=C3C[C@@H](OS(=O)(=O)[Li]O)CC[C@]3(C)[C@@]1([H])CC[C@]1(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@@]21[H].[Li]O UYKMGKOXOSVHIO-OHZOQVCSSA-L 0.000 description 1
- ZWEFRLSTAXGVEZ-CZJUTKDGSA-M [H][C@@]12C/C=C3/C[C@@H](OC(=O)CCC(=O)[Li]O)CC[C@]3(C)[C@@]1([H])CC[C@]1(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@@]21[H] Chemical compound [H][C@@]12C/C=C3/C[C@@H](OC(=O)CCC(=O)[Li]O)CC[C@]3(C)[C@@]1([H])CC[C@]1(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@@]21[H] ZWEFRLSTAXGVEZ-CZJUTKDGSA-M 0.000 description 1
- FUPFNHZZHHWOPZ-KPTJSDMNSA-M [H][C@@]12C/C=C3/C[C@@H](OCC(=O)[Li]O)CC[C@]3(C)[C@@]1([H])CC[C@]1(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@@]21[H] Chemical compound [H][C@@]12C/C=C3/C[C@@H](OCC(=O)[Li]O)CC[C@]3(C)[C@@]1([H])CC[C@]1(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@@]21[H] FUPFNHZZHHWOPZ-KPTJSDMNSA-M 0.000 description 1
- QIKMZMOOPARGHS-UFUGHDFUSA-M [H][C@@]12C/C=C3/C[C@@H](OP(=O)([Li]O)O[Li])CC[C@]3(C)[C@@]1([H])CC[C@]1(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@@]21[H] Chemical compound [H][C@@]12C/C=C3/C[C@@H](OP(=O)([Li]O)O[Li])CC[C@]3(C)[C@@]1([H])CC[C@]1(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@@]21[H] QIKMZMOOPARGHS-UFUGHDFUSA-M 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical class OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 239000000674 adrenergic antagonist Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- 108091005588 alkylated proteins Proteins 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium group Chemical group [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 239000002280 amphoteric surfactant Substances 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- 230000006933 amyloid-beta aggregation Effects 0.000 description 1
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 229940031955 anhydrous lanolin Drugs 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000000578 anorexic effect Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001466 anti-adreneric effect Effects 0.000 description 1
- 230000002456 anti-arthritic effect Effects 0.000 description 1
- 230000001078 anti-cholinergic effect Effects 0.000 description 1
- 230000003556 anti-epileptic effect Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000001022 anti-muscarinic effect Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 230000001139 anti-pruritic effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000002921 anti-spasmodic effect Effects 0.000 description 1
- 239000003416 antiarrhythmic agent Substances 0.000 description 1
- 229940124346 antiarthritic agent Drugs 0.000 description 1
- 239000000924 antiasthmatic agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940125681 anticonvulsant agent Drugs 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229960005475 antiinfective agent Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000002579 antinauseant Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 229940125716 antipyretic agent Drugs 0.000 description 1
- 229940124575 antispasmodic agent Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 229940005530 anxiolytics Drugs 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 201000007201 aphasia Diseases 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000006736 behavioral deficit Effects 0.000 description 1
- 208000013404 behavioral symptom Diseases 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- 235000012216 bentonite Nutrition 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- RWCCWEUUXYIKHB-UHFFFAOYSA-N benzophenone Chemical compound C=1C=CC=CC=1C(=O)C1=CC=CC=C1 RWCCWEUUXYIKHB-UHFFFAOYSA-N 0.000 description 1
- 239000012965 benzophenone Substances 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 229940125388 beta agonist Drugs 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 229960004853 betadex Drugs 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 239000003858 bile acid conjugate Substances 0.000 description 1
- 239000012867 bioactive agent Substances 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 239000002617 bone density conservation agent Substances 0.000 description 1
- 230000008468 bone growth Effects 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- VFGRALUHHHDIQI-UHFFFAOYSA-N butyl 2-hydroxyacetate Chemical compound CCCCOC(=O)CO VFGRALUHHHDIQI-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 150000001722 carbon compounds Chemical class 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 239000008004 cell lysis buffer Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 229920003086 cellulose ether Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- PBAYDYUZOSNJGU-UHFFFAOYSA-N chelidonic acid Natural products OC(=O)C1=CC(=O)C=C(C(O)=O)O1 PBAYDYUZOSNJGU-UHFFFAOYSA-N 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- XUGISPSHIFXEHZ-VEVYEIKRSA-N cholesteryl acetate Chemical compound C1C=C2C[C@@H](OC(C)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 XUGISPSHIFXEHZ-VEVYEIKRSA-N 0.000 description 1
- WLNARFZDISHUGS-MIXBDBMTSA-N cholesteryl hemisuccinate Chemical compound C1C=C2C[C@@H](OC(=O)CCC(O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 WLNARFZDISHUGS-MIXBDBMTSA-N 0.000 description 1
- 229940080277 cholesteryl sulfate Drugs 0.000 description 1
- 230000000718 cholinopositive effect Effects 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000003026 cod liver oil Substances 0.000 description 1
- 235000012716 cod liver oil Nutrition 0.000 description 1
- 230000003931 cognitive performance Effects 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 239000007859 condensation product Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 229940037530 cough and cold preparations Drugs 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 239000000850 decongestant Substances 0.000 description 1
- 229940124581 decongestants Drugs 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 201000010064 diabetes insipidus Diseases 0.000 description 1
- 229940099371 diacetylated monoglycerides Drugs 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- PCYQQSKDZQTOQG-NXEZZACHSA-N dibutyl (2r,3r)-2,3-dihydroxybutanedioate Chemical compound CCCCOC(=O)[C@H](O)[C@@H](O)C(=O)OCCCC PCYQQSKDZQTOQG-NXEZZACHSA-N 0.000 description 1
- 229960002097 dibutylsuccinate Drugs 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229960004132 diethyl ether Drugs 0.000 description 1
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 1
- 229940075557 diethylene glycol monoethyl ether Drugs 0.000 description 1
- 230000009699 differential effect Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 1
- 229940113088 dimethylacetamide Drugs 0.000 description 1
- 150000004862 dioxolanes Chemical class 0.000 description 1
- POLCUAVZOMRGSN-UHFFFAOYSA-N dipropyl ether Chemical compound CCCOCCC POLCUAVZOMRGSN-UHFFFAOYSA-N 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 230000036267 drug metabolism Effects 0.000 description 1
- 238000010410 dusting Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000002101 electrospray ionisation tandem mass spectrometry Methods 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 201000000523 end stage renal failure Diseases 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 125000005912 ethyl carbonate group Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 229940093476 ethylene glycol Drugs 0.000 description 1
- 229940012017 ethylenediamine Drugs 0.000 description 1
- 229960005387 etofylline Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000020764 fibrinolysis Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 208000001130 gallstones Diseases 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 229940005494 general anesthetics Drugs 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000002518 glial effect Effects 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000021312 gluten Nutrition 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 235000019443 glyceryl diacetate Nutrition 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 229940051250 hexylene glycol Drugs 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 210000000003 hoof Anatomy 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 description 1
- 239000003326 hypnotic agent Substances 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000000185 intracerebroventricular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007919 intrasynovial administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 208000037806 kidney injury Diseases 0.000 description 1
- SXQFCVDSOLSHOQ-UHFFFAOYSA-N lactamide Chemical class CC(O)C(N)=O SXQFCVDSOLSHOQ-UHFFFAOYSA-N 0.000 description 1
- 150000003893 lactate salts Chemical class 0.000 description 1
- 235000014666 liquid concentrate Nutrition 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- GKQWYZBANWAFMQ-UHFFFAOYSA-M lithium;2-hydroxypropanoate Chemical compound [Li+].CC(O)C([O-])=O GKQWYZBANWAFMQ-UHFFFAOYSA-M 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 1
- 238000010197 meta-analysis Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- YLGXILFCIXHCMC-JHGZEJCSSA-N methyl cellulose Chemical compound COC1C(OC)C(OC)C(COC)O[C@H]1O[C@H]1C(OC)C(OC)C(OC)OC1COC YLGXILFCIXHCMC-JHGZEJCSSA-N 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 210000000274 microglia Anatomy 0.000 description 1
- 230000006775 microglial inflammation Effects 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000000897 modulatory effect Effects 0.000 description 1
- 239000002991 molded plastic Substances 0.000 description 1
- 239000007932 molded tablet Substances 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 229940051866 mouthwash Drugs 0.000 description 1
- 239000000472 muscarinic agonist Substances 0.000 description 1
- 239000003149 muscarinic antagonist Substances 0.000 description 1
- 229940035363 muscle relaxants Drugs 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- 230000001016 myotrophic effect Effects 0.000 description 1
- AJFDBNQQDYLMJN-UHFFFAOYSA-N n,n-diethylacetamide Chemical compound CCN(CC)C(C)=O AJFDBNQQDYLMJN-UHFFFAOYSA-N 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 210000001577 neostriatum Anatomy 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000001123 neurodevelopmental effect Effects 0.000 description 1
- 230000001703 neuroimmune Effects 0.000 description 1
- 239000003176 neuroleptic agent Substances 0.000 description 1
- 230000007658 neurological function Effects 0.000 description 1
- 239000002698 neuron blocking agent Substances 0.000 description 1
- 230000007171 neuropathology Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000001956 neutron scattering Methods 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- 229960001597 nifedipine Drugs 0.000 description 1
- MGFYIUFZLHCRTH-UHFFFAOYSA-N nitrilotriacetic acid Chemical compound OC(=O)CN(CC(O)=O)CC(O)=O MGFYIUFZLHCRTH-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 238000006053 organic reaction Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000003961 penetration enhancing agent Substances 0.000 description 1
- 230000009984 peri-natal effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000003209 petroleum derivative Substances 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 238000011458 pharmacological treatment Methods 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000008105 phosphatidylcholines Chemical class 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 150000003021 phthalic acid derivatives Chemical class 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920000724 poly(L-arginine) polymer Polymers 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 108010011110 polyarginine Proteins 0.000 description 1
- 229920000223 polyglycerol Chemical class 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 229920006324 polyoxymethylene Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 235000014483 powder concentrate Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 229960000249 pregnenolone Drugs 0.000 description 1
- OZZAYJQNMKMUSD-DMISRAGPSA-N pregnenolone succinate Chemical compound C1C=C2C[C@@H](OC(=O)CCC(O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 OZZAYJQNMKMUSD-DMISRAGPSA-N 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 150000003138 primary alcohols Chemical class 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 229940001470 psychoactive drug Drugs 0.000 description 1
- 239000003368 psychostimulant agent Substances 0.000 description 1
- 239000004089 psychotropic agent Substances 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- GHBFNMLVSPCDGN-UHFFFAOYSA-N rac-1-monooctanoylglycerol Chemical compound CCCCCCCC(=O)OCC(O)CO GHBFNMLVSPCDGN-UHFFFAOYSA-N 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 238000009118 salvage therapy Methods 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000008299 semisolid dosage form Substances 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229920002379 silicone rubber Polymers 0.000 description 1
- 235000020374 simple syrup Nutrition 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 229910001467 sodium calcium phosphate Inorganic materials 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 235000019337 sorbitan trioleate Nutrition 0.000 description 1
- 229960000391 sorbitan trioleate Drugs 0.000 description 1
- 239000004544 spot-on Substances 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 125000003696 stearoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 210000001768 subcellular fraction Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229940014800 succinic anhydride Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 230000001180 sulfating effect Effects 0.000 description 1
- UDYFLDICVHJSOY-UHFFFAOYSA-N sulfur trioxide-pyridine complex Substances O=S(=O)=O.C1=CC=NC=C1 UDYFLDICVHJSOY-UHFFFAOYSA-N 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 235000020238 sunflower seed Nutrition 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000007939 sustained release tablet Substances 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 230000003977 synaptic function Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 238000009492 tablet coating Methods 0.000 description 1
- 239000002700 tablet coating Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 150000003899 tartaric acid esters Chemical class 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- WAQBISPOEAOCOG-DYKIIFRCSA-N testosterone sulfate Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)OS(O)(=O)=O)[C@@H]4[C@@H]3CCC2=C1 WAQBISPOEAOCOG-DYKIIFRCSA-N 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- BSYVTEYKTMYBMK-UHFFFAOYSA-N tetrahydrofurfuryl alcohol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 238000007070 tosylation reaction Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 229940100640 transdermal system Drugs 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 1
- STCOOQWBFONSKY-UHFFFAOYSA-N tributyl phosphate Chemical compound CCCCOP(=O)(OCCCC)OCCCC STCOOQWBFONSKY-UHFFFAOYSA-N 0.000 description 1
- WEAPVABOECTMGR-UHFFFAOYSA-N triethyl 2-acetyloxypropane-1,2,3-tricarboxylate Chemical compound CCOC(=O)CC(C(=O)OCC)(OC(C)=O)CC(=O)OCC WEAPVABOECTMGR-UHFFFAOYSA-N 0.000 description 1
- 239000001069 triethyl citrate Substances 0.000 description 1
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 1
- 235000013769 triethyl citrate Nutrition 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 238000013024 troubleshooting Methods 0.000 description 1
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 description 1
- 239000002452 tumor necrosis factor alpha inhibitor Substances 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000010497 wheat germ oil Substances 0.000 description 1
- 239000005019 zein Substances 0.000 description 1
- 229940093612 zein Drugs 0.000 description 1
- 229930195724 β-lactose Natural products 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
Definitions
- AD Alzheimer's disease
- ASD Autism spectrum disorder
- Lithium salts long used in psychiatry to treat bipolar disorder, are still considered as a first-line therapy for both the acute and long-term treatment of bipolar disorder (11).
- Recent studies demonstrated neuroprotective effects of lithium salts, including preventing apoptosis and increasing neurotrophins and other cell-survival molecules (12).
- Beneficial effects of lithium salts on neurogenesis, angiogenesis, inflammation, and other neurological functions have been revealed, indicating the possible use of lithium salts in the treatment of AD and related neurological disorders (13).
- Unfortunately despite the long use of lithium salts in the treatment of bipolar disorder, there remain drawbacks to the use of the current, clinically available lithium salts. Concerns such as potential for toxicity, need for monitoring of side effects, and patient compliance limit the use of currently available lithium salts for broader treatment of neurological conditions.
- the disclosure in various aspects, relates to lithium cholesterol compounds and compositions, pharmaceutical compositions including therapeutically effective amounts of lithium cholesterol compositions, kits including lithium cholesterol pharmaceutical compositions, and methods of using the pharmaceutical compositions including lithium cholesterol compounds for the treatment of a neurological disorder.
- compositions of the present disclosure comprise a therapeutically effective amount of a lithium cholesterol composition, and a pharmaceutically acceptable carrier; wherein the lithium cholesterol composition has a structure having the formula:
- the lithium cholesterol composition is selected from a structure having the formula:
- lithium cholesterol composition is a lithium cholesterol sulfate structure having the formula:
- kits comprising a lithium cholesterol pharmaceutical composition of the present disclosure and instructions for administering the compound to treat a neurological disorder.
- the kits also include at least one additional therapeutic agent for treatment of the neurological disorder and instructions for administering the additional therapeutic agent with the lithium cholesterol pharmaceutical composition.
- R is selected from —SO 4 Li, —PO 3 (Li) 2 , —(CH 2 ) n (C ⁇ O)OLi, or —(C ⁇ O)(CH 2 ) n (C ⁇ O)OLi, where n is integer selected from 1, 2, 3, 4, 5, and 6.
- the neurological disorder is selected from: Alzheimer's disease, autism spectrum disorder (ASD), Parkinson's disease, suicidal ideation, bipolar disorder, mood disorders, traumatic brain injury, radiation induced brain injury, amyotrophic laterals sclerosis, schizoaffective disorder, and tic disorder.
- administration of the pharmaceutical composition produces one or more of the following effects in the subject: increasing levels of inhibitory phosphorylation of GSK3 ⁇ , decreasing levels of phosphorylation of tau, and decreasing levels of LPS-induced TNF ⁇ , as compared to the levels of said compounds in a subject not receiving treatment with the pharmaceutical composition.
- administration of the pharmaceutical composition produces a greater brain to blood lithium level ratio in the subject than administration of lithium chloride and/or does not substantially increase lithium levels in the liver or kidney of the subject.
- compositions comprise a compound produced by a synthetic method described herein.
- present disclosure comprises a method for manufacturing a medicament comprising combining at least one product of the disclosed methods with a pharmaceutically acceptable carrier or diluent.
- FIGS. 1A-1B illustrate the chemical structure and an embodiment of synthesis of lithium cholesterol sulfate (LiCS).
- LiCS was synthesized as described in Example 1 and illustrated in FIG. 1A , and its identification and purity was confirmed by HPLC-MS/MS ( FIG. 1B )
- FIGS. 2A-F illustrate a comparison of LiCS and LiCl in mediating inhibitory GSK3 ⁇ phosphorylation.
- CHO FIGS. 2A and 2B
- SH-SY5Y cell cultures FIGS. 2C and 2D
- LiCS or NaCS at 0-90 ⁇ M or LiCl at 60 ⁇ M to 2.5 mM for 18 h
- inhibitory phospho-GSK3 ⁇ Ser9
- total GSK3 ⁇ levels in cell homogenates by WB.
- Levels of phospo-GSK3 ⁇ (Ser9) were determined by densitometry analysis of three independent experiments and represented as mean ⁇ SD in the graphs presented in FIGS. 2E and 2F .
- Asterisk indicates P ⁇ 0.05 compared with no treatment (control, 100%). Note that NaCS did not alter pGSK3 ⁇ and neither LiCS, LiCl nor NaCS altered total GSK3 ⁇ levels.
- FIGS. 3A-3D illustrate a comparison of LiCS vs. LiCl effect on tau (Thr231) phosphorylation and that LiCS reduces tau (Thr231) phosphorylation at micromolar levels.
- HEK293/tau cells were treated with LiCS ( FIG. 3A ) or NaCS at 0-60 ⁇ M ( FIG. 3B ) or LiCl at 60 ⁇ M to 1.25 mM for 18 h ( FIG. 3C ) followed by analysis of phosphor-tau (Thr231) and total tau levels in cell homogenates by WB.
- Levels of phosphor-tau (Thr231) were determined by densitometry analysis of three independent experiments and represented as means ⁇ SD ( FIG. 3D ).
- Asterisk indicates P ⁇ 0.05 compared with no treatment (100% of control). Note that neither NaCS nor LiCl altered ptau, and neither LiCS, LiCl nor NaCS altered total tau levels.
- FIG. 4 is a graph illustrating that LiCS is more effective than LiCl in reducing microglial LPS-induced TNF ⁇ production.
- Microglial BV2 cells were treated with LPS at 100 ng/ml in the absence or presence of LiCS or NaCS at 0, 20, 40 or 80 ⁇ M or LiCl at 5, 10 or 20 mM for 3 h, followed by analysis of TNF ⁇ levels in conditioned media by ELISA, represented as means ⁇ SD.
- Asterisk indicates P ⁇ 0.05 compared with LPS treatment alone.
- the graph in FIG. 5A and table in FIG. 5B illustrate the pharmacokinetics of lithium cholesterol sulfate (LiCS) in adult male mice.
- the graph in FIG. 5A illustrates the comparison of lithium levels in the blood after treatment with LiCl and LiCS at 0.5, 1, 2, 3, 5 and 24 h after oral administration, where the table in FIG. 5B presents the comparison of lithium levels in brain, kidney and liver at 0.5 and 5 h after gavage.
- Lithium ELISA results are presented as the mean ( ⁇ s.d.).
- Asterisk indicates P ⁇ 0.05 versus LiCl treatment as determined by ANOVA.
- x to y includes the range from ‘x’ to ‘y’ as well as the range greater than ‘x’ and less than ‘y’.
- the range can also be expressed as an upper limit, e.g. ‘about x, y, z, or less’ and should be interpreted to include the specific ranges of ‘about x’, ‘about y’, and ‘about z’ as well as the ranges of ‘less than x’, less than y′, and ‘less than z’.
- the phrase ‘about x, y, z, or greater’ should be interpreted to include the specific ranges of ‘about x’, ‘about y’, and ‘about z’ as well as the ranges of ‘greater than x’, greater than y′, and ‘greater than z’.
- the phrase “about ‘x’ to ‘y’”, where ‘x’ and ‘y’ are numerical values, includes “about ‘x’ to about ‘y’”.
- a numerical range of “about 0.1% to 5%” should be interpreted to include not only the explicitly recited values of about 0.1% to about 5%, but also include individual values (e.g., about 1%, about 2%, about 3%, and about 4%) and the sub-ranges (e.g., about 0.5% to about 1.1%; about 5% to about 2.4%; about 0.5% to about 3.2%, and about 0.5% to about 4.4%, and other possible sub-ranges) within the indicated range.
- Embodiments of the present disclosure will employ, unless otherwise indicated, techniques of biochemistry, molecular biology, pharmacology, medicine, neuropathology, and the like, which are within the skill of the art. Such techniques are explained fully in the literature.
- compositions like those disclosed herein, but which may contain additional structural groups, composition components or method steps (or analogs or derivatives thereof as discussed above). Such additional structural groups, composition components or method steps, etc., however, do not materially affect the basic and novel characteristic(s) of the compositions or methods, compared to those of the corresponding compositions or methods disclosed herein.
- Consisting essentially of” or “consists essentially” or the like, when applied to methods and compositions encompassed by the present disclosure have the meaning ascribed in U.S. Patent law and the term is open-ended, allowing for the presence of more than that which is recited so long as basic or novel characteristics of that which is recited is not changed by the presence of more than that which is recited, but excludes prior art embodiments.
- “about,” “approximately,” “substantially,” and the like when used in connection with a numerical variable, can generally refers to the value of the variable and to all values of the variable that are within the experimental error (e.g., within the 95% confidence interval for the mean) or within +/ ⁇ 10% of the indicated value, whichever is greater.
- the terms “about,” “approximate,” “at or about,” and “substantially” can mean that the amount or value in question can be the exact value or a value that provides equivalent results or effects as recited in the claims or taught herein.
- an amount, size, formulation, parameter or other quantity or characteristic is “about,” “approximate,” or “at or about” whether or not expressly stated to be such. It is understood that where “about,” “approximate,” or “at or about” is used before a quantitative value, the parameter also includes the specific quantitative value itself, unless specifically stated otherwise.
- the terms “optional” or “optionally” means that the subsequently described event or circumstance can or cannot occur, and that the description includes instances where said event or circumstance occurs and instances where it does not.
- administering can refer to an administration that is oral, topical, intravenous, subcutaneous, transcutaneous, transdermal, intramuscular, intra-joint, parenteral, intra-arteriole, intradermal, intraventricular, intraosseous, intraocular, intracranial, intraperitoneal, intralesional, intranasal, intracardiac, intraarticular, intracavernous, intrathecal, intravireal, intracerebral, and intracerebroventricular, intratympanic, intracochlear, rectal, vaginal, by inhalation, by catheters, stents or via an implanted reservoir or other device that administers, either actively or passively (e.g.
- a composition the perivascular space and adventitia can contain a composition or formulation disposed on its surface, which can then dissolve or be otherwise distributed to the surrounding tissue and cells.
- parenteral can include subcutaneous, intravenous, intramuscular, intra-articular, intra-synovial, intrasternal, intrathecal, intrahepatic, intralesional, and intracranial injections or infusion techniques. Administration can be continuous or intermittent.
- a preparation can be administered therapeutically; that is, administered to treat an existing disease or condition.
- a preparation can be administered prophylactically; that is, administered for prevention of a disease or condition.
- therapeutic agent can refer to any substance, compound, molecule, and the like, which can be biologically active or otherwise can induce a pharmacologic, immunogenic, biologic and/or physiologic effect on a subject to which it is administered to by local and/or systemic action.
- a therapeutic agent can be a primary active agent, or in other words, the component(s) of a composition to which the whole or part of the effect of the composition is attributed.
- a therapeutic agent can be a secondary therapeutic agent, or in other words, the component(s) of a composition to which an additional part and/or other effect of the composition is attributed.
- the term therefore encompasses those compounds or chemicals traditionally regarded as drugs, vaccines, and biopharmaceuticals including molecules such as proteins, peptides, hormones, nucleic acids, gene constructs and the like.
- therapeutic agents are described in well-known literature references such as the Merck Index (14th edition), the Physicians' Desk Reference (64th edition), and The Pharmacological Basis of Therapeutics (12th edition), and they include, without limitation, medicaments; vitamins; mineral supplements; substances used for the treatment, prevention, diagnosis, cure or mitigation of a disease or illness; substances that affect the structure or function of the body, or pro-drugs, which become biologically active or more active after they have been placed in a physiological environment.
- the term “therapeutic agent” includes compounds or compositions for use in all of the major therapeutic areas including, but not limited to, adjuvants; anti-infectives such as antibiotics and antiviral agents; analgesics and analgesic combinations, anorexics, anti-inflammatory agents, anti-epileptics, local and general anesthetics, hypnotics, sedatives, antipsychotic agents, neuroleptic agents, antidepressants, anxiolytics, antagonists, neuron blocking agents, anticholinergic and cholinomimetic agents, antimuscarinic and muscarinic agents, antiadrenergics, antiarrhythmics, antihypertensive agents, hormones, and nutrients, antiarthritics, antiasthmatic agents, anticonvulsants, antihistamines, antinauseants, antineoplastics, antipruritics, antipyretics; antispasmodics, cardiovascular preparations (including calcium channel blockers, beta-blockers, an
- the agent may be a biologically active agent used in medical, including veterinary, applications and in agriculture, such as with plants, as well as other areas.
- therapeutic agent also includes without limitation, medicaments; vitamins; mineral supplements; substances used for the treatment, prevention, diagnosis, cure or mitigation of disease or illness; or substances which affect the structure or function of the body; or pro-drugs, which become biologically active or more active after they have been placed in a predetermined physiological environment.
- kit means a collection of at least two components constituting the kit. Together, the components constitute a functional unit for a given purpose. Individual member components may be physically packaged together or separately. For example, a kit comprising an instruction for using the kit may or may not physically include the instruction with other individual member components. Instead, the instruction can be supplied as a separate member component, either in a paper form or an electronic form which may be supplied on computer readable memory device or downloaded from an internet website, or as recorded presentation.
- instruction(s) means documents describing relevant materials or methodologies pertaining to a kit. These materials may include any combination of the following: background information, list of components and their availability information (purchase information, etc.), brief or detailed protocols for using the kit, trouble-shooting, references, technical support, and any other related documents. Instructions can be supplied with the kit or as a separate member component, either as a paper form or an electronic form which may be supplied on computer readable memory device or downloaded from an internet website, or as recorded presentation. Instructions can comprise one or multiple documents and are meant to include future updates.
- Non-covalent interactions can include ionic bonds, electrostatic interactions, van der Walls forces, dipole-dipole interactions, dipole-induced-dipole interactions, London dispersion forces, hydrogen bonding, halogen bonding, electromagnetic interactions, ⁇ - ⁇ interactions, cation- ⁇ interactions, anion- ⁇ interactions, polar ⁇ -interactions, and hydrophobic effects.
- subject can refer to a vertebrate organism, such as a mammal (e.g. human). “Subject” can also refer to a cell, a population of cells, a tissue, an organ, or an organism, preferably to human and constituents thereof.
- the terms “treating” and “treatment” can refer generally to obtaining a desired pharmacological and/or physiological effect.
- the effect can be, but does not necessarily have to be, prophylactic in terms of preventing or partially preventing a disease, symptom or condition thereof, such as those related to a neurodegenerative condition, and neurodevelopmental disorder, or other neurological disorder, such as but not limited to Alzheimer's disease, autism spectrum disorder, bipolar disorder, suicidal ideation, traumatic brain injury, radiation induced brain injury, and the like.
- the effect can be therapeutic in terms of a partial or complete cure of a disease, condition, symptom or adverse effect attributed to the disease, disorder, or condition.
- treatment can include any treatment of a neurological disorder in a subject, particularly a human, and can include any one or more of the following: (a) preventing the disease from occurring in a subject which may be predisposed to the disease but has not yet been diagnosed as having it; (b) inhibiting the disease, i.e., arresting its development; and (c) relieving the disease, i.e., mitigating or ameliorating the disease and/or its symptoms or conditions.
- treatment as used herein can refer to both therapeutic treatment alone, prophylactic treatment alone, or both therapeutic and prophylactic treatment.
- Those in need of treatment can include those already with the disorder and/or those in which the disorder is to be prevented.
- treating can include inhibiting the disease, disorder or condition, e.g., impeding its progress; and relieving the disease, disorder, or condition, e.g., causing regression of the disease, disorder and/or condition.
- Treating the disease, disorder, or condition can include ameliorating at least one symptom of the particular disease, disorder, or condition, even if the underlying pathophysiology is not affected, e.g., such as treating the pain of a subject by administration of an analgesic agent even though such agent does not treat the cause of the pain.
- dose can refer to physically discrete units suitable for use in a subject, each unit containing a predetermined quantity of a disclosed compound and/or a pharmaceutical composition thereof calculated to produce the desired response or responses in association with its administration.
- terapéutica can refer to treating, healing, and/or ameliorating a disease, disorder, condition, or side effect, or to decreasing in the rate of advancement of a disease, disorder, condition, or side effect.
- an effective amount can refer to the amount of a disclosed compound or pharmaceutical composition provided herein that is sufficient to effect beneficial or desired biological, emotional, medical, or clinical response of a cell, tissue, system, animal, or human.
- An effective amount can be administered in one or more administrations, applications, or dosages.
- the term can also include within its scope amounts effective to enhance or restore to substantially normal physiological function.
- the term “therapeutically effective amount” refers to an amount that is sufficient to achieve the desired therapeutic result or to have an effect on undesired symptoms but is generally insufficient to cause adverse side effects.
- the specific therapeutically effective dose level for any particular patient will depend upon a variety of factors including the disorder being treated and the severity of the disorder; the specific composition employed; the age, body weight, general health, sex and diet of the patient; the time of administration; the route of administration; the rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or coincidental with the specific compound employed and like factors within the knowledge and expertise of the health practitioner and which may be well known in the medical arts.
- the desired response can be inhibiting the progression of the disease or condition. This may involve only slowing the progression of the disease temporarily. However, in other instances, it may be desirable to halt the progression of the disease permanently. This can be monitored by routine diagnostic methods known to one of ordinary skill in the art for any particular disease.
- the desired response to treatment of the disease or condition also can be delaying the onset or even preventing the onset of the disease or condition.
- the effective daily dose can be divided into multiple doses for purposes of administration. Consequently, single dose compositions can contain such amounts or submultiples thereof to make up the daily dose.
- the dosage can be adjusted by the individual physician in the event of any contraindications. It is generally preferred that a maximum dose of the pharmacological agents of the invention (alone or in combination with other therapeutic agents) be used, that is, the highest safe dose according to sound medical judgment. It will be understood by those of ordinary skill in the art however, that a patient may insist upon a lower dose or tolerable dose for medical reasons, psychological reasons or for virtually any other reasons.
- a response to a therapeutically effective dose of a disclosed compound and/or pharmaceutical composition can be measured by determining the physiological effects of the treatment or medication, such as the decrease or lack of disease symptoms following administration of the treatment or pharmacological agent.
- Other assays will be known to one of ordinary skill in the art and can be employed for measuring the level of the response.
- the amount of a treatment may be varied for example by increasing or decreasing the amount of a disclosed compound and/or pharmaceutical composition, by changing the disclosed compound and/or pharmaceutical composition administered, by changing the route of administration, by changing the dosage timing and so on. Dosage can vary, and can be administered in one or more dose administrations daily, for one or several days. Guidance can be found in the literature for appropriate dosages for given classes of pharmaceutical products.
- prophylactically effective amount refers to an amount effective for preventing onset or initiation of a disease or condition.
- prevent refers to precluding, averting, obviating, forestalling, stopping, or hindering something from happening, especially by advance action. It is understood that where reduce, inhibit or prevent are used herein, unless specifically indicated otherwise, the use of the other two words is also expressly disclosed.
- pharmaceutically acceptable describes a material that is not biologically or otherwise undesirable, i.e., without causing an unacceptable level of undesirable biological effects or interacting in a deleterious manner.
- prodrug or “prodrug” represents those prodrugs of the compounds of the present disclosure which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response, and the like, commensurate with a reasonable benefit/risk ratio, and effective for their intended use.
- Prodrugs of the present disclosure can be rapidly transformed in vivo to a parent compound having a structure of a disclosed compound, for example, by hydrolysis in blood.
- a thorough discussion is provided in T. Higuchi and V. Stella, Pro-drugs as Novel Delivery Systems, V. 14 of the A.C.S. Symposium Series, and in Edward B. Roche, ed., Bioreversible Carriers in Drug Design, American Pharmaceutical Association and Pergamon Press (1987).
- derivative refers to a compound having a structure derived from the structure of a parent compound (e.g., a compound disclosed herein) and whose structure is sufficiently similar to those disclosed herein and based upon that similarity, would be expected by one skilled in the art to exhibit the same or similar activities and utilities as the claimed compounds, or to induce, as a precursor, the same or similar activities and utilities as the claimed compounds.
- exemplary derivatives include salts, esters, amides, salts of esters or amides, and N-oxides of a parent compound.
- contacting refers to bringing a disclosed compound or pharmaceutical composition in proximity to a cell, a target protein, or other biological entity together in such a manner that the disclosed compound or pharmaceutical composition can affect the activity of the a cell, target protein, or other biological entity, either directly; i.e., by interacting with the cell, target protein, or other biological entity itself, or indirectly; i.e., by interacting with another molecule, co-factor, factor, or protein on which the activity of the cell, target protein, or other biological entity itself is dependent.
- stable refers to compounds that are not substantially altered when subjected to conditions to allow for their production, detection, and, in certain aspects, their recovery, purification, and use for one or more of the purposes disclosed herein.
- the compounds described in the invention can be present as a solvate.
- the solvent used to prepare the solvate is an aqueous solution, and the solvate is then often referred to as a hydrate.
- the compounds can be present as a hydrate, which can be obtained, for example, by crystallization from a solvent or from aqueous solution.
- one, two, three or any arbitrary number of solvent or water molecules can combine with the compounds according to the invention to form solvates and hydrates.
- the invention includes all such possible solvates.
- co-crystal means a physical association of two or more molecules which owe their stability through non-covalent interaction.
- One or more components of this molecular complex provide a stable framework in the crystalline lattice.
- the guest molecules are incorporated in the crystalline lattice as anhydrates or solvates, see e.g. “Crystal Engineering of the Composition of Pharmaceutical Phases. Do Pharmaceutical Co-crystals Represent a New Path to Improved Medicines?” Almarasson, O., et al., The Royal Society of Chemistry, 1889-1896, 2004.
- Examples of co-crystals include p-toluenesulfonic acid and benzenesulfonic acid.
- Certain materials, compounds, compositions, and components disclosed herein can be obtained commercially or readily synthesized using techniques generally known to those of skill in the art.
- the starting materials and reagents used in preparing the disclosed compounds and compositions are either available from commercial suppliers such as Aldrich Chemical Co., (Milwaukee, Wis.), Acros Organics (Morris Plains, N.J.), Fisher Scientific (Pittsburgh, Pa.); or Sigma (St.
- compositions of the invention Disclosed are the components to be used to prepare the compositions of the invention as well as the compositions themselves to be used within the methods disclosed herein.
- these and other materials are disclosed herein, and it is understood that when combinations, subsets, interactions, groups; etc. of these materials are disclosed that while specific reference of each various individual and collective combinations and permutation of these compounds cannot be explicitly disclosed; each is specifically contemplated and described herein. For example, if a particular compound is disclosed and discussed and a number of modifications that can be made to a number of molecules including the compounds are discussed; specifically contemplated is each and every combination and permutation of the compound and the modifications that are possible unless specifically indicated to the contrary.
- compositions disclosed herein have certain functions. Disclosed herein are certain structural requirements for performing the disclosed functions, and it is understood that there are a variety of structures that can perform the same function that are related to the disclosed structures, and that these structures will typically achieve the same result.
- temperatures referred to herein are based on atmospheric pressure (i.e., one atmosphere).
- lithium cholesterol compositions including, but not limited to lithium cholesterol sulfate compositions, and pharmaceutical compositions that have therapeutic or clinical utility. Also described herein are methods of synthesizing the lithium cholesterol sulfate and compositions containing the LiCS. Also described herein are methods of administering the lithium cholesterol sulfate to a subject in need thereof.
- the subject can have a neurological disorder such as a neurodegenerative condition, a neurological developmental disorder, a neurological injury, and other conditions resulting from neurological disorders.
- a neurological disorder such as a neurodegenerative condition, a neurological developmental disorder, a neurological injury, and other conditions resulting from neurological disorders.
- embodiments of the present disclosure relate to pharmaceutical compositions including lithium cholesterol sulfate and compositions and methods for the treatment of neurodegenerative conditions, neurodevelopmental conditions, and other neurological conditions.
- AD Alzheimer's disease
- aphasia loss of motor function
- impairment of visual space skills impairment of visual space skills
- executive dysfunction and personality and behavior change.
- AD is the main cause of dementia and one of the great health-care challenges of the 21st century, accounting for more than 50% of all clinically diagnosed dementia (1).
- People in the final stages of AD are bed bound and require constant care, ultimately leading to death.
- a new case of AD is expected to occur every 33 s, causing nearly 1 million new AD cases per year.
- Approximately 13% of the population over the age of 65 years is estimated to have AD and the total number of cases is expected to increase over the coming decades.
- AD pathogenesis is complex, involving abnormal amyloid-8 (A ⁇ ) metabolism, tau hyperphosphorylation, oxidative stress, inflammation, reactive glial and microglial changes, and other pathological events (2, 3). AD not only causes severe distress for patients and caregivers, but also results in a large economic burden on society (4). Therefore, it is very important to treat or prevent this disease progression.
- a ⁇ amyloid-8
- Autism spectrum disorder is a neurodevelopmental disorder characterized by persistent difficulties in social communication and social interaction, coupled with restricted, repetitive patterns of behavior or interest (5). These children also present with symptoms of mood disorder, such as elevated moods/euphoria, mania, and paranoia, whether accompanied or not by irritability (6, 7). According to a recent report from the Centers for Disease Control and Prevention (CDC), around 20 per 1000 children aged 6-17 in the United States are diagnosed with ASD in 2011-2012 (8). The cause of autism appears to be primarily genetic, but recent studies also indicate the presence of a strong inflammatory state associated with ASD (9).
- Lithium salts have been used in psychiatry to treat bipolar disorder for many years, and now they are still considered as a first-line therapy for both the acute and long-term treatment of bipolar disorder (11). Simultaneously, recent studies found that lithium salts also have neuroprotective effects that include preventing apoptosis and increasing neurotrophins and other cell-survival molecules (12). Furthermore, beneficial effects of lithium salts on neurogenesis, brain remodeling, angiogenesis, mesenchymal stem cells functioning, and inflammation have been revealed (13). In particular, recent studies have found that lithium can act as a potential therapeutic for AD (13). Studies have showed that patients who were given lithium would progress less over the course of AD compared with the placebo-group (12, 14).
- Lithium may not only have beneficial effects on cognitive performance in subjects with AD dementia, but also may have positive treatment effects in ASD (7, 13).
- treatment of Sprague-Dawley rats with lithium chloride (2 mmol/kg i.p./day) reversed autistic features, such as social interaction deficit, excessive repetitive self-grooming behavior, increased anxiety and depression (15).
- lithium therapy reversed clinical regression stabilized behavioral symptoms and allowed patients to recover their pre-catatonia level of functioning, without significant side effects (16).
- lithium carbonate is usually applied in clinic, but other lithium salts such as lithium citrate, lithium sulfate, lithium orotate and lithium chloride are also used as alternatives.
- lithium treatment has serious short- and long-term side effects in humans and requires frequent monitoring of blood chemistry and lithium plasma levels so as to avoid toxicity, discouraging patients from choosing these drugs.
- a safer and more effective lithium formulation to treat AD and ASD there is a demand for a safer and more effective lithium formulation to treat AD and ASD.
- the present disclosure provides a novel lithium salt that is useful for treating AD, ASD, and other neurological conditions.
- the examples below describe tests and data illustrating the therapeutic potential of lithium cholesterol compositions, including, but not limited to lithium cholesterol sulfate compositions (LiCS, FIG. 1 ).
- LiCS lithium cholesterol sulfate compositions
- Cholesterol sulfate is a normal constituent in a variety of human tissues (17, 18). This compound has a hydrophobic/hydrophilic property suited for interactions with membrane constituents and crossing the cell membrane and intestinal and blood-brain barriers (19).
- cholesterol sulfate itself can provide benefits in the treatment of AD and ASD, as well as other diseases potentially resulting from sulfur shortage, including eczema and asthma (20).
- LiCS Cholesterol has also been shown to directly bind APP and A ⁇ , making LiCS more effective in targeting A ⁇ aggregation (21).
- the present disclosure including the following examples, illustrates that LiCS will have a superior pharmacokinetic and safety profile compared with traditional lithium chemical forms for treatment of neurodegenerative diseases.
- lithium cholesterol compositions including, but not limited to lithium cholesterol sulfate compositions (LiCS).
- LiCS lithium cholesterol sulfate compositions
- the lithium cholesterol compositions of the disclosure have the following structure:
- R is selected from —SO 4 Li, —PO 3 (Li) 2 , —(CH 2 ) n (C ⁇ O)OLi, or —(C ⁇ O)(CH 2 ) n (C ⁇ O)OLi, where n is integer selected from 1, 2, 3, 4, 5, and 6.
- the lithium cholesterol compositions of the disclosure can have a structure selected from:
- the lithium cholesterol compositions of the disclosure can have the following structure:
- LiCS has a formula weight of 472.65.
- the lithium cholesterol compositions of the disclosure can have the following structure:
- LiCP has a formula weight of 478.51.
- the lithium cholesterol compositions of the disclosure can have the following structure:
- LiCSc has a formula weight of 492.67.
- the lithium cholesterol compositions of the disclosure can have the following structure:
- LiCAc has a formula weight of 450.63.
- the present disclosure relates to pharmaceutical compositions comprising a therapeutically effective amount of a lithium cholesterol sulfate compound of the present disclosure or a derivative thereof and a pharmaceutically acceptable carrier.
- pharmaceutically-acceptable carriers means one or more of a pharmaceutically acceptable diluents, preservatives, antioxidants, solubilizers, emulsifiers, coloring agents, releasing agents, coating agents, sweetening, flavoring and perfuming agents, and adjuvants.
- the disclosed pharmaceutical compositions can be conveniently presented in unit dosage form and prepared by any of the methods well known in the art of pharmacy and pharmaceutical sciences.
- the disclosed pharmaceutical compositions comprise a therapeutically effective amount of at least one disclosed lithium cholesterol composition, including, but not limited to lithium cholesterol sulfate, at least one product of a disclosed method as an active ingredient, a pharmaceutically acceptable carrier, optionally one or more other therapeutic agent, and optionally one or more adjuvant.
- the disclosed pharmaceutical compositions include those suitable for oral, rectal, topical, pulmonary, nasal, and parenteral administration, although the most suitable route in any given case will depend on the particular host, and nature and severity of the conditions for which the active ingredient is being administered.
- the disclosed pharmaceutical composition can be formulated to allow administration orally, nasally, via inhalation, parenterally, paracancerally, transmucosally, transdermally, intramuscularly, intravenously, intradermally, subcutaneously, intraperitonealy, intraventricularly, intracranially and intratumorally.
- parenteral administration includes administration by bolus injection or infusion, as well as administration by intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular subarachnoid, intraspinal, epidural and intrasternal injection and infusion.
- the present disclosure also relates to a pharmaceutical composition
- a pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and, as active ingredient, a therapeutically effective amount of a disclosed lithium cholesterol composition, including, but not limited to lithium cholesterol sulfate, a product of a disclosed method of making, a pharmaceutically acceptable salt, a hydrate thereof, a solvate thereof, a polymorph thereof, or a stereochemically isomeric form thereof.
- a disclosed compound, a product of a disclosed method of making, a pharmaceutically acceptable salt, a hydrate thereof, a solvate thereof, a polymorph thereof, or a stereochemically isomeric form thereof, or any subgroup or combination thereof may be formulated into various pharmaceutical forms for administration purposes.
- the compounds of the present disclosure can be combined as the active ingredient in intimate admixture with a pharmaceutical carrier according to conventional pharmaceutical compounding techniques.
- the carrier can take a wide variety of forms depending on the form of preparation desired for administration, e.g., oral or parenteral (including intravenous).
- the pharmaceutical compositions of the present disclosure can be presented as discrete units suitable for oral administration such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient.
- the compositions can be presented as a powder, as granules, as a solution, as a suspension in an aqueous liquid, as a non-aqueous liquid, as an oil-in-water emulsion or as a water-in-oil liquid emulsion.
- the compounds of the present disclosure, and/or pharmaceutically acceptable salt(s) thereof can also be administered by controlled release means and/or delivery devices.
- the compositions can be prepared by any of the methods of pharmacy. In general, such methods include a step of bringing into association the active ingredient with the carrier that constitutes one or more necessary ingredients. In general, the compositions are prepared by uniformly and intimately admixing the active ingredient with liquid carriers or finely divided solid carriers or both. The product can then be conveniently shaped into the desired presentation.
- unit dosage form refers to physically discrete units suitable as unitary dosages, each unit containing a predetermined quantity of active ingredient calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. That is, a “unit dosage form” is taken to mean a single dose wherein all active and inactive ingredients are combined in a suitable system, such that the patient or person administering the drug to the patient can open a single container or package with the entire dose contained therein, and does not have to mix any components together from two or more containers or packages.
- unit dosage forms are tablets (including scored or coated tablets), capsules or pills for oral administration; single dose vials for injectable solutions or suspension; suppositories for rectal administration; powder packets; wafers; and segregated multiples thereof.
- This list of unit dosage forms is not intended to be limiting in any way, but merely to represent typical examples of unit dosage forms.
- compositions disclosed herein comprise a compound of the present disclosure (or pharmaceutically acceptable salts or derivatives thereof) as an active ingredient, a pharmaceutically acceptable carrier, and optionally one or more additional therapeutic agents.
- the disclosed pharmaceutical compositions can include a pharmaceutically acceptable carrier and a disclosed lithium cholesterol composition, including, but not limited to lithium cholesterol sulfate.
- a disclosed lithium cholesterol composition including, but not limited to lithium cholesterol sulfate, can also be included in a pharmaceutical composition in combination with one or more other therapeutically active compounds.
- compositions suitable for oral, rectal, topical, and parenteral (including subcutaneous, intramuscular, and intravenous) administration although the most suitable route in any given case will depend on the particular host, and nature and severity of the conditions for which the active ingredient is being administered.
- the pharmaceutical compositions can be conveniently presented in unit dosage form and prepared by any of the methods well known in the art of pharmacy.
- the compounds described herein are typically to be administered in admixture with suitable pharmaceutical diluents, excipients, extenders, or carriers (termed herein as a pharmaceutically acceptable carrier, or a carrier) suitably selected with respect to the intended form of administration and as consistent with conventional pharmaceutical practices.
- suitable pharmaceutical diluents, excipients, extenders, or carriers suitably selected with respect to the intended form of administration and as consistent with conventional pharmaceutical practices.
- the deliverable compound will be in a form suitable for oral, rectal, topical, intravenous injection or parenteral administration.
- Carriers include solids or liquids, and the type of carrier is chosen based on the type of administration being used.
- the compounds may be administered as a dosage that has a known quantity of the compound.
- oral administration can be a preferred dosage form, and tablets and capsules represent the most advantageous oral dosage unit forms in which case solid pharmaceutical carriers are obviously employed.
- other dosage forms may be suitable depending upon clinical population (e.g., age and severity of clinical condition), solubility properties of the specific disclosed compound used, and the like.
- the disclosed compounds can be used in oral dosage forms such as pills, powders, granules, elixirs, tinctures, suspensions, syrups, and emulsions.
- any convenient pharmaceutical media can be employed.
- oral liquid preparations such as suspensions, elixirs and solutions
- carriers such as starches, sugars, microcrystalline cellulose, diluents, granulating agents, lubricants, binders, disintegrating agents, and the like
- oral solid preparations such as powders, capsules and tablets.
- tablets and capsules are the preferred oral dosage units whereby solid pharmaceutical carriers are employed.
- tablets can be coated by standard aqueous or nonaqueous techniques.
- compositions in an oral dosage form can comprise one or more pharmaceutical excipient and/or additive.
- suitable excipients and additives include gelatin, natural sugars such as raw sugar or lactose, lecithin, pectin, starches (for example corn starch or amylose), dextran, polyvinyl pyrrolidone, polyvinyl acetate, gum arabic, alginic acid, tylose, talcum, lycopodium, silica gel (for example colloidal), cellulose, cellulose derivatives (for example cellulose ethers in which the cellulose hydroxy groups are partially etherified with lower saturated aliphatic alcohols and/or lower saturated, aliphatic oxyalcohols, for example methyl oxypropyl cellulose, methyl cellulose, hydroxypropyl methyl cellulose, hydroxypropyl methyl cellulose phthalate), fatty acids as well as magnesium, calcium or aluminum salts of fatty acids with 12 to 22 carbon atoms,
- auxiliary substances useful in preparing an oral dosage form are those which cause disintegration (so-called disintegrants), such as: cross-linked polyvinyl pyrrolidone, sodium carboxymethyl starch, sodium carboxymethyl cellulose or microcrystalline cellulose.
- Conventional coating substances may also be used to produce the oral dosage form.
- Plasticizing agents that may be considered as coating substances in the disclosed oral dosage forms are: citric and tartaric acid esters (acetyl-triethyl citrate, acetyl tributyl-, tributyl-, triethyl-citrate); glycerol and glycerol esters (glycerol diacetate, -triacetate, acetylated monoglycerides, castor oil); phthalic acid esters (dibutyl-, diamyl-, diethyl-, dimethyl-, dipropyl-phthalate), di-(2-methoxy- or 2-ethoxyethyl)-phthalate, ethylphthalyl glycolate, butylphthalylethyl glycolate and butylglycolate; alcohols (propylene glycol, polyethylene glycol of various chain lengths), adipates (diethyladipate, di-(2-methoxy- or 2-ethoxyethyl)
- suitable binders, lubricants, disintegrating agents, coloring agents, flavoring agents, flow-inducing agents, and melting agents may be included as carriers.
- the pharmaceutical carrier employed can be, for example, a solid, liquid, or gas.
- solid carriers include, but are not limited to, lactose, terra alba, sucrose, glucose, methylcellulose, dicalcium phosphate, calcium sulfate, mannitol, sorbitol talc, starch, gelatin, agar, pectin, acacia, magnesium stearate, and stearic acid.
- liquid carriers are sugar syrup, peanut oil, olive oil, and water.
- gaseous carriers include carbon dioxide and nitrogen.
- a binder can include, for example, starch, gelatin, natural sugars such as glucose or beta-lactose, corn sweeteners, natural and synthetic gums such as acacia, tragacanth, or sodium alginate, carboxymethylcellulose, polyethylene glycol, waxes, and the like.
- Lubricants used in these dosage forms include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride, and the like.
- a disintegrator can include, for example, starch, methyl cellulose, agar, bentonite, xanthan gum, and the like.
- an oral dosage form such as a solid dosage form
- Suitable biodegradable polymers useful in achieving controlled release of a drug include, for example, polylactic acid, polyglycolic acid, copolymers of polylactic and polyglycolic acid, caprolactones, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacylates, and hydrogels, preferably covalently crosslinked hydrogels.
- Tablets may contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets.
- excipients may be, for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example starch, gelatin or acacia, and lubricating agents, for example magnesium stearate, stearic acid or talc.
- the tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period.
- a tablet containing a disclosed compound can be prepared by compression or molding, optionally with one or more accessory ingredients or adjuvants.
- Compressed tablets can be prepared by compressing, in a suitable machine, the active ingredient in a free-flowing form such as powder or granules, optionally mixed with a binder, lubricant, inert diluent, surface active or dispersing agent.
- Molded tablets can be made by molding in a suitable machine, a mixture of the powdered compound moistened with an inert liquid diluent.
- a solid oral dosage form such as a tablet
- enteric coating agents include, but are not limited to, hydroxypropylmethylcellulose phthalate, methacrylic acid-methacrylic acid ester copolymer, polyvinyl acetate-phthalate and cellulose acetate phthalate.
- enteric coating materials may be selected on the basis of testing to achieve an enteric coated dosage form designed ab initio to have a preferable combination of dissolution time, coating thicknesses and diametral crushing strength (e.g., see S. C. Porter et al. “The Properties of Enteric Tablet Coatings Made From Polyvinyl Acetate-phthalate and Cellulose acetate Phthalate”, J. Pharm. Pharmacol. 22:42p (1970)).
- the enteric coating may comprise hydroxypropyl-methylcellulose phthalate, methacrylic acid-methacrylic acid ester copolymer, polyvinyl acetate-phthalate and cellulose acetate phthalate.
- an oral dosage form can be a solid dispersion with a water soluble or a water insoluble carrier.
- water soluble or water insoluble carrier include, but are not limited to, polyethylene glycol, polyvinylpyrrolidone, hydroxypropylmethyl-cellulose, phosphatidylcholine, polyoxyethylene hydrogenated castor oil, hydroxypropylmethylcellulose phthalate, carboxymethylethylcellulose, or hydroxypropylmethylcellulose, ethyl cellulose, or stearic acid.
- an oral dosage form can be in a liquid dosage form, including those that are ingested, or alternatively, administered as a mouth wash or gargle.
- a liquid dosage form can include aqueous suspensions, which contain the active materials in admixture with excipients suitable for the manufacture of aqueous suspensions.
- oily suspensions may be formulated by suspending the active ingredient in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin. Oily suspensions may also contain various excipients.
- the pharmaceutical compositions of the present disclosure may also be in the form of oil-in-water emulsions, which may also contain excipients such as sweetening and flavoring agents.
- water particularly sterile water, or physiologically acceptable organic solvents, such as alcohols (ethanol, propanol, isopropanol, 1,2-propylene glycol, polyglycols and their derivatives, fatty alcohols, partial esters of glycerol), oils (for example peanut oil, olive oil, sesame oil, almond oil, sunflower oil, soya bean oil, castor oil, bovine hoof oil), paraffins, dimethyl sulphoxide, triglycerides and the like.
- alcohols ethanol, propanol, isopropanol, 1,2-propylene glycol, polyglycols and their derivatives, fatty alcohols, partial esters of glycerol
- oils for example peanut oil, olive oil, sesame oil, almond oil, sunflower oil, soya bean oil, castor oil, bovine hoof oil
- paraffins dimethyl sulphoxide, triglycerides and the like.
- a liquid dosage form such as a drinkable solutions
- the following substances may be used as stabilizers or solubilizers: lower aliphatic mono- and multivalent alcohols with 2-4 carbon atoms, such as ethanol, n-propanol, glycerol, polyethylene glycols with molecular weights between 200-600 (for example 1 to 40% aqueous solution), diethylene glycol monoethyl ether, 1,2-propylene glycol, organic amides, for example amides of aliphatic C1-06-carboxylic acids with ammonia or primary, secondary or tertiary C1-04-amines or C1-04-hydroxy amines such as urea, urethane, acetamide, N-methyl acetamide, N,N-diethyl acetamide, N,N-dimethyl acetamide, lower aliphatic amines and diamines with 2-6 carbon atoms, such as ethylene diamine, hydroxyethyl
- solubilizers and emulsifiers such as the following non-limiting examples can be used: polyvinyl pyrrolidone, sorbitan fatty acid esters such as sorbitan trioleate, phosphatides such as lecithin, acacia, tragacanth, polyoxyethylated sorbitan monooleate and other ethoxylated fatty acid esters of sorbitan, polyoxyethylated fats, polyoxyethylated oleotriglycerides, linolizated oleotriglycerides, polyethylene oxide condensation products of fatty alcohols, alkylphenols or fatty acids or also 1-methyl-3-(2-hydroxyethyl)imidazolidone-(2).
- solubilizers and emulsifiers such as the following non-limiting examples can be used: polyvinyl pyrrolidone, sorbitan fatty acid esters such as sorbitan trioleate, phosphatides such
- polyoxyethylated means that the substances in question contain polyoxyethylene chains, the degree of polymerization of which generally lies between 2 and 40 and in particular between 10 and 20.
- Polyoxyethylated substances of this kind may for example be obtained by reaction of hydroxyl group-containing compounds (for example mono- or diglycerides or unsaturated compounds such as those containing oleic acid radicals) with ethylene oxide (for example 40 Mol ethylene oxide per 1 Mol glyceride).
- hydroxyl group-containing compounds for example mono- or diglycerides or unsaturated compounds such as those containing oleic acid radicals
- ethylene oxide for example 40 Mol ethylene oxide per 1 Mol glyceride
- oleotriglycerides are olive oil, peanut oil, castor oil, sesame oil, cottonseed oil, corn oil. See also Dr. H. P. Fiedler “Lexikon der Hillsstoffe für Pharmazie, Kostnetik and angrenzende füre” 1971, pages 191-195.
- a liquid dosage form can further comprise preservatives, stabilizers, buffer substances, flavor correcting agents, sweeteners, colorants, antioxidants and complex formers and the like.
- Complex formers which may be for example be considered are: chelate formers such as ethylene diamine retrascetic acid, nitrilotriacetic acid, diethylene triamine pentacetic acid and their salts.
- a liquid dosage form with physiologically acceptable bases or buffers may optionally be necessary to stabilize a liquid dosage form with physiologically acceptable bases or buffers to a pH range of approximately 6 to 9. Preference may be given to as neutral or weakly basic a pH value as possible (up to pH 8).
- ⁇ -, ⁇ - or ⁇ -cyclodextrins or their derivatives in particular hydroxyalkyl substituted cyclodextrins, e.g. 2-hydroxypropyl- ⁇ -cyclodextrin or sulfobutyl- ⁇ -cyclodextrin.
- co-solvents such as alcohols may improve the solubility and/or the stability of the compounds according to the present disclosure in pharmaceutical compositions.
- a disclosed liquid dosage form, a parenteral injection form, or an intravenous injectable form can further comprise liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles, and multilamellar vesicles.
- liposomes can be formed from a variety of phospholipids, such as cholesterol, stearylamine, or phosphatidylcholines.
- compositions of the present disclosure suitable injection, such as parenteral administration, such as intravenous, intramuscular, or subcutaneous administration.
- Pharmaceutical compositions for injection can be prepared as solutions or suspensions of the active compounds in water.
- a suitable surfactant can be included such as, for example, hydroxypropylcellulose.
- Dispersions can also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof in oils. Further, a preservative can be included to prevent the detrimental growth of microorganisms.
- compositions of the present disclosure suitable for parenteral administration can include sterile aqueous or oleaginous solutions, suspensions, or dispersions.
- the compositions can be in the form of sterile powders for the extemporaneous preparation of such sterile injectable solutions or dispersions.
- the final injectable form is sterile and must be effectively fluid for use in a syringe.
- the pharmaceutical compositions should be stable under the conditions of manufacture and storage; thus, preferably should be preserved against the contaminating action of microorganisms such as bacteria and fungi.
- the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g., glycerol, propylene glycol and liquid polyethylene glycol), vegetable oils, and suitable mixtures thereof.
- Injectable solutions for example, can be prepared in which the carrier comprises saline solution, glucose solution or a mixture of saline and glucose solution. Injectable suspensions may also be prepared in which case appropriate liquid carriers, suspending agents and the like may be employed.
- a disclosed parenteral formulation can comprise about 0.01-0.1 M, e.g. about 0.05 M, phosphate buffer. In a further aspect, a disclosed parenteral formulation can comprise about 0.9% saline.
- a disclosed parenteral pharmaceutical composition can comprise pharmaceutically acceptable carriers such as aqueous or non-aqueous solutions, suspensions, and emulsions.
- pharmaceutically acceptable carriers such as aqueous or non-aqueous solutions, suspensions, and emulsions.
- non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate.
- Aqueous carriers include but not limited to water, alcoholic/aqueous solutions, emulsions or suspensions, including saline and buffered media.
- Parenteral vehicles can include mannitol, normal serum albumin, sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's and fixed oils.
- Intravenous vehicles include fluid and nutrient replenishers, electrolyte replenishers such as those based on Ringer's dextrose, and the like. Preservatives and other additives may also be present, such as, for example, antimicrobials, antioxidants, collating agents, inert gases and the like.
- a disclosed parenteral pharmaceutical composition can comprise may contain minor amounts of additives such as substances that enhance isotonicity and chemical stability, e.g., buffers and preservatives.
- Also contemplated for injectable pharmaceutical compositions are solid form preparations that are intended to be converted, shortly before use, to liquid form preparations. Furthermore, other adjuvants can be included to render the formulation isotonic with the blood of the subject or patient.
- the disclosed compounds can also be formulated as a depot preparation.
- Such long acting formulations can be administered by implantation (e.g., subcutaneously or intramuscularly) or by intramuscular injection.
- the compounds can be formulated with suitable polymeric or hydrophobic materials (e.g., as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, e.g., as a sparingly soluble salt.
- compositions of the present disclosure can be in a form suitable for topical administration.
- topical application means administration onto a biological surface, whereby the biological surface includes, for example, a skin area (e.g., hands, forearms, elbows, legs, face, nails, anus and genital areas) or a mucosal membrane.
- a skin area e.g., hands, forearms, elbows, legs, face, nails, anus and genital areas
- a mucosal membrane e.g., a skin area (e.g., hands, forearms, elbows, legs, face, nails, anus and genital areas) or a mucosal membrane.
- a topical pharmaceutical composition can be in a form of a cream, an ointment, a paste, a gel, a lotion, milk, a suspension, an aerosol, a spray, foam, a dusting powder, a pad, and a patch. Further, the compositions can be in a form suitable for use in transdermal devices. These formulations can be prepared, utilizing a compound of the present disclosure, or pharmaceutically acceptable salts thereof, via conventional processing methods. As an example, a cream or ointment is prepared by mixing hydrophilic material and water, together with about 5 wt % to about 10 wt % of the compound, to produce a cream or ointment having a desired consistency.
- the carrier optionally comprises a penetration enhancing agent and/or a suitable wetting agent, optionally combined with suitable additives of any nature in minor proportions, which additives do not introduce a significant deleterious effect on the skin. Said additives may facilitate the administration to the skin and/or may be helpful for preparing the desired compositions.
- These compositions may be administered in various ways, e.g., as a transdermal patch, as a spot-on, as an ointment.
- Ointments are semisolid preparations, typically based on petrolatum or petroleum derivatives.
- the specific ointment base to be used is one that provides for optimum delivery for the active agent chosen for a given formulation, and, preferably, provides for other desired characteristics as well (e.g., emollience).
- an ointment base should be inert, stable, nonirritating and nonsensitizing.
- ointment bases may be grouped in four classes: oleaginous bases; emulsifiable bases; emulsion bases; and water-soluble bases.
- Oleaginous ointment bases include, for example, vegetable oils, fats obtained from animals, and semisolid hydrocarbons obtained from petroleum.
- Emulsifiable ointment bases also known as absorbent ointment bases, contain little or no water and include, for example, hydroxystearin sulfate, anhydrous lanolin and hydrophilic petrolatum.
- Emulsion ointment bases are either water-in-oil (W/O) emulsions or oil-in-water (O/W) emulsions, and include, for example, cetyl alcohol, glyceryl monostearate, lanolin and stearic acid.
- Preferred water-soluble ointment bases are prepared from polyethylene glycols of varying molecular weight.
- Lotions are preparations that are to be applied to the skin surface without friction. Lotions are typically liquid or semiliquid preparations in which solid particles, including the active agent, are present in a water or alcohol base. Lotions are typically preferred for treating large body areas, due to the ease of applying a more fluid composition. Lotions are typically suspensions of solids, and oftentimes comprise a liquid oily emulsion of the oil-in-water type. It is generally necessary that the insoluble matter in a lotion be finely divided. Lotions typically contain suspending agents to produce better dispersions as well as compounds useful for localizing and holding the active agent in contact with the skin, such as methylcellulose, sodium carboxymethyl-cellulose, and the like.
- Creams are viscous liquids or semisolid emulsions, either oil-in-water or water-in-oil.
- Cream bases are typically water-washable, and contain an oil phase, an emulsifier and an aqueous phase.
- the oil phase also called the “internal” phase, is generally comprised of petrolatum and/or a fatty alcohol such as cetyl or stearyl alcohol.
- the aqueous phase typically, although not necessarily, exceeds the oil phase in volume, and generally contains a humectant.
- the emulsifier in a cream formulation is generally a nonionic, anionic, cationic or amphoteric surfactant. Reference may be made to Remington: The Science and Practice of Pharmacy, supra, for further information.
- Pastes are semisolid dosage forms in which the bioactive agent is suspended in a suitable base. Depending on the nature of the base, pastes are divided between fatty pastes or those made from a single-phase aqueous gel.
- the base in a fatty paste is generally petrolatum, hydrophilic petrolatum and the like.
- the pastes made from single-phase aqueous gels generally incorporate carboxymethylcellulose or the like as a base. Additional reference may be made to Remington: The Science and Practice of Pharmacy, for further information.
- Gel formulations are semisolid, suspension-type systems.
- Single-phase gels contain organic macromolecules distributed substantially uniformly throughout the carrier liquid, which is typically aqueous, but also, preferably, contain an alcohol and, optionally, an oil.
- Preferred organic macromolecules, i.e., gelling agents are crosslinked acrylic acid polymers such as the family of carbomer polymers, e.g., carboxypolyalkylenes that may be obtained commercially under the trademark CarbopolTM.
- hydrophilic polymers such as polyethylene oxides, polyoxyethylene-polyoxypropylene copolymers and polyvinylalcohol; modified cellulose, such as hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxypropyl methylcellulose, hydroxypropyl methylcellulose phthalate, and methyl cellulose; gums such as tragacanth and xanthan gum; sodium alginate; and gelatin.
- dispersing agents such as alcohol or glycerin can be added, or the gelling agent can be dispersed by trituration, mechanical mixing or stirring, or combinations thereof.
- Sprays generally provide the active agent in an aqueous and/or alcoholic solution which can be misted onto the skin for delivery.
- Such sprays include those formulated to provide for concentration of the active agent solution at the site of administration following delivery, e.g., the spray solution can be primarily composed of alcohol or other like volatile liquid in which the active agent can be dissolved.
- the carrier evaporates, leaving concentrated active agent at the site of administration.
- Foam compositions are typically formulated in a single or multiple phase liquid form and housed in a suitable container, optionally together with a propellant which facilitates the expulsion of the composition from the container, thus transforming it into a foam upon application.
- Other foam forming techniques include, for example the “Bag-in-a-can” formulation technique.
- Compositions thus formulated typically contain a low-boiling hydrocarbon, e.g., isopropane. Application and agitation of such a composition at the body temperature cause the isopropane to vaporize and generate the foam, in a manner similar to a pressurized aerosol foaming system.
- Foams can be water-based or aqueous alkanolic, but are typically formulated with high alcohol content which, upon application to the skin of a user, quickly evaporates, driving the active ingredient through the upper skin layers to the site of treatment.
- Skin patches typically comprise a backing, to which a reservoir containing the active agent is attached.
- the reservoir can be, for example, a pad in which the active agent or composition is dispersed or soaked, or a liquid reservoir.
- Patches typically further include a frontal water permeable adhesive, which adheres and secures the device to the treated region. Silicone rubbers with self-adhesiveness can alternatively be used. In both cases, a protective permeable layer can be used to protect the adhesive side of the patch prior to its use.
- Skin patches may further comprise a removable cover, which serves for protecting it upon storage.
- Examples of patch configuration which can be utilized with the present invention include a single-layer or multi-layer drug-in-adhesive systems which are characterized by the inclusion of the drug directly within the skin-contacting adhesive.
- the adhesive not only serves to affix the patch to the skin, but also serves as the formulation foundation, containing the drug and all the excipients under a single backing film.
- a membrane is disposed between two distinct drug-in-adhesive layers or multiple drug-in-adhesive layers are incorporated under a single backing film.
- Examples of pharmaceutically acceptable carriers that are suitable for pharmaceutical compositions for topical applications include carrier materials that are well-known for use in the cosmetic and medical arts as bases for e.g., emulsions, creams, aqueous solutions, oils, ointments, pastes, gels, lotions, milks, foams, suspensions, aerosols and the like, depending on the final form of the composition.
- suitable carriers according to the present invention therefore include, without limitation, water, liquid alcohols, liquid glycols, liquid polyalkylene glycols, liquid esters, liquid amides, liquid protein hydrolysates, liquid alkylated protein hydrolysates, liquid lanolin and lanolin derivatives, and like materials commonly employed in cosmetic and medicinal compositions.
- suitable carriers include, without limitation, alcohols, such as, for example, monohydric and polyhydric alcohols, e.g., ethanol, isopropanol, glycerol, sorbitol, 2-methoxyethanol, diethyleneglycol, ethylene glycol, hexyleneglycol, mannitol, and propylene glycol; ethers such as diethyl or dipropyl ether; polyethylene glycols and methoxypolyoxyethylenes (carbowaxes having molecular weight ranging from 200 to 20,000); polyoxyethylene glycerols, polyoxyethylene sorbitols, stearoyl diacetin, and the like.
- alcohols such as, for example, monohydric and polyhydric alcohols, e.g., ethanol, isopropanol, glycerol, sorbitol, 2-methoxyethanol, diethyleneglycol, ethylene glycol, hexyleneglycol, mannito
- Topical compositions of the present disclosure can, if desired, be presented in a pack or dispenser device, such as an FDA-approved kit, which may contain one or more unit dosage forms containing the active ingredient.
- the dispenser device may, for example, comprise a tube.
- the pack or dispenser device may be accompanied by instructions for administration.
- the pack or dispenser device may also be accompanied by a notice in a form prescribed by a governmental agency regulating the manufacture, use, or sale of pharmaceuticals, which notice is reflective of approval by the agency of the form of the compositions for human or veterinary administration.
- Such notice for example, may include labeling approved by the U.S. Food and Drug Administration for prescription drugs or of an approved product insert.
- Compositions comprising the topical composition of the invention formulated in a pharmaceutically acceptable carrier may also be prepared, placed in an appropriate container, and labeled for treatment of an indicated condition.
- Another patch system configuration which can be used by the present invention is a reservoir transdermal system design which is characterized by the inclusion of a liquid compartment containing a drug solution or suspension separated from the release liner by a semi-permeable membrane and adhesive.
- the adhesive component of this patch system can either be incorporated as a continuous layer between the membrane and the release liner or in a concentric configuration around the membrane.
- Yet another patch system configuration which can be utilized by the present invention is a matrix system design which is characterized by the inclusion of a semisolid matrix containing a drug solution or suspension which is in direct contact with the release liner.
- the component responsible for skin adhesion is incorporated in an overlay and forms a concentric configuration around the semisolid matrix.
- compositions of the present disclosure can be in a form suitable for rectal administration wherein the carrier is a solid. It is preferable that the mixture forms unit dose suppositories. Suitable carriers include cocoa butter and other materials commonly used in the art. The suppositories can be conveniently formed by first admixing the composition with the softened or melted carrier(s) followed by chilling and shaping in molds.
- compositions containing a compound of the present disclosure, and/or pharmaceutically acceptable salts thereof, can also be prepared in powder or liquid concentrate form.
- the pharmaceutical composition may be packaged in a variety of ways.
- an article for distribution includes a container that contains the pharmaceutical composition in an appropriate form.
- Suitable containers are well known to those skilled in the art and include materials such as bottles (plastic and glass), sachets, foil blister packs, and the like.
- the container may also include a tamper proof assemblage to prevent indiscreet access to the contents of the package.
- the container typically has deposited thereon a label that describes the contents of the container and any appropriate warnings or instructions.
- the disclosed pharmaceutical compositions may, if desired, be presented in a pack or dispenser device which may contain one or more unit dosage forms containing the active ingredient.
- the pack may for example comprise metal or plastic foil, such as a blister pack.
- the pack or dispenser device may be accompanied by instructions for administration.
- the pack or dispenser may also be accompanied with a notice associated with the container in form prescribed by a governmental agency regulating the manufacture, use, or sale of pharmaceuticals, which notice is reflective of approval by the agency of the form of the drug for human or veterinary administration. Such notice, for example, may be the labeling approved by the U.S. Food and Drug Administration for prescription drugs, or the approved product insert.
- Pharmaceutical compositions comprising a disclosed compound formulated in a compatible pharmaceutical carrier may also be prepared, placed in an appropriate container, and labeled for treatment of an indicated condition.
- the exact dosage and frequency of administration depends on the particular disclosed lithium cholesterol composition, including, but not limited to lithium cholesterol sulfate, or derivative thereof; the particular condition being treated and the severity of the condition being treated; various factors specific to the medical history of the subject to whom the dosage is administered such as the age, weight, sex, extent of disorder and general physical condition of the particular subject, as well as other medication the individual may be taking; as is well known to those skilled in the art. Furthermore, it is evident that said effective daily amount may be lowered or increased depending on the response of the treated subject and/or depending on the evaluation of the physician prescribing the compounds of the present disclosure.
- the pharmaceutical composition will comprise from 0.05 to 99% by weight, preferably from 0.1 to 70% by weight, more preferably from 0.1 to 50% by weight of the active ingredient, and, from 1 to 99.95% by weight, preferably from 30 to 99.9% by weight, more preferably from 50 to 99.9% by weight of a pharmaceutically acceptable carrier, all percentages being based on the total weight of the composition.
- an appropriate dosage level will generally be about 0.01 to 1000 mg per kg patient body weight per day and can be administered in single or multiple doses.
- the dosage level will be about 0.1 to about 500 mg/kg per day, about 0.1 to 250 mg/kg per day, or about 0.5 to 100 mg/kg per day.
- a suitable dosage level can be about 0.01 to 1000 mg/kg per day, about 0.01 to 500 mg/kg per day, about 0.01 to 250 mg/kg per day, about 0.05 to 100 mg/kg per day, or about 0.1 to 50 mg/kg per day.
- the dosage can be 0.05 to 0.5, 0.5 to 5.0 or 5.0 to 50 mg/kg per day.
- the compositions are preferably provided in the form of tablets containing 1.0 to 1000 mg of the active ingredient, particularly 1.0, 5.0, 10, 15, 20, 25, 50, 75, 100, 150, 200, 250, 300, 400, 500, 600, 750, 800, 900 and 1000 mg of the active ingredient for the symptomatic adjustment of the dosage of the patient to be treated.
- the compound can be administered on a regimen of 1 to 4 times per day, preferably once or twice per day. This dosing regimen can be adjusted to provide the optimal therapeutic response.
- Such unit doses as described hereinabove and hereinafter can be administered more than once a day, for example, 2, 3, 4, 5 or 6 times a day.
- such unit doses can be administered 1 or 2 times per day, so that the total dosage for a 70 kg adult is in the range of 0.001 to about 500 mg per kg weight of subject per administration.
- dosage is 0.001 to about 300 mg per kg weight of subject per administration, and such therapy can extend for a number of weeks or months, and in some cases, years.
- the specific dose level for any particular patient will depend on a variety of factors including the activity of the specific compound employed; the age, body weight, general health, sex and diet of the individual being treated; the time and route of administration; the rate of excretion; other drugs that have previously been administered; and the severity of the particular disease undergoing therapy, as is well understood by those of skill in the area.
- a typical dosage can be one 1 mg to about 1000 mg tablet or 1 mg to about 300 mg taken once a day, or, multiple times per day, or one time-release capsule or tablet taken once a day and containing a proportionally higher content of active ingredient.
- the time-release effect can be obtained by capsule materials that dissolve at different pH values, by capsules that release slowly by osmotic pressure, or by any other known means of controlled release.
- the present disclosure is further directed to a method for the manufacture of a medicament comprising an effective amount of lithium cholesterol sulfate for treating a neurological disorder (e.g., treatment of one or more neurological disorders such as neurodegenerative conditions and/or neurodevelopmental disorders, and other disorders, such as bipolar disorder or conditions caused by brain injury) in mammals (e.g., humans) comprising combining one or more disclosed lithium cholesterol compositions, including, but not limited to lithium cholesterol sulfate, products, or compositions with a pharmaceutically acceptable carrier or diluent.
- a neurological disorder e.g., treatment of one or more neurological disorders such as neurodegenerative conditions and/or neurodevelopmental disorders, and other disorders, such as bipolar disorder or conditions caused by brain injury
- mammals e.g., humans
- combining one or more disclosed lithium cholesterol compositions including, but not limited to lithium cholesterol sulfate, products, or compositions with a pharmaceutically acceptable carrier or diluent.
- the present disclosure further relates to a method for manufacturing a medicament comprising combining at least one disclosed lithium cholesterol composition, including, but not limited to lithium cholesterol sulfate, or at least one disclosed product with a pharmaceutically acceptable carrier or diluent.
- compositions can further comprise other therapeutically active compounds, which are usually applied in the treatment of the above mentioned pathological or clinical conditions.
- compositions can be prepared from the disclosed compounds. It is also understood that the disclosed compositions can be employed in the disclosed methods of using.
- the present disclosure relates to a pharmaceutical composition
- a pharmaceutical composition comprising a therapeutically effective amount of a disclosed lithium cholesterol composition, including, but not limited to lithium cholesterol sulfate, a product of a disclosed method of making, and a pharmaceutically acceptable carrier.
- the present disclosure relates to a process for preparing such a pharmaceutical composition, characterized in that a pharmaceutically acceptable carrier is intimately mixed with a therapeutically effective amount of a disclosed lithium cholesterol composition, including, but not limited to lithium cholesterol sulfate, according to the present disclosure.
- the present disclosure also relates to a pharmaceutical composition
- a pharmaceutical composition comprising a disclosed lithium cholesterol composition, including, but not limited to lithium cholesterol sulfate, a product of a disclosed method of making, or a pharmaceutically acceptable derivative thereof, and one or more other drugs in the treatment, prevention, control, amelioration, or reduction of risk of diseases or conditions for a disclosed compound or the other drugs may have utility as well as to the use of such a composition for the manufacture of a medicament.
- the present disclosure also relates to a combination of disclosed lithium cholesterol composition, including, but not limited to lithium cholesterol sulfate, a product of a disclosed method of making, a pharmaceutically acceptable derivative thereof, a polymorph thereof, and an additional therapeutic agent, as a combined preparation for simultaneous, separate or sequential use in the treatment or prevention of a condition in a mammal, including a human, the treatment or prevention of which is affected or facilitated by the modulatory effect of the disclosed compound and the additional therapeutic agent.
- the different drugs of such a combination or product may be combined in a single preparation together with pharmaceutically acceptable carriers or diluents, or they may each be present in a separate preparation together with pharmaceutically acceptable carriers or diluents.
- the present disclosure provides compounds and/or pharmaceutical compositions comprising lithium cholesterol sulfate for use as a medicament.
- This disclosure also provides compounds and pharmaceutical compositions comprising lithium cholesterol sulfate for use in the treatment of a neurological disorder.
- the neurological disorder is selected from the group consisting of: Alzheimer's disease, Autism spectrum disorder (ASD), bipolar disorder, traumatic brain injury, radiation induced brain injury and other neuropsychiatric disorders inducing, but not limited to amyotrophic laterals sclerosis (ALS), Parkinson's disease (PD), depressive disorder, suicidality, schizoaffective disorder, tic disorder (e.g., Tourette's syndrome), etc.
- the disclosure relates to methods of making compounds useful for the treatment for neurodegenerative conditions (such as Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic laterals sclerosis (ALS), and the like), neurodevelopmental disorders (such as Autism spectrum disorders, and the like), traumatic brain injury and acute brain injury (such as caused by ischemic stroke, head trauma, and the like), radiation induced brain injury, mood disorders (such as suicidal ideation, bipolar disorder, depressive disorder), and other neuropsychiatric disorders, including but not limited to schizoaffective disorder, tic disorder (e.g., Tourette's syndrome), and the like.
- the disclosure relates to the disclosed synthetic manipulations.
- the disclosed compositions such as lithium cholesterol compositions, including, but not limited to lithium cholesterol sulfate compositions (LiCS), comprise the products of the synthetic methods described herein.
- the compounds of this disclosure can be prepared by employing reactions as shown in the disclosed schemes, in addition to other standard manipulations that are known in the literature, exemplified in the experimental sections or clear to one skilled in the art. For clarity, examples having a fewer substituent can be shown where multiple substituents are allowed under the definitions disclosed herein. Thus, the following examples are provided so that the disclosure might be more fully understood, are illustrative only, and should not be construed as limiting.
- each disclosed method can further comprise additional steps, manipulations, and/or components. It is also contemplated that any one or more step, manipulation, and/or component can be optionally omitted from the disclosure. It is understood that a disclosed method can be used to provide the disclosed compounds. It is also understood that the products of the disclosed methods can be employed in the disclosed compositions, kits, and uses.
- the disclosed lithium cholesterol compositions included, but not limited to compositions comprising a lithium cholesterol sulfate compound.
- a lithium cholesterol sulfate compound of the present disclosure can be prepared under mild conditions by a dicyclohexylcarbodiimide-mediated sulfation reaction of a hydroxyl moiety as shown immediately below. This type of reaction can be carried out as described in various methods, including, but not limited to, those described by R. O. Mumma (Lipids (1966) 1: 221) and R. O. Mumma, et al.
- Steproids (1969) 14(1):67-74), and the reaction conditions set forth in this exemplary method can be suitably modified by the skilled artisan with regard to reaction amounts and ratios, temperature, time, and specific methods of purification. It should be noted that in the various following reaction schemes, the preparation of a lithium salt in the last step is shown utilizing LiOH, under conditions as generally described in the indicated reference or alternatively, as described S. Natelson, et al. (J. Biol. Chem. 1934, 105:761-765). However, other suitable bases can be used such as lithium carbonate.
- a method of obtaining the disclosed lithium cholesterol sulfate compounds can utilize chlorosulfuric acid comprising a suitable protecting group (indicated as “PG” in the reaction scheme shown below) on the acid group, e.g., an alkyl protecting group such as isobutyl.
- PG protecting group
- Suitable methods such as these are described by L. S. Simpson and T. S. Widlanski (JACS (2006) 128(5):1605-1610), and the reaction conditions set forth in this exemplary method can be suitably modified by the skilled artisan with regard to reaction amounts and ratios, temperature, time, and specific methods of purification.
- the overall reaction is shown below.
- a further alternative sulfation method is as described by H. Noda, et al. (J. Clin. Biochem. Nutr. (1991) 10:83-91) involving reaction of excess cholesterol with sulfur trioxide-pyridine complex, followed by isolation using LiOH instead of NaOH.
- Preparation of lithium cholesterol sulfate from a sodium salt can also be generally carried out as described by S. Natelson, et al. (J. Biol. Chem. 1934, 105:761-765).
- Cholesterol sulfate is commercially available as the sodium salt, and this can be converted to the lithium salt by a variety of methods, including those described by S. Natelson, et al. (J. Biol. Chem. 1934, 105:761-765).
- commercially available sodium cholesterol sulfate can be dissolved in methanol with a molar equivalent of lithium chloride and heated, followed by differential precipitation and filtration to first remove sodium chloride, then with further cooling and addition of water, pure lithium cholesterol sulfate can be crystalizeed and obtained by filtration.
- a lithium cholesterol oxoalkanoate compounds i.e., wherein R is —(C ⁇ O)(CH 2 ) n (C ⁇ O)OLi), where n is an integer having a value of 1, 2, 3, 4, 5, or 6, of the present disclosure
- R is —(C ⁇ O)(CH 2 ) n (C ⁇ O)OLi)
- n is an integer having a value of 1, 2, 3, 4, 5, or 6, of the present disclosure
- a lithium cholesterol phosphate compounds of the present disclosure can be prepared by reaction of cholesterol with a suitable cyclic dicarboxylic anhydride essentially as described by S. C. Davis and F. C. Szoka, Jr. (Bioconj. Chem. (1998) 9:783-792), and the reaction conditions set forth in this exemplary method can be suitably modified by the skilled artisan with regard to reaction amounts and ratios, temperature, time, and specific methods of purification. A generalized reaction approach is shown immediately below.
- a lithium cholesterol carboxylate compounds i.e., wherein R is —(CH 2 ) n (C ⁇ O)OLi), where n is an integer having a value of 1, 2, 3, 4, 5, or 6, of the present disclosure can be prepared as generally described in U.S. Pat. Publ. No. 2015/0018436 for acids of general formula IX therein.
- the lithium cholesterol carboxylate compounds i.e., wherein R is —(CH 2 ) n (C ⁇ O)OLi), where n is an integer having a value of 1, 2, 3, 4, 5, or 6, of the present disclosure can be prepared base catalyzed alkylation of cholesterol by tert-butylester of ⁇ -bromoalkane acids having C 2 -C 13 carbon atoms in an aprotic solvent followed by acidic cleavage (preferably using formic acid in diethylether) of the obtained tert-butylesters.
- the lithium cholesterol carboxylate compounds i.e., wherein R is —(CH 2 ) n (C ⁇ O)OLi), where n is an integer having a value of 1, 2, 3, 4, 5, or 6, of the present disclosure can be prepared by O-tosylation of cholesterol using standard techniques, followed by reaction w-hydroxyalkanenitriles having C 2 -C 6 carbon atoms in a nonpolar aprotic solvent at increased temperature (prefer-ably in boiling toluene) followed by basic hydrolysis (preferably in a mixture of toluene and aqueous solution of NaOH at elevated temperature) of the intermediary O-[(3 ⁇ )-cholest-5-en-3-yl]- ⁇ -hydroxyalkanenitrile.
- the present disclosure provides methods of treatment comprising administration of a therapeutically effective amount of a disclosed lithium cholesterol composition, including, but not limited to lithium cholesterol sulfate, or pharmaceutical composition as disclosed herein above to a subject in need thereof.
- a subject in need of treatment with the lithium cholesterol composition, including, but not limited to lithium cholesterol sulfate, or pharmaceutical compositions of the present disclosure can include, but are not necessarily limited to, subjects in need of treatment for neurodegenerative conditions (such as Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic laterals sclerosis (ALS), and the like), neurodevelopmental disorders (such as Autism spectrum disorders, and the like), traumatic brain injury and acute brain injury (such as caused by ischemic stroke, head trauma, and the like), radiation induced brain injury, mood disorders (such as suicidal ideation, bipolar disorder, depressive disorder), and other neuropsychiatric disorders, including but not limited to schizoaffective disorder, tic disorder (e.g., Tourette's syndrome), and the
- methods of the present disclosure include treatment of a patient in need of treatment for Alzheimer's disease, bipolar disorder, or autism spectrum disorder with a therapeutically effective amount of a lithium cholesterol composition, including, but not limited to lithium cholesterol sulfate, or lithium cholesterol composition, including, but not limited to lithium cholesterol sulfate, pharmaceutical composition of the present disclosure.
- a lithium cholesterol composition including, but not limited to lithium cholesterol sulfate, or lithium cholesterol composition, including, but not limited to lithium cholesterol sulfate, pharmaceutical composition of the present disclosure.
- methods of the present disclosure also include increasing levels of inhibitory phosphorylation of GSK3 ⁇ in cells or in a subject by exposing the cells or subject to an effective amount of a lithium cholesterol composition, including, but not limited to lithium cholesterol sulfate, or a lithium cholesterol composition, including, but not limited to lithium cholesterol sulfate, pharmaceutical composition of the present disclosure.
- methods of the present disclosure include decreasing levels of phosphorylation of tau in cells or in a subject by exposing the cells or subject to an effective amount of a lithium cholesterol composition, including, but not limited to lithium cholesterol sulfate, or a lithium cholesterol composition, including, but not limited to lithium cholesterol sulfate, pharmaceutical composition of the present disclosure.
- methods of the present disclosure include decreasing levels of LPS-induced TNF ⁇ in cells or in a subject by exposing the cells or subject to an effective amount of a lithium cholesterol composition, including, but not limited to lithium cholesterol sulfate, or a lithium cholesterol composition, including, but not limited to lithium cholesterol sulfate, pharmaceutical composition of the present disclosure.
- a lithium cholesterol composition including, but not limited to lithium cholesterol sulfate, or a lithium cholesterol composition, including, but not limited to lithium cholesterol sulfate, pharmaceutical composition of the present disclosure.
- Embodiments of the present disclosure also include a combination of one or more of increasing levels of inhibitory phosphorylation of GSK3 ⁇ , decreasing levels of phosphorylation of tau, and/or decreasing levels of LPS-induced TNF ⁇ in cells or in a subject by exposing the cells or subject to an effective amount of a lithium cholesterol composition, including, but not limited to lithium cholesterol sulfate, or lithium cholesterol composition, including, but not limited to lithium cholesterol sulfate, pharmaceutical composition of the present disclosure.
- a lithium cholesterol composition including, but not limited to lithium cholesterol sulfate, or lithium cholesterol composition, including, but not limited to lithium cholesterol sulfate, pharmaceutical composition of the present disclosure.
- administration of the pharmaceutical compositions including lithium cholesterol sulfate increases the lithium levels in the brain such that a subject has a greater brain to blood lithium level ratio than the brain to blood lithium level in a subject administered lithium chloride. Also, in methods of the present disclosure, administration of the pharmaceutical compositions including lithium cholesterol sulfate does not substantially increase lithium levels in the liver or kidney of the subject.
- the methods of the present disclosure may further comprise administering an additional therapeutic and/or active agent for treating the neurological disorder before, during, or after the administration of the lithium cholesterol composition.
- the additional agent may be administered to the subject in the same composition as the lithium cholesterol composition or in separate compositions administered by the same or different anatomical routes. Accordingly, the compositions of the disclosure discussed above may include one or more such additional agents as well.
- the additional agent is an anti-depressant, anti-convulsant, or mood stabilizer, or a combination of two or more of the foregoing.
- the additional agent is a selective serotonin reuptake inhibitor (SSRI), serotonin-noroepinephrine reuptake inhibitor (SNRI), serotonin antagonist and reuptake inhibitor (SARI), monamine oxidase inhibitor (MAOI), carboxamide, fructose derivative, triazine, or a combination of two or more of the foregoing.
- the disorder is a neurodegenerative disease such as Alzheimer's disease
- the additional agent is selected from the group consisting of a cholinesterase inhibitor (e.g., donepezil, rivastigmine, galantamine), N-methyl D-aspartate antagonist (e.g., memantine), or vitamin E, or a combination.
- the additional agent is donepezil, rivastigmine, galantamine, memantine, or a combination of two or more of the foregoing.
- kits comprising a disclosed lithium cholesterol sulfate compound, or a pharmaceutically composition comprising lithium cholesterol composition, including, but not limited to lithium cholesterol sulfate, and instructions for administering the compound to treat a neurological disorder.
- the kit may further contain additional instructions for combining the pharmaceutical composition comprising lithium cholesterol composition, including, but not limited to lithium cholesterol sulfate, with additional components and/or additional therapeutic agents and administration of the composition to a subject to treat a neurological disorder.
- kits whereby two or more components, which may be active or inactive ingredients, carriers, diluents, and the like, are provided with instructions for preparation of the actual dosage form by the patient or person administering the drug to the patient.
- Such kits may be provided with all necessary materials and ingredients contained therein, or they may contain instructions for using or making materials or components that must be obtained independently by the patient or person administering the drug to the patient.
- a kit can include optional components that aid in the administration of the unit dose to patients, such as vials for reconstituting powder forms, syringes for injection, customized IV delivery systems, inhalers, etc.
- kits can contain instructions for preparation and administration of the compositions.
- the kit can be manufactured as a single use unit dose for one patient, multiple uses for a particular patient (at a constant dose or in which the individual compounds may vary in potency as therapy progresses); or the kit may contain multiple doses suitable for administration to multiple patients (“bulk packaging”).
- the kit components may be assembled in cartons, blister packs, bottles, tubes, and the like.
- the disclosed kits can be packaged in a daily dosing regimen (e.g., packaged on cards, packaged with dosing cards, packaged on blisters or blow-molded plastics, etc.). Such packaging promotes products and increases patient compliance with drug regimens. Such packaging can also reduce patient confusion.
- the present invention also features such kits further containing instructions for use.
- the present disclosure also provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the pharmaceutical compositions of the invention.
- a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the pharmaceutical compositions of the invention.
- Associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration.
- kits can also comprise compounds and/or products co-packaged, co-formulated, and/or co-delivered with other components.
- a drug manufacturer, a drug reseller, a physician, a compounding shop, or a pharmacist can provide a kit comprising a disclosed compound and/or product and another component for delivery to a patient.
- the kit further includes at least one additional therapeutic agent for treatment of the neurological disorder.
- the neurological disorder can include neurodegenerative conditions, such as, but not limited to Alzheimer's disease, Parkinson's disease, and myotrophic laterals sclerosis (ALS); neurodevelopmental disorders, such as, but not limited to Autism spectrum disorders; traumatic brain injury, radiation induced brain injury, and acute brain injury, such as but not limited to, neurological injury caused by ischemic stroke, head trauma, and the like; mood disorders, such as but not limited to suicidal ideation, bipolar disorder, and depressive disorder; and other neuropsychiatric disorders, including but not limited to schizoaffective disorder, tic disorder (e.g., Tourette's syndrome).
- ALS myotrophic laterals sclerosis
- neurodevelopmental disorders such as, but not limited to Autism spectrum disorders
- traumatic brain injury, radiation induced brain injury, and acute brain injury such as but not limited to, neurological injury caused by ischemic stroke, head trauma, and the like
- mood disorders such as but not
- the additional agent is an anti-depressant, anti-convulsant, or mood stabilizer, or a combination of two or more of the foregoing.
- the additional agent is a selective serotonin reuptake inhibitor (SSRI), serotonin-noroepinephrine reuptake inhibitor (SNRI), serotonin antagonist and reuptake inhibitor (SARI), monamine oxidase inhibitor (MAOI), carboxamide, fructose derivative, triazine, or a combination of two or more of the foregoing.
- the disorder is a neurodegenerative disease such as Alzheimer's disease
- the additional agent is selected from the group consisting of a cholinesterase inhibitor (e.g., donepezil, rivastigmine, galantamine), N-methyl D-aspartate antagonist (e.g., memantine), or vitamin E, or a combination.
- the additional agent is donepezil, rivastigmine, galantamine, memantine, or a combination of two or more of the foregoing.
- kits can be used in connection with the disclosed methods of making, the disclosed methods of using or treating, and/or the disclosed compositions.
- the disclosed compounds and pharmaceutical compositions have activity as activators/inhibitors of biomarkers associated with various neurological disorders.
- the lithium cholesterol sulfate compounds and pharmaceutical compositions of the present disclosure have activity as activating/increasing levels of inhibitory phosphorylation of GSK3 ⁇ , as inhibiting/decreasing levels of phosphorylation of tau, and inhibiting/decreasing levels of LPS-induced TNF ⁇ .
- the examples below demonstrate these effects in particular as compared to the levels of said compounds in a subject not receiving treatment with the lithium cholesterol composition, including, but not limited to lithium cholesterol sulfate, and/or pharmaceutical compositions or as compared to a subject or cells receiving treatment with a different lithium salt compounds, such as LiCl.
- one aspect of the present disclosure relates to a method of using a lithium cholesterol composition, including, but not limited to lithium cholesterol sulfate, of the disclosure as a research tool, the method comprising conducting a biological assay using a lithium cholesterol composition, including, but not limited to lithium cholesterol sulfate, of the invention.
- Compounds of the invention can also be used to evaluate new chemical compounds.
- Another aspect of the invention relates to a method of evaluating a test compound in a biological assay, comprising: (a) conducting a biological assay with a test compound to provide a first assay value; (b) conducting the biological assay with a compound of the invention to provide a second assay value; wherein step (a) is conducted either before, after or concurrently with step (b); and (c) comparing the first assay value from step (a) with the second assay value from step (b).
- Exemplary biological assays include, but are not limited to, a GSK3 ⁇ activator assay, a tau phosphorylation inhibitor assay, and/or a LPS-induced TNF ⁇ inhibitor assay that can be conducted in vitro or in a cell culture system.
- Still another aspect of the invention relates to a method of studying a biological system, e.g., a model animal for a clinical condition, or biological sample.
- ratios, concentrations, amounts, and other numerical data may be expressed herein in a range format. It is to be understood that such a range format is used for convenience and brevity, and thus, should be interpreted in a flexible manner to include not only the numerical values explicitly recited as the limits of the range, but also to include all the individual numerical values or sub-ranges encompassed within that range as if each numerical value and sub-range is explicitly recited.
- a concentration range of “about 0.1% to about 5%” should be interpreted to include not only the explicitly recited concentration of about 0.1 wt % to about 5 wt %, but also include individual concentrations (e.g., 1%, 2%, 3%, and 4%) and the sub-ranges (e.g., 0.5%, 1.1%, 2.2%, 3.3%, and 4.4%) within the indicated range.
- the term “about” can include traditional rounding according to significant figures of the numerical value.
- the phrase “about ‘x’ to ‘y’” includes “about ‘x’ to about ‘y’”.
- the present example describes the synthesis of a disclosed lithium salt, lithium cholesterol sulfate (LiCS) ( FIG. 1 ) and its therapeutic potential. This example also provides a comparison of the pharmacological effects of LiCS with that of lithium chloride (LiCl) and sodium cholesterol sulfate (NaCS) on markers of neurodegenerative disease in cell cultures.
- LiCS lithium cholesterol sulfate
- LiCS proved more potent than LiCl in increasing inhibitory GSK3 ⁇ (Ser9) phosphorylation (pGSK3 ⁇ ) in both CHO and SH-SY5Y cells.
- LiCS reduced tau (Thr231) phosphorylation (ptau) starting at 10 ⁇ M and maximally by 63% at 40 ⁇ M without altering total tau levels, but ptau levels were not altered by LiCl at any dose between 60 ⁇ M and 1.25 mM.
- LiCS and LiCl decreased LPS-induced TNF ⁇ levels, starting at 20 ⁇ M for LiCS and 5 mM for LiCl, and maximally by approximately 30% at 80 ⁇ M for LiCS and 20 mM for LiCl. NaCS at any dose between 5 and 90 ⁇ M did not alter pGSK3 ⁇ , ptau or LPS-induced TNF ⁇ .
- LiCS represents a new pharmaceutical compound with potent pharmacodynamics for treatment of AD and ASD.
- Lithium cholesterol sulfate (LiCS, 96%) was synthetized by New England Discovery Partners (USF) using variations of procedures for sulfating molecules (22, 23, incorporated by reference herein). Specifically, LiCS was synthesized as generally described in FIG. 1A .
- LiCS and lithium chloride were dissolved in methanol at 250 mM, and sodium cholesterol sulfate (NaCS, ⁇ 98.0%, Millipore Sigma) was dissolved in methanol at 100 mM.
- LPS (Millipore Sigma) was diluted in Dulbecco's Modified Eagle's Medium (DMEM) at 10 ⁇ g/ml.
- Mouse TNF ⁇ uncoated ELISA Kit was purchased from Thermo Fisher Scientific (Waltham, Mass.).
- Primary antibodies include anti-pGSK3 ⁇ (Ser9) and anti-total GSK3 ⁇ (Thermo Fisher Scientific), anti-p-tau (Thr231) and anti-total tau (tau12, Millipore Sigma).
- the secondary antibodies used were anti-rabbit Ig G and anti-mouse Ig G, respectively (Millipore Sigma).
- SH-SY5Y cells (ATCC, Manassas, Va.) were cultured in DMEM/Nutrient Mixture F-12 (DMEM/F-12), 10% fetal bovine serum (FBS) and 15 mM HEPES.
- DMEM/F-12 DMEM/Nutrient Mixture F-12
- FBS fetal bovine serum
- Chinese Hamster Ovary cells (CHO, Millipore Sigma), human embryonic kidney 293 cells expressing wild-type tau (HEK293/tau cells, ATCC) and mouse BV2 microglial cells (Creative Bioarray, Shirley, N.Y.) were cultured in DMEM with 10% FBS.
- SH-SY5Y cells and CHO cells were cultured in 24-well plates at a density of 2.5 ⁇ 10 5 cells/well.
- HEK293/tau cells were cultured in 24-well plates at a density of 3.5 ⁇ 10 5 cells/well, after being treated with Tetracycline (1:1000) for about 24 h to create high
- Cells were treated with LiCS or NaCS at 0, 5, 10, 20, 40, 60 or 90 ⁇ M or LiCl at 0, 0.06, 0.15, 0.3, 0.6, 1.2 and 2.5 mM for 18 hours, followed by washing with ice-cold PBS 3 ⁇ , lysis with cell lysis buffer and centrifugation at 1.4 ⁇ 10 4 rpm for 20 minutes. The supernatants were then used for analysis of GSK3 ⁇ (Ser 9 ) and tau (Thr 231 ) phosphorylation by Western Blot (WB) and WB bands were calculated by Image J software (Java 1.6.0_20, NIH, USA).
- Microglial cells (3.5 ⁇ 10 5 /well) were treated with LPS at 100 ng/mL in the presence of LiCS, NaCS or LiCl at increasing concentrations for 3 hours, followed by analysis of TNF ⁇ levels in conditioned media by ELISA according to the manufacturer's instructions.
- LiCS LiCS was synthesized, and its pharmacological effects on three biomarkers of the conditions—(GSK3 ⁇ (Ser 9 ) phosphorylation, tau (Thr 231 ) phosphorylation, and LPS-induced TNF ⁇ production)—were determined and compared with that of LiCl and NaCS in cell cultures.
- pGSK3 ⁇ inhibitory GSK3 ⁇
- pGSK3 ⁇ inhibitory GSK3 ⁇
- LiCS increased pGSK3 ⁇ starting at 10 ⁇ M and maximally by 92% at 60 ⁇ M.
- LiCl increased pGSK3 ⁇ starting at 160 ⁇ M and maximally by 91% at 1.25 mM ( FIGS. 2A, 2B & 2E ).
- LiCS increased pGSK3 ⁇ starting at 10 ⁇ M and maximally by 90% at 90 ⁇ M
- LiCl increased pGSK3 ⁇ starting at 60 ⁇ M and maximally by 119% at 2.5 mM
- NaCS at 5-90 ⁇ M did not alter pGSK3 ⁇
- neither LiCS, LiCl nor NaCS altered total GSK3 ⁇ at any dose.
- LiCS is approximately 21-28 fold more potent than LiCl in increasing inhibitory GSK3 ⁇ (Ser 9 ) phosphorylation.
- LiCS maximally while LiCl minimally increased pGSK3 ⁇ levels.
- LiCS dose-dependently decreased tau (Thr231) phosphorylation (ptau) in HEK293/tau cells.
- LiCS decreased ptau starting at 10 ⁇ M and maximally by 63% at 40 ⁇ M ( FIGS. 3A & 3D ).
- neither LiCl at any dose between 60 ⁇ M and 1.25 mM nor NaCS at any dose between 5 and 60 ⁇ M altered ptau, and neither LiCS, NaCS nor LiCl at any dose altered total tau ( FIGS. 3B & 3C ).
- LiCS reduces tau phosphorylation at micromolar levels, while LiCl is ineffective even at millimolar levels.
- BV2 mouse microglial cells
- LPS lipopolysaccharides
- LiCS LiCl
- LiCl increased inhibitory GSK3 ⁇ (Ser9) phosphorylation (pGSK3 ⁇ ) in a dose-dependent fashion in CHO and SH-SY5Y cells
- pGSK3 ⁇ inhibitory GSK3 ⁇
- LiCl required high micromolar and low millimolar levels
- FIGS. 2A-2F LiCS was 21-28 fold more potent than LiCl.
- LiCS did not alter tau phosphorylation at even millimolar levels ( FIG. 3C ), in HEK293/tau cells.
- LiCS was approximately 250 fold more potent than LiCl for reducing LPS-induced TNF ⁇ production ( FIG. 4 ).
- NaCS at any dose between 5 and 90 ⁇ M failed to alter pGSK3 ⁇ ( FIGS. 2A and 2C ), ptau ( FIG. 3B ), or LPS-induced TNF ⁇ ( FIG. 4 ).
- LiCS modulates important markers of AD and ASD and thus provides a novel and effective treatment for AD, ASD and other related neurodegenerative diseases.
- Lithium as a mood stabilizer has been used in the standard pharmacological treatment of bipolar disorder (BD) for more than 60 years (11, 12). It remains to be recommended by many treatment guidelines as the first-line treatment for acute mania, and prophylactically for recurrent manic and depressive episodes. Lithium can help prevent suicide and is associated with a lower risk for all-cause mortality in patients with mood disorders (11, 12). In recent years, there have appeared many experimental studies describing new effects of lithium for treatment of neurodegenerative diseases such as AD (13, 14), ASD (7, 15, 16), Parkinson's disease (PD) (25, 26), stroke and spinal cord injury (27, 28).
- AD neurodegenerative diseases
- PD Parkinson's disease
- stroke and spinal cord injury 27, 28.
- hNT neurons tyrosine hydroxylase (TH) activity, the rate limiting enzyme in the synthesis of dopamine (25).
- TH tyrosine hydroxylase
- hNT neurons brief exposure of hNT neurons to lithium increases cell survival, TH expression and fibre outgrowth after transplantation into the striatum of hemiparkinsonian rats.
- recent studies suggest that lithium treatment may also be effective for peripheral disorders such as atherosclerosis and ischemic coronary disease, which may be mediated in part by suppression of MMP-9 gene expression in macrophages (29, 30). Inhibition of MMP-9 by lithium may help maintain the BBB, since toxic free radicals can disrupt the BBB via increased activity of MMP (31, 32).
- lithium has been suggested to be beneficial for treatment of granulocytopenia resulting from radiation and chemotherapy, to boost immunoglobulins after vaccination and enhance natural killer cell activity (27).
- Lithium may also increase gut microbial richness and diversity, which can play an important role in its therapeutic effectiveness for neurodegenerative diseases (33). Therefore, lithium salts represent potential drugs for the treatment of diverse central and peripheral diseases.
- lithium is formulated in lithium salts.
- Lithium carbonate is usually applied in the clinic, but other lithium salts such as lithium citrate, lithium sulfate, lithium orotate and lithium chloride, are also sometimes used as alternatives. All conventional lithium salt treatments require frequent monitoring of blood chemistry and plasma lithium levels so as to avoid toxicity, which may discourage patients from choosing these drugs. For this reason, some novel lithium salts such as lithium carbonate sustained-release tablets or controlled-release tablets have been developed. Remarkably, recent studies from our laboratory have also found that different lithium salts can have profoundly different pharmacokinetic effects depending on the associated anion. For example, treatment with lithium salicylate produced longer elevated plasma lithium levels with a slower elimination process compared with lithium lactate treatment in rats (34).
- LISPRO a novel ionic co-crystal of lithium salicylate and L-proline, produced significantly higher brain lithium levels and more steady plasma lithium levels compared with lithium carbonate or lithium salicylate in mice (35) and rats (36).
- Long term oral administration of LISPRO reduced AD pathology, including ⁇ -amyloid plaques, tau hyperphosphorylation, neuroninflammation, neuronal and synaptic protein loss and GSK3 ⁇ activity, without eliciting renal inflammation, in Tg2576 and 3XTg AD mice models (35).
- LISPRO might be a superior form of lithium with improved safety and efficacy as a potentially new disease modifying therapeutic for AD.
- continued exploration of ways to improve lithium's therapeutic profile lent to the surprising discovery of the improved potency and safety of the novel lithium salts of the present disclosure.
- Cholesterol sulfate was first isolated from human plasma in 1965 and found to be present in a concentration of 300 ⁇ g/100 ml (37), thus being one of the most abundant sterol sulfates in the plasma.
- cholesterol sulfate is a normal constituent in a variety of human tissues including cell membranes, platelets and red blood cells (18).
- the sulfate moiety of cholesterol sulfate has a pKa of 3.3, indicating that it is normally ionized under physiologic conditions (18).
- the sulfoconjugation of cholesterol results in the conversion of a rather rigid hydrophobic molecule into a very amphiphilic compound containing a highly charged subgroup.
- the hydrophobic/hydrophilic property of cholesterol sulfate represents an important characteristic underlying its biologic action and making it better suited for interactions with membrane constituents.
- the rate of intermembrane exchange for cholesterol sulfate was found to be approximately 10-fold faster than for cholesterol in all liposomes tested (38).
- cholesterol sulfate can be considered to be a potent thermosensitizer, which enhances the selectivity of biological drug carriers (39).
- cholesterol sulfate was tested as a carrier for lithium in the development of a novel lithium salt, LiCS. It was discovered that the use of LiCS may allow lithium to more easily pass through the cell membrane as well as intestinal and blood brain barriers after peripheral or oral administration, thereby allowing it to more readily target intracellular pathological processes than clinically available lithium chloride.
- AD Alzheimer's disease
- ASD Autism spectrum disorder
- LiCS represents a new treatment option with good pharmacological potential for treatment of neurodegenerative disorders such as AD and ASD by allowing lithium to more readily access intracellular pathological processes. Additional studies described in the examples below using animal models further explore its pharmacokinetic, pharmacodynamics and therapeutic potential.
- LISPRO lithium cocrystal
- LISPRO lithium cocrystal
- LISPRO reduced AD pathology in two AD mouse models, Tg2576 and 3XTg-AD.
- LISPRO reduced AD-related behavioral impairment
- Cholesterol is present in all cellular membranes, where its supports proper structure and function. The brain contains about 25% of the body's cholesterol and is essential for synaptic function. Cholesterol sulfate a quantitatively important sterol sulfate in human plasma.
- Cholesterol sulfate is also a normal constituent in a variety of human tissues including skin, hair, nails, aorta, adrenal, liver, and kidney.
- the highest level of cholesterol sulfate in the rat brain occurred in subcellular fraction rich in nerve endings. It stabilizes cell membranes, regulates the activity of serine proteases and protein kinase C, such as those involved in blood clotting, fibrinolysis, epidermal cell adhesion and barrier formation, and is a substrate for the synthesis of neurosteroids, such as pregnenolone, DHEA, estrogen and testosterone sulfate.
- cholesterol sulfate Sulfoconjugation of cholesterol results in the conversion of a rather rigid hydrophobic molecule into a very amphiphilic compound containing a highly charged subgroup.
- the hydrophobic/hydrophilic property of cholesterol sulfate represents an important characteristic in its biologic action. This aspect of the structure of cholesterol sulfate makes it a candidate for interactions with membrane constituents as well as absorption and transport freely into the blood stream and across the blood brain barrier.
- LiCS LiCS was first synthesized by collaboration with New England Discovery Partners (NEDP) as described above in Example 1 ( FIG. 1 ). The preparations and purity of the final product were confirmed by mass spectrometry.
- NEDP New England Discovery Partners
- Blood and tissue lithium ELISA At 0.5, 1, 2, 3, 5 and 24 h after treating mice with LiCl or LiCS p.o. by gavage, mice were anesthetized with isoflourane (50 mg/kg) (Sigma-Aldrich), euthanized by bilateral thoracotomy, and blood was collected. Brain, kidney, and liver were harvested, homogenized in 400 ⁇ L ddH2O with Minilys tissue homogenizer (Bertin Technologies, Montigny-le-Bretonneux, France), and centrifuged for 30 min.
- Lithium levels in plasma and supernatants from brain, kidney, and liver homogenates were determined by ELISA (Biovision, Milpitas, Calif.) following the manufacturer's instructions. Plasma, brain, kidney and liver homogenates from control mice were used to generate standard curve.
- Lithium levels in the blood increased between 0.5 and 5 h after LiCl and between 0.5 and 24 h after LiCS treatment.
- lithium levels in the brain increased at 5 h after LiCl and at 0.5 and 5 h after LiCS treatment ( FIG. 5B )
- lithium levels in the kidney increased at 0.5 and 5 h after LiCl but failed to increase at any time after LiCS treatment ( FIG. 5B ).
- Lithium levels in the liver failed to increase at any time after LiCl or LiCS treatment ( FIG. 5B ).
- Lithium ELISA results are presented as the mean ( ⁇ s.d.). Asterisk indicates P ⁇ 0.05 versus LiCl treatment as determined by ANOVA.
- LiCS Lithium salts have been used in psychiatry to treat bipolar disorder for many years and are now still considered as a first-line therapy for acute and long-term treatment of bipolar disorder. In recent years, lithium has also been shown to be a potential therapeutic for other neurodegenerative diseases, such as Alzheimer's disease (AD) and autism (ASD).
- CS has a hydrophobic/hydrophilic property which is well-suited for interaction with membrane constituents and present results demonstrate CS as a suitable carrier for the delivery of drugs across the intestinal and blood brain barriers.
- CS a normal constituent of a variety of human tissues, may also be beneficial in the treatment of AD and ASD, as well as other diseases potentially resulting from sulfur shortage, including eczema and asthma.
- the results from the present examples demonstrate that LiCS appears particularly beneficial for treating neurodegenerative disease.
Abstract
In one aspect, the disclosure relates to compositions of lithium cholesterol compositions, including but not limited to lithium cholesterol sulfate compositions which are useful as therapeutic agents. The disclosure also relates to methods of making lithium cholesterol compositions and pharmaceutical compositions comprising therapeutically effective amounts of the lithium cholesterol compositions. The present disclosure also includes methods of treating one or more clinical neurological conditions with the lithium cholesterol compositions, such as Alzheimer's disease, autism spectrum disorder, bipolar disorder, or other neuropsychiatric disorders.
Description
- This application is a Divisional of U.S. Utility application entitled “Lithium Cholesterol Compositions, Including, But Not Limited To Lithium Cholesterol Sulfate Compositions, and Methods of Treatment for Alzheimer's Disease and Neurological Disorders,” having Ser. No. 16/432,367, filed on Jun. 5, 2019, which claims the benefit of U.S. Provisional application entitled “Use of the lithium salt of cholesterol sulfate (LCS) for preventing and treating Alzheimer's disease, suicidal ideation, bipolar disorder, traumatic brain injury, radiation induced brain injury, and autism,” having Ser. No. 62/752,251, filed on Oct. 29, 2018, which is incorporated herein by reference in its entirety.
- Alzheimer's disease (AD), a progressive neurodegenerative disease represents the main cause of dementia and one of the great health-care challenges of the 21st century. AD causes severe distress for patients and their caregivers and results in a large societal economic burden. While AD is neurodegenerative, Autism spectrum disorder (ASD), is neurodevelopmental disorder afflicting up to 20 out of 100 children aged 6-17 in the United States (8). The cause of autism appears to be primarily genetic, but recent studies also indicate the presence of a strong inflammatory state associated with ASD (9).
- Lithium salts, long used in psychiatry to treat bipolar disorder, are still considered as a first-line therapy for both the acute and long-term treatment of bipolar disorder (11). Recent studies demonstrated neuroprotective effects of lithium salts, including preventing apoptosis and increasing neurotrophins and other cell-survival molecules (12). Beneficial effects of lithium salts on neurogenesis, angiogenesis, inflammation, and other neurological functions have been revealed, indicating the possible use of lithium salts in the treatment of AD and related neurological disorders (13). Unfortunately, despite the long use of lithium salts in the treatment of bipolar disorder, there remain drawbacks to the use of the current, clinically available lithium salts. Concerns such as potential for toxicity, need for monitoring of side effects, and patient compliance limit the use of currently available lithium salts for broader treatment of neurological conditions.
- In accordance with the purpose(s) of the disclosure, as embodied and broadly described herein, the disclosure, in various aspects, relates to lithium cholesterol compounds and compositions, pharmaceutical compositions including therapeutically effective amounts of lithium cholesterol compositions, kits including lithium cholesterol pharmaceutical compositions, and methods of using the pharmaceutical compositions including lithium cholesterol compounds for the treatment of a neurological disorder.
- Pharmaceutical compositions of the present disclosure, in various aspects, comprise a therapeutically effective amount of a lithium cholesterol composition, and a pharmaceutically acceptable carrier; wherein the lithium cholesterol composition has a structure having the formula:
- where R is selected from —SO4Li, —PO3(Li)2, —(CH2)n(C═O)OLi, or —(C═O)(CH2)n(C═O)OLi, where n is integer selected from 1, 2, 3, 4, 5, and 6. In embodiments of the pharmaceutical compositions of the present disclosure, the lithium cholesterol composition is selected from a structure having the formula:
- and combinations thereof. In some embodiments, lithium cholesterol composition is a lithium cholesterol sulfate structure having the formula:
- The present disclosure also provides, in various aspects, kits comprising a lithium cholesterol pharmaceutical composition of the present disclosure and instructions for administering the compound to treat a neurological disorder. In embodiments, the kits also include at least one additional therapeutic agent for treatment of the neurological disorder and instructions for administering the additional therapeutic agent with the lithium cholesterol pharmaceutical composition.
- Also provided are methods of treatment for a neurological disorder by administering to a subject in need of treatment for a neurological disorder a therapeutically effective amount of a pharmaceutical composition comprising a therapeutically effective amount of a lithium cholesterol composition, and a pharmaceutically acceptable carrier; wherein the lithium cholesterol composition has a structure having the formula:
- where R is selected from —SO4Li, —PO3(Li)2, —(CH2)n(C═O)OLi, or —(C═O)(CH2)n(C═O)OLi, where n is integer selected from 1, 2, 3, 4, 5, and 6. In embodiments, the neurological disorder is selected from: Alzheimer's disease, autism spectrum disorder (ASD), Parkinson's disease, suicidal ideation, bipolar disorder, mood disorders, traumatic brain injury, radiation induced brain injury, amyotrophic laterals sclerosis, schizoaffective disorder, and tic disorder. In embodiments of the methods of the present disclosure, administration of the pharmaceutical composition produces one or more of the following effects in the subject: increasing levels of inhibitory phosphorylation of GSK3β, decreasing levels of phosphorylation of tau, and decreasing levels of LPS-induced TNFα, as compared to the levels of said compounds in a subject not receiving treatment with the pharmaceutical composition. In embodiments, administration of the pharmaceutical composition produces a greater brain to blood lithium level ratio in the subject than administration of lithium chloride and/or does not substantially increase lithium levels in the liver or kidney of the subject.
- In a further aspect, the disclosed compositions comprise a compound produced by a synthetic method described herein. In a still further aspect, the present disclosure comprises a method for manufacturing a medicament comprising combining at least one product of the disclosed methods with a pharmaceutically acceptable carrier or diluent.
- Other systems, methods, features, and advantages of the present disclosure will be or will become apparent to one with skill in the art upon examination of the following drawings and detailed description. It is intended that all such additional systems, methods, features, and advantages be included within this description, and be within the scope of the present disclosure.
- Further aspects of the present disclosure will be more readily appreciated upon review of the detailed description of its various embodiments, described below, when taken in conjunction with the accompanying drawings.
-
FIGS. 1A-1B illustrate the chemical structure and an embodiment of synthesis of lithium cholesterol sulfate (LiCS). LiCS was synthesized as described in Example 1 and illustrated inFIG. 1A , and its identification and purity was confirmed by HPLC-MS/MS (FIG. 1B ) -
FIGS. 2A-F illustrate a comparison of LiCS and LiCl in mediating inhibitory GSK3β phosphorylation. CHO (FIGS. 2A and 2B ) and SH-SY5Y cell cultures (FIGS. 2C and 2D ) were treated with LiCS or NaCS at 0-90 μM or LiCl at 60 μM to 2.5 mM for 18 h followed by analysis of inhibitory phospho-GSK3β (Ser9) and total GSK3β levels in cell homogenates by WB. Levels of phospo-GSK3β (Ser9) were determined by densitometry analysis of three independent experiments and represented as mean±SD in the graphs presented inFIGS. 2E and 2F . Asterisk indicates P<0.05 compared with no treatment (control, 100%). Note that NaCS did not alter pGSK3β and neither LiCS, LiCl nor NaCS altered total GSK3β levels. -
FIGS. 3A-3D illustrate a comparison of LiCS vs. LiCl effect on tau (Thr231) phosphorylation and that LiCS reduces tau (Thr231) phosphorylation at micromolar levels. HEK293/tau cells were treated with LiCS (FIG. 3A ) or NaCS at 0-60 μM (FIG. 3B ) or LiCl at 60 μM to 1.25 mM for 18 h (FIG. 3C ) followed by analysis of phosphor-tau (Thr231) and total tau levels in cell homogenates by WB. Levels of phosphor-tau (Thr231) were determined by densitometry analysis of three independent experiments and represented as means±SD (FIG. 3D ). Asterisk indicates P<0.05 compared with no treatment (100% of control). Note that neither NaCS nor LiCl altered ptau, and neither LiCS, LiCl nor NaCS altered total tau levels. -
FIG. 4 is a graph illustrating that LiCS is more effective than LiCl in reducing microglial LPS-induced TNFα production. Microglial BV2 cells were treated with LPS at 100 ng/ml in the absence or presence of LiCS or NaCS at 0, 20, 40 or 80 μM or LiCl at 5, 10 or 20 mM for 3 h, followed by analysis of TNFα levels in conditioned media by ELISA, represented as means±SD. Asterisk indicates P<0.05 compared with LPS treatment alone. - The graph in
FIG. 5A and table inFIG. 5B illustrate the pharmacokinetics of lithium cholesterol sulfate (LiCS) in adult male mice. The graph inFIG. 5A illustrates the comparison of lithium levels in the blood after treatment with LiCl and LiCS at 0.5, 1, 2, 3, 5 and 24 h after oral administration, where the table inFIG. 5B presents the comparison of lithium levels in brain, kidney and liver at 0.5 and 5 h after gavage. Lithium ELISA results are presented as the mean (±s.d.). Asterisk indicates P<0.05 versus LiCl treatment as determined by ANOVA. - Before the present disclosure is described in greater detail, it is to be understood that this disclosure is not limited to particular embodiments described, as such may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting, since the scope of the present disclosure will be limited only by the appended claims.
- Where a range of values is provided, it is understood that each intervening value, to the tenth of the unit of the lower limit (unless the context clearly dictates otherwise), between the upper and lower limit of that range, and any other stated or intervening value in that stated range, is encompassed within the disclosure. The upper and lower limits of these smaller ranges may independently be included in the smaller ranges and are also encompassed within the disclosure, subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the disclosure. For example, where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the disclosure, e.g. the phrase “x to y” includes the range from ‘x’ to ‘y’ as well as the range greater than ‘x’ and less than ‘y’. The range can also be expressed as an upper limit, e.g. ‘about x, y, z, or less’ and should be interpreted to include the specific ranges of ‘about x’, ‘about y’, and ‘about z’ as well as the ranges of ‘less than x’, less than y′, and ‘less than z’. Likewise, the phrase ‘about x, y, z, or greater’ should be interpreted to include the specific ranges of ‘about x’, ‘about y’, and ‘about z’ as well as the ranges of ‘greater than x’, greater than y′, and ‘greater than z’. In addition, the phrase “about ‘x’ to ‘y’”, where ‘x’ and ‘y’ are numerical values, includes “about ‘x’ to about ‘y’”.
- It is to be understood that such a range format is used for convenience and brevity, and thus, should be interpreted in a flexible manner to include not only the numerical values explicitly recited as the limits of the range, but also to include all the individual numerical values or sub-ranges encompassed within that range as if each numerical value and sub-range is explicitly recited. To illustrate, a numerical range of “about 0.1% to 5%” should be interpreted to include not only the explicitly recited values of about 0.1% to about 5%, but also include individual values (e.g., about 1%, about 2%, about 3%, and about 4%) and the sub-ranges (e.g., about 0.5% to about 1.1%; about 5% to about 2.4%; about 0.5% to about 3.2%, and about 0.5% to about 4.4%, and other possible sub-ranges) within the indicated range.
- Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. Although any methods and materials similar or equivalent to those described herein can also be used in the practice or testing of the present disclosure, the preferred methods and materials are now described.
- As will be apparent to those of skill in the art upon reading this disclosure, each of the individual embodiments described and illustrated herein has discrete components and features which may be readily separated from or combined with the features of any of the other several embodiments without departing from the scope or spirit of the present disclosure. Any recited method can be carried out in the order of events recited or in any other order that is logically possible.
- Embodiments of the present disclosure will employ, unless otherwise indicated, techniques of biochemistry, molecular biology, pharmacology, medicine, neuropathology, and the like, which are within the skill of the art. Such techniques are explained fully in the literature.
- The following examples are put forth so as to provide those of ordinary skill in the art with a complete disclosure and description of how to perform the methods and use the compositions and compounds disclosed and claimed herein. Efforts have been made to ensure accuracy with respect to numbers (e.g., amounts, temperature, etc.), but some errors and deviations should be accounted for. Unless indicated otherwise, parts are parts by weight, temperature is in ° C., and pressure is at or near atmospheric. Standard temperature and pressure are defined as 20° C. and 1 atmosphere.
- Before the embodiments of the present disclosure are described in detail, it is to be understood that, unless otherwise indicated, the present disclosure is not limited to particular materials, reagents, reaction materials, manufacturing processes, or the like, as such can vary. It is also to be understood that the terminology used herein is for purposes of describing particular embodiments only and is not intended to be limiting. It is also possible in the present disclosure that steps can be executed in different sequence where this is logically possible.
- All publications and patents cited in this specification are cited to disclose and describe the methods and/or materials in connection with which the publications are cited. Publications and patents that are incorporated by reference, where noted, are incorporated by reference as if each individual publication or patent were specifically and individually indicated to be incorporated by reference. Such incorporation by reference is expressly limited to the methods and/or materials described in the cited publications and patents and does not extend to any lexicographical definitions from the cited publications and patents. Any lexicographical definition in the publications and patents cited that is not also expressly repeated in the instant application should not be treated as such and should not be read as defining any terms appearing in the accompanying claims. Any terms not specifically defined within the instant application, including terms of art, are interpreted as would be understood by one of ordinary skill in the relevant art; thus, is not intended for any such terms to be defined by a lexicographical definition in any cited art, whether or not incorporated by reference herein, including but not limited to, published patents and patent applications. The citation of any publication is for its disclosure prior to the filing date and should not be construed as an admission that the present disclosure is not entitled to antedate such publication by virtue of prior disclosure. Further, the dates of publication provided could be different from the actual publication dates that may need to be independently confirmed.
- Prior to describing the various embodiments, the following definitions are provided and should be used unless otherwise indicated.
- In describing and claiming the disclosed subject matter, the following terminology will be used in accordance with the definitions set forth below.
- It must be noted that, as used in the specification and the appended claims, the singular forms “a,” “an,” and “the” include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to “a cell” includes a plurality of cells. In this specification and in the claims that follow, reference will be made to a number of terms that shall be defined to have the following meanings unless a contrary intention is apparent.
- As used herein, “comprising” is to be interpreted as specifying the presence of the stated features, integers, steps, or components as referred to, but does not preclude the presence or addition of one or more features, integers, steps, or components, or groups thereof. Moreover, each of the terms “by”, “comprising,” “comprises”, “comprised of,” “including,” “includes,” “included,” “involving,” “involves,” “involved,” and “such as” are used in their open, non-limiting sense and may be used interchangeably. Further, the term “comprising” is intended to include examples and aspects encompassed by the terms “consisting essentially of” and “consisting of.” Similarly, the term “consisting essentially of” is intended to include examples encompassed by the term “consisting of.
- In this disclosure, “consisting essentially of” or “consists essentially” or the like, when applied to methods and compositions encompassed by the present disclosure refers to compositions like those disclosed herein, but which may contain additional structural groups, composition components or method steps (or analogs or derivatives thereof as discussed above). Such additional structural groups, composition components or method steps, etc., however, do not materially affect the basic and novel characteristic(s) of the compositions or methods, compared to those of the corresponding compositions or methods disclosed herein. “Consisting essentially of” or “consists essentially” or the like, when applied to methods and compositions encompassed by the present disclosure have the meaning ascribed in U.S. Patent law and the term is open-ended, allowing for the presence of more than that which is recited so long as basic or novel characteristics of that which is recited is not changed by the presence of more than that which is recited, but excludes prior art embodiments.
- As used herein, “about,” “approximately,” “substantially,” and the like, when used in connection with a numerical variable, can generally refers to the value of the variable and to all values of the variable that are within the experimental error (e.g., within the 95% confidence interval for the mean) or within +/−10% of the indicated value, whichever is greater. As used herein, the terms “about,” “approximate,” “at or about,” and “substantially” can mean that the amount or value in question can be the exact value or a value that provides equivalent results or effects as recited in the claims or taught herein. That is, it is understood that amounts, sizes, formulations, parameters, and other quantities and characteristics are not and need not be exact, but may be approximate and/or larger or smaller, as desired, reflecting tolerances, conversion factors, rounding off, measurement error and the like, and other factors known to those of skill in the art such that equivalent results or effects are obtained. In some circumstances, the value that provides equivalent results or effects cannot be reasonably determined. In general, an amount, size, formulation, parameter or other quantity or characteristic is “about,” “approximate,” or “at or about” whether or not expressly stated to be such. It is understood that where “about,” “approximate,” or “at or about” is used before a quantitative value, the parameter also includes the specific quantitative value itself, unless specifically stated otherwise.
- As used herein, the terms “optional” or “optionally” means that the subsequently described event or circumstance can or cannot occur, and that the description includes instances where said event or circumstance occurs and instances where it does not.
- As used herein, “administering” can refer to an administration that is oral, topical, intravenous, subcutaneous, transcutaneous, transdermal, intramuscular, intra-joint, parenteral, intra-arteriole, intradermal, intraventricular, intraosseous, intraocular, intracranial, intraperitoneal, intralesional, intranasal, intracardiac, intraarticular, intracavernous, intrathecal, intravireal, intracerebral, and intracerebroventricular, intratympanic, intracochlear, rectal, vaginal, by inhalation, by catheters, stents or via an implanted reservoir or other device that administers, either actively or passively (e.g. by diffusion) a composition the perivascular space and adventitia. For example, a medical device such as a stent can contain a composition or formulation disposed on its surface, which can then dissolve or be otherwise distributed to the surrounding tissue and cells. The term “parenteral” can include subcutaneous, intravenous, intramuscular, intra-articular, intra-synovial, intrasternal, intrathecal, intrahepatic, intralesional, and intracranial injections or infusion techniques. Administration can be continuous or intermittent. In various aspects, a preparation can be administered therapeutically; that is, administered to treat an existing disease or condition. In further various aspects, a preparation can be administered prophylactically; that is, administered for prevention of a disease or condition.
- As used herein, “therapeutic agent” can refer to any substance, compound, molecule, and the like, which can be biologically active or otherwise can induce a pharmacologic, immunogenic, biologic and/or physiologic effect on a subject to which it is administered to by local and/or systemic action. A therapeutic agent can be a primary active agent, or in other words, the component(s) of a composition to which the whole or part of the effect of the composition is attributed. A therapeutic agent can be a secondary therapeutic agent, or in other words, the component(s) of a composition to which an additional part and/or other effect of the composition is attributed. The term therefore encompasses those compounds or chemicals traditionally regarded as drugs, vaccines, and biopharmaceuticals including molecules such as proteins, peptides, hormones, nucleic acids, gene constructs and the like. Examples of therapeutic agents are described in well-known literature references such as the Merck Index (14th edition), the Physicians' Desk Reference (64th edition), and The Pharmacological Basis of Therapeutics (12th edition), and they include, without limitation, medicaments; vitamins; mineral supplements; substances used for the treatment, prevention, diagnosis, cure or mitigation of a disease or illness; substances that affect the structure or function of the body, or pro-drugs, which become biologically active or more active after they have been placed in a physiological environment. For example, the term “therapeutic agent” includes compounds or compositions for use in all of the major therapeutic areas including, but not limited to, adjuvants; anti-infectives such as antibiotics and antiviral agents; analgesics and analgesic combinations, anorexics, anti-inflammatory agents, anti-epileptics, local and general anesthetics, hypnotics, sedatives, antipsychotic agents, neuroleptic agents, antidepressants, anxiolytics, antagonists, neuron blocking agents, anticholinergic and cholinomimetic agents, antimuscarinic and muscarinic agents, antiadrenergics, antiarrhythmics, antihypertensive agents, hormones, and nutrients, antiarthritics, antiasthmatic agents, anticonvulsants, antihistamines, antinauseants, antineoplastics, antipruritics, antipyretics; antispasmodics, cardiovascular preparations (including calcium channel blockers, beta-blockers, beta-agonists and antiarrythmics), antihypertensives, diuretics, vasodilators; mood stabilizers; central nervous system stimulants; cough and cold preparations; decongestants; diagnostics; hormones; bone growth stimulants and bone resorption inhibitors; immunosuppressives; muscle relaxants; psychostimulants; sedatives; tranquilizers; proteins, peptides, and fragments thereof (whether naturally occurring, chemically synthesized or recombinantly produced); and nucleic acid molecules (polymeric forms of two or more nucleotides, either ribonucleotides (RNA) or deoxyribonucleotides (DNA) including both double- and single-stranded molecules, gene constructs, expression vectors, antisense molecules and the like), small molecules (e.g., doxorubicin) and other biologically active macromolecules such as, for example, proteins and enzymes. The agent may be a biologically active agent used in medical, including veterinary, applications and in agriculture, such as with plants, as well as other areas. The term therapeutic agent also includes without limitation, medicaments; vitamins; mineral supplements; substances used for the treatment, prevention, diagnosis, cure or mitigation of disease or illness; or substances which affect the structure or function of the body; or pro-drugs, which become biologically active or more active after they have been placed in a predetermined physiological environment.
- As used herein, “kit” means a collection of at least two components constituting the kit. Together, the components constitute a functional unit for a given purpose. Individual member components may be physically packaged together or separately. For example, a kit comprising an instruction for using the kit may or may not physically include the instruction with other individual member components. Instead, the instruction can be supplied as a separate member component, either in a paper form or an electronic form which may be supplied on computer readable memory device or downloaded from an internet website, or as recorded presentation.
- As used herein, “instruction(s)” means documents describing relevant materials or methodologies pertaining to a kit. These materials may include any combination of the following: background information, list of components and their availability information (purchase information, etc.), brief or detailed protocols for using the kit, trouble-shooting, references, technical support, and any other related documents. Instructions can be supplied with the kit or as a separate member component, either as a paper form or an electronic form which may be supplied on computer readable memory device or downloaded from an internet website, or as recorded presentation. Instructions can comprise one or multiple documents and are meant to include future updates.
- As used herein, “attached” can refer to covalent or non-covalent interaction between two or more molecules. Non-covalent interactions can include ionic bonds, electrostatic interactions, van der Walls forces, dipole-dipole interactions, dipole-induced-dipole interactions, London dispersion forces, hydrogen bonding, halogen bonding, electromagnetic interactions, π-π interactions, cation-π interactions, anion-π interactions, polar π-interactions, and hydrophobic effects.
- As used interchangeably herein, “subject,” “individual,” or “patient” can refer to a vertebrate organism, such as a mammal (e.g. human). “Subject” can also refer to a cell, a population of cells, a tissue, an organ, or an organism, preferably to human and constituents thereof.
- As used herein, the terms “treating” and “treatment” can refer generally to obtaining a desired pharmacological and/or physiological effect. The effect can be, but does not necessarily have to be, prophylactic in terms of preventing or partially preventing a disease, symptom or condition thereof, such as those related to a neurodegenerative condition, and neurodevelopmental disorder, or other neurological disorder, such as but not limited to Alzheimer's disease, autism spectrum disorder, bipolar disorder, suicidal ideation, traumatic brain injury, radiation induced brain injury, and the like. The effect can be therapeutic in terms of a partial or complete cure of a disease, condition, symptom or adverse effect attributed to the disease, disorder, or condition. The term “treatment” as used herein can include any treatment of a neurological disorder in a subject, particularly a human, and can include any one or more of the following: (a) preventing the disease from occurring in a subject which may be predisposed to the disease but has not yet been diagnosed as having it; (b) inhibiting the disease, i.e., arresting its development; and (c) relieving the disease, i.e., mitigating or ameliorating the disease and/or its symptoms or conditions. The term “treatment” as used herein can refer to both therapeutic treatment alone, prophylactic treatment alone, or both therapeutic and prophylactic treatment. Those in need of treatment (subjects in need thereof) can include those already with the disorder and/or those in which the disorder is to be prevented. As used herein, the term “treating”, can include inhibiting the disease, disorder or condition, e.g., impeding its progress; and relieving the disease, disorder, or condition, e.g., causing regression of the disease, disorder and/or condition. Treating the disease, disorder, or condition can include ameliorating at least one symptom of the particular disease, disorder, or condition, even if the underlying pathophysiology is not affected, e.g., such as treating the pain of a subject by administration of an analgesic agent even though such agent does not treat the cause of the pain.
- As used herein, “dose,” “unit dose,” or “dosage” can refer to physically discrete units suitable for use in a subject, each unit containing a predetermined quantity of a disclosed compound and/or a pharmaceutical composition thereof calculated to produce the desired response or responses in association with its administration.
- As used herein, “therapeutic” can refer to treating, healing, and/or ameliorating a disease, disorder, condition, or side effect, or to decreasing in the rate of advancement of a disease, disorder, condition, or side effect.
- As used herein, “effective amount” can refer to the amount of a disclosed compound or pharmaceutical composition provided herein that is sufficient to effect beneficial or desired biological, emotional, medical, or clinical response of a cell, tissue, system, animal, or human. An effective amount can be administered in one or more administrations, applications, or dosages. The term can also include within its scope amounts effective to enhance or restore to substantially normal physiological function.
- As used herein, the term “therapeutically effective amount” refers to an amount that is sufficient to achieve the desired therapeutic result or to have an effect on undesired symptoms but is generally insufficient to cause adverse side effects. The specific therapeutically effective dose level for any particular patient will depend upon a variety of factors including the disorder being treated and the severity of the disorder; the specific composition employed; the age, body weight, general health, sex and diet of the patient; the time of administration; the route of administration; the rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or coincidental with the specific compound employed and like factors within the knowledge and expertise of the health practitioner and which may be well known in the medical arts. In the case of treating a particular disease or condition, in some instances, the desired response can be inhibiting the progression of the disease or condition. This may involve only slowing the progression of the disease temporarily. However, in other instances, it may be desirable to halt the progression of the disease permanently. This can be monitored by routine diagnostic methods known to one of ordinary skill in the art for any particular disease. The desired response to treatment of the disease or condition also can be delaying the onset or even preventing the onset of the disease or condition.
- For example, it is well within the skill of the art to start doses of a compound at levels lower than those required to achieve the desired therapeutic effect and to gradually increase the dosage until the desired effect is achieved. If desired, the effective daily dose can be divided into multiple doses for purposes of administration. Consequently, single dose compositions can contain such amounts or submultiples thereof to make up the daily dose. The dosage can be adjusted by the individual physician in the event of any contraindications. It is generally preferred that a maximum dose of the pharmacological agents of the invention (alone or in combination with other therapeutic agents) be used, that is, the highest safe dose according to sound medical judgment. It will be understood by those of ordinary skill in the art however, that a patient may insist upon a lower dose or tolerable dose for medical reasons, psychological reasons or for virtually any other reasons.
- A response to a therapeutically effective dose of a disclosed compound and/or pharmaceutical composition, for example, can be measured by determining the physiological effects of the treatment or medication, such as the decrease or lack of disease symptoms following administration of the treatment or pharmacological agent. Other assays will be known to one of ordinary skill in the art and can be employed for measuring the level of the response. The amount of a treatment may be varied for example by increasing or decreasing the amount of a disclosed compound and/or pharmaceutical composition, by changing the disclosed compound and/or pharmaceutical composition administered, by changing the route of administration, by changing the dosage timing and so on. Dosage can vary, and can be administered in one or more dose administrations daily, for one or several days. Guidance can be found in the literature for appropriate dosages for given classes of pharmaceutical products.
- As used herein, the term “prophylactically effective amount” refers to an amount effective for preventing onset or initiation of a disease or condition.
- As used herein, the term “prevent” or “preventing” refers to precluding, averting, obviating, forestalling, stopping, or hindering something from happening, especially by advance action. It is understood that where reduce, inhibit or prevent are used herein, unless specifically indicated otherwise, the use of the other two words is also expressly disclosed.
- The term “pharmaceutically acceptable” describes a material that is not biologically or otherwise undesirable, i.e., without causing an unacceptable level of undesirable biological effects or interacting in a deleterious manner.
- The term “pharmaceutically acceptable prodrug” or “prodrug” represents those prodrugs of the compounds of the present disclosure which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response, and the like, commensurate with a reasonable benefit/risk ratio, and effective for their intended use. Prodrugs of the present disclosure can be rapidly transformed in vivo to a parent compound having a structure of a disclosed compound, for example, by hydrolysis in blood. A thorough discussion is provided in T. Higuchi and V. Stella, Pro-drugs as Novel Delivery Systems, V. 14 of the A.C.S. Symposium Series, and in Edward B. Roche, ed., Bioreversible Carriers in Drug Design, American Pharmaceutical Association and Pergamon Press (1987).
- As used herein, the term “derivative” refers to a compound having a structure derived from the structure of a parent compound (e.g., a compound disclosed herein) and whose structure is sufficiently similar to those disclosed herein and based upon that similarity, would be expected by one skilled in the art to exhibit the same or similar activities and utilities as the claimed compounds, or to induce, as a precursor, the same or similar activities and utilities as the claimed compounds. Exemplary derivatives include salts, esters, amides, salts of esters or amides, and N-oxides of a parent compound.
- The term “contacting” as used herein refers to bringing a disclosed compound or pharmaceutical composition in proximity to a cell, a target protein, or other biological entity together in such a manner that the disclosed compound or pharmaceutical composition can affect the activity of the a cell, target protein, or other biological entity, either directly; i.e., by interacting with the cell, target protein, or other biological entity itself, or indirectly; i.e., by interacting with another molecule, co-factor, factor, or protein on which the activity of the cell, target protein, or other biological entity itself is dependent.
- The term “stable,” as used herein, refers to compounds that are not substantially altered when subjected to conditions to allow for their production, detection, and, in certain aspects, their recovery, purification, and use for one or more of the purposes disclosed herein.
- The compounds described in the invention can be present as a solvate. In some cases, the solvent used to prepare the solvate is an aqueous solution, and the solvate is then often referred to as a hydrate. The compounds can be present as a hydrate, which can be obtained, for example, by crystallization from a solvent or from aqueous solution. In this connection, one, two, three or any arbitrary number of solvent or water molecules can combine with the compounds according to the invention to form solvates and hydrates. Unless stated to the contrary, the invention includes all such possible solvates.
- The term “co-crystal” means a physical association of two or more molecules which owe their stability through non-covalent interaction. One or more components of this molecular complex provide a stable framework in the crystalline lattice. In certain instances, the guest molecules are incorporated in the crystalline lattice as anhydrates or solvates, see e.g. “Crystal Engineering of the Composition of Pharmaceutical Phases. Do Pharmaceutical Co-crystals Represent a New Path to Improved Medicines?” Almarasson, O., et al., The Royal Society of Chemistry, 1889-1896, 2004. Examples of co-crystals include p-toluenesulfonic acid and benzenesulfonic acid.
- Certain materials, compounds, compositions, and components disclosed herein can be obtained commercially or readily synthesized using techniques generally known to those of skill in the art. For example, the starting materials and reagents used in preparing the disclosed compounds and compositions are either available from commercial suppliers such as Aldrich Chemical Co., (Milwaukee, Wis.), Acros Organics (Morris Plains, N.J.), Fisher Scientific (Pittsburgh, Pa.); or Sigma (St. Louis, Mo.) or are prepared by methods known to those skilled in the art following procedures set forth in references such as Fieser and Fieser's Reagents for Organic Synthesis, Volumes 1-17 (John Wiley and Sons, 1991); Rodd's Chemistry of Carbon Compounds; Volumes 1-5 and Supplementals (Elsevier Science Publishers, 1989); Organic Reactions, Volumes 1-40 (John Wiley and Sons, 1991); March's Advanced Organic Chemistry, (John Wiley and Sons, 4th Edition); and Larock's Comprehensive Organic Transformations (VCH Publishers Inc., 1989).
- Unless otherwise expressly stated, it is in no way intended that any method set forth herein be construed as requiring that its steps be performed in a specific order. Accordingly; where a method claim does not actually recite an order to be followed by its steps or it is not otherwise specifically stated in the claims or descriptions that the steps are to be limited to a specific order, it is no way intended that an order be inferred, in any respect. This holds for any possible non-express basis for interpretation, including: matters of logic with respect to arrangement of steps or operational flow; plain meaning derived from grammatical organization or punctuation; and the number or type of aspects described in the specification.
- Disclosed are the components to be used to prepare the compositions of the invention as well as the compositions themselves to be used within the methods disclosed herein. These and other materials are disclosed herein, and it is understood that when combinations, subsets, interactions, groups; etc. of these materials are disclosed that while specific reference of each various individual and collective combinations and permutation of these compounds cannot be explicitly disclosed; each is specifically contemplated and described herein. For example, if a particular compound is disclosed and discussed and a number of modifications that can be made to a number of molecules including the compounds are discussed; specifically contemplated is each and every combination and permutation of the compound and the modifications that are possible unless specifically indicated to the contrary. Thus, if a class of molecules A, B, and C are disclosed as well as a class of molecules D, E, and F and an example of a combination molecule, A-D is disclosed; then even if each is not individually recited each is individually and collectively contemplated meaning combinations, A-E, A-F, B-D, B-E, B-F, C-D, C-E, and C-F are considered disclosed. Likewise; any subset or combination of these is also disclosed. Thus, for example, the sub-group of A-E, B-F, and C-E would be considered disclosed. This concept applies to all aspects of this application including, but not limited to; steps in methods of making and using the compositions of the invention. Thus, if there are a variety of additional steps that can be performed it is understood that each of these additional steps can be performed with any specific aspect or combination of aspects of the methods of the invention.
- It is understood that the compositions disclosed herein have certain functions. Disclosed herein are certain structural requirements for performing the disclosed functions, and it is understood that there are a variety of structures that can perform the same function that are related to the disclosed structures, and that these structures will typically achieve the same result.
- As used herein, nomenclature for compounds, including organic compounds, can be given using common names, IUPAC, IUBMB, or CAS recommendations for nomenclature. When one or more stereochemical features are present, Cahn-Ingold-Prelog rules for stereochemistry can be employed to designate stereochemical priority. E/Z specification, and the like. One of skill in the art can readily ascertain the structure of a compound if given a name, either by systemic reduction of the compound structure using naming conventions, or by commercially available software, such as CHEMDRAW™ (Cambridgesoft Corporation, U.S.A.).
- It is understood, that unless otherwise specified, temperatures referred to herein are based on atmospheric pressure (i.e., one atmosphere).
- Described herein are lithium cholesterol compositions, including, but not limited to lithium cholesterol sulfate compositions, and pharmaceutical compositions that have therapeutic or clinical utility. Also described herein are methods of synthesizing the lithium cholesterol sulfate and compositions containing the LiCS. Also described herein are methods of administering the lithium cholesterol sulfate to a subject in need thereof. In some aspects, the subject can have a neurological disorder such as a neurodegenerative condition, a neurological developmental disorder, a neurological injury, and other conditions resulting from neurological disorders. Other compositions, compounds, methods, features, and advantages of the present disclosure will be or become apparent to one having ordinary skill in the art upon examination of the following drawings, detailed description, and examples. It is intended that all such additional compositions, compounds, methods, features, and advantages be included within this description, and be within the scope of the present disclosure.
- Neurodegenerative Diseases and Lithium.
- In accordance with the purpose(s) of the present disclosure, as embodied and broadly described herein, embodiments of the present disclosure, in some aspects, relate to pharmaceutical compositions including lithium cholesterol sulfate and compositions and methods for the treatment of neurodegenerative conditions, neurodevelopmental conditions, and other neurological conditions.
- Alzheimer's disease (AD) is a progressive neurodegenerative disease with clinical manifestations of dementia, aphasia, loss of motor function, impairment of visual space skills, executive dysfunction, and personality and behavior change. AD is the main cause of dementia and one of the great health-care challenges of the 21st century, accounting for more than 50% of all clinically diagnosed dementia (1). People in the final stages of AD are bed bound and require constant care, ultimately leading to death. By 2050, a new case of AD is expected to occur every 33 s, causing nearly 1 million new AD cases per year. Approximately 13% of the population over the age of 65 years is estimated to have AD and the total number of cases is expected to increase over the coming decades. AD pathogenesis is complex, involving abnormal amyloid-8 (Aβ) metabolism, tau hyperphosphorylation, oxidative stress, inflammation, reactive glial and microglial changes, and other pathological events (2, 3). AD not only causes severe distress for patients and caregivers, but also results in a large economic burden on society (4). Therefore, it is very important to treat or prevent this disease progression.
- Autism spectrum disorder (ASD) is a neurodevelopmental disorder characterized by persistent difficulties in social communication and social interaction, coupled with restricted, repetitive patterns of behavior or interest (5). These children also present with symptoms of mood disorder, such as elevated moods/euphoria, mania, and paranoia, whether accompanied or not by irritability (6, 7). According to a recent report from the Centers for Disease Control and Prevention (CDC), around 20 per 1000 children aged 6-17 in the United States are diagnosed with ASD in 2011-2012 (8). The cause of autism appears to be primarily genetic, but recent studies also indicate the presence of a strong inflammatory state associated with ASD (9). Indeed, neuroinflammation and neuroimmune abnormalities have now been established in ASD as key factors in its development and maintenance, with increased expression of IL-1β, IL-6, IL-17 and TNF-α in the autistic brain. At the same time, hyperphosphorylation of Tau may also be involved in the pathogenesis of autism (10).
- Lithium salts have been used in psychiatry to treat bipolar disorder for many years, and now they are still considered as a first-line therapy for both the acute and long-term treatment of bipolar disorder (11). Simultaneously, recent studies found that lithium salts also have neuroprotective effects that include preventing apoptosis and increasing neurotrophins and other cell-survival molecules (12). Furthermore, beneficial effects of lithium salts on neurogenesis, brain remodeling, angiogenesis, mesenchymal stem cells functioning, and inflammation have been revealed (13). In particular, recent studies have found that lithium can act as a potential therapeutic for AD (13). Studies have showed that patients who were given lithium would progress less over the course of AD compared with the placebo-group (12, 14).
- Lithium may not only have beneficial effects on cognitive performance in subjects with AD dementia, but also may have positive treatment effects in ASD (7, 13). In the neonatal isolation animal model, treatment of Sprague-Dawley rats with lithium chloride (2 mmol/kg i.p./day) reversed autistic features, such as social interaction deficit, excessive repetitive self-grooming behavior, increased anxiety and depression (15). In addition, lithium therapy reversed clinical regression, stabilized behavioral symptoms and allowed patients to recover their pre-catatonia level of functioning, without significant side effects (16). At present, lithium carbonate is usually applied in clinic, but other lithium salts such as lithium citrate, lithium sulfate, lithium orotate and lithium chloride are also used as alternatives. However, lithium treatment has serious short- and long-term side effects in humans and requires frequent monitoring of blood chemistry and lithium plasma levels so as to avoid toxicity, discouraging patients from choosing these drugs. Hence, there is a demand for a safer and more effective lithium formulation to treat AD and ASD.
- The present disclosure provides a novel lithium salt that is useful for treating AD, ASD, and other neurological conditions. The examples below describe tests and data illustrating the therapeutic potential of lithium cholesterol compositions, including, but not limited to lithium cholesterol sulfate compositions (LiCS,
FIG. 1 ). Cholesterol sulfate is a normal constituent in a variety of human tissues (17, 18). This compound has a hydrophobic/hydrophilic property suited for interactions with membrane constituents and crossing the cell membrane and intestinal and blood-brain barriers (19). In addition, cholesterol sulfate itself can provide benefits in the treatment of AD and ASD, as well as other diseases potentially resulting from sulfur shortage, including eczema and asthma (20). Cholesterol has also been shown to directly bind APP and Aβ, making LiCS more effective in targeting Aβ aggregation (21). The present disclosure, including the following examples, illustrates that LiCS will have a superior pharmacokinetic and safety profile compared with traditional lithium chemical forms for treatment of neurodegenerative diseases. - Compounds.
- Compounds of the present disclosure pertain to lithium cholesterol compositions, including, but not limited to lithium cholesterol sulfate compositions (LiCS). In embodiments, the lithium cholesterol compositions of the disclosure have the following structure:
- where R is selected from —SO4Li, —PO3(Li)2, —(CH2)n(C═O)OLi, or —(C═O)(CH2)n(C═O)OLi, where n is integer selected from 1, 2, 3, 4, 5, and 6.
- In some aspects, the lithium cholesterol compositions of the disclosure can have a structure selected from:
- and combinations thereof.
- In an aspect, the lithium cholesterol compositions of the disclosure can have the following structure:
- The foregoing compound can be referred to as either lithium cholesterol sulfate or LiCS herein throughout. LiCS has a formula weight of 472.65.
- In an aspect, the lithium cholesterol compositions of the disclosure can have the following structure:
- The foregoing compound can be referred to as either lithium cholesterol phosphate or LiCP herein throughout. LiCP has a formula weight of 478.51.
- In an aspect, the lithium cholesterol compositions of the disclosure can have the following structure:
- The foregoing compound can be referred to as either lithium cholesterol succinate, lithium cholesterol hemisuccinate or LiCSc herein throughout. LiCSc has a formula weight of 492.67.
- In an aspect, the lithium cholesterol compositions of the disclosure can have the following structure:
- The foregoing compound can be referred to as either lithium cholesterol acetate or LiCAc herein throughout. LiCAc has a formula weight of 450.63.
- Pharmaceutical Compositions.
- In various aspects, the present disclosure relates to pharmaceutical compositions comprising a therapeutically effective amount of a lithium cholesterol sulfate compound of the present disclosure or a derivative thereof and a pharmaceutically acceptable carrier. As used herein, “pharmaceutically-acceptable carriers” means one or more of a pharmaceutically acceptable diluents, preservatives, antioxidants, solubilizers, emulsifiers, coloring agents, releasing agents, coating agents, sweetening, flavoring and perfuming agents, and adjuvants. The disclosed pharmaceutical compositions can be conveniently presented in unit dosage form and prepared by any of the methods well known in the art of pharmacy and pharmaceutical sciences.
- In a further aspect, the disclosed pharmaceutical compositions comprise a therapeutically effective amount of at least one disclosed lithium cholesterol composition, including, but not limited to lithium cholesterol sulfate, at least one product of a disclosed method as an active ingredient, a pharmaceutically acceptable carrier, optionally one or more other therapeutic agent, and optionally one or more adjuvant. The disclosed pharmaceutical compositions include those suitable for oral, rectal, topical, pulmonary, nasal, and parenteral administration, although the most suitable route in any given case will depend on the particular host, and nature and severity of the conditions for which the active ingredient is being administered. In a further aspect, the disclosed pharmaceutical composition can be formulated to allow administration orally, nasally, via inhalation, parenterally, paracancerally, transmucosally, transdermally, intramuscularly, intravenously, intradermally, subcutaneously, intraperitonealy, intraventricularly, intracranially and intratumorally.
- As used herein, “parenteral administration” includes administration by bolus injection or infusion, as well as administration by intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular subarachnoid, intraspinal, epidural and intrasternal injection and infusion.
- In various aspects, the present disclosure also relates to a pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and, as active ingredient, a therapeutically effective amount of a disclosed lithium cholesterol composition, including, but not limited to lithium cholesterol sulfate, a product of a disclosed method of making, a pharmaceutically acceptable salt, a hydrate thereof, a solvate thereof, a polymorph thereof, or a stereochemically isomeric form thereof. In a further aspect, a disclosed compound, a product of a disclosed method of making, a pharmaceutically acceptable salt, a hydrate thereof, a solvate thereof, a polymorph thereof, or a stereochemically isomeric form thereof, or any subgroup or combination thereof may be formulated into various pharmaceutical forms for administration purposes.
- In practice, the compounds of the present disclosure can be combined as the active ingredient in intimate admixture with a pharmaceutical carrier according to conventional pharmaceutical compounding techniques. The carrier can take a wide variety of forms depending on the form of preparation desired for administration, e.g., oral or parenteral (including intravenous). Thus, the pharmaceutical compositions of the present disclosure can be presented as discrete units suitable for oral administration such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient. Further, the compositions can be presented as a powder, as granules, as a solution, as a suspension in an aqueous liquid, as a non-aqueous liquid, as an oil-in-water emulsion or as a water-in-oil liquid emulsion. In addition to the common dosage forms set out above, the compounds of the present disclosure, and/or pharmaceutically acceptable salt(s) thereof, can also be administered by controlled release means and/or delivery devices. The compositions can be prepared by any of the methods of pharmacy. In general, such methods include a step of bringing into association the active ingredient with the carrier that constitutes one or more necessary ingredients. In general, the compositions are prepared by uniformly and intimately admixing the active ingredient with liquid carriers or finely divided solid carriers or both. The product can then be conveniently shaped into the desired presentation.
- It is especially advantageous to formulate the aforementioned pharmaceutical compositions in unit dosage form for ease of administration and uniformity of dosage. The term “unit dosage form,” as used herein, refers to physically discrete units suitable as unitary dosages, each unit containing a predetermined quantity of active ingredient calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. That is, a “unit dosage form” is taken to mean a single dose wherein all active and inactive ingredients are combined in a suitable system, such that the patient or person administering the drug to the patient can open a single container or package with the entire dose contained therein, and does not have to mix any components together from two or more containers or packages. Typical examples of unit dosage forms are tablets (including scored or coated tablets), capsules or pills for oral administration; single dose vials for injectable solutions or suspension; suppositories for rectal administration; powder packets; wafers; and segregated multiples thereof. This list of unit dosage forms is not intended to be limiting in any way, but merely to represent typical examples of unit dosage forms.
- The pharmaceutical compositions disclosed herein comprise a compound of the present disclosure (or pharmaceutically acceptable salts or derivatives thereof) as an active ingredient, a pharmaceutically acceptable carrier, and optionally one or more additional therapeutic agents. In various aspects, the disclosed pharmaceutical compositions can include a pharmaceutically acceptable carrier and a disclosed lithium cholesterol composition, including, but not limited to lithium cholesterol sulfate. In a further aspect, a disclosed lithium cholesterol composition, including, but not limited to lithium cholesterol sulfate, can also be included in a pharmaceutical composition in combination with one or more other therapeutically active compounds. The instant compositions include compositions suitable for oral, rectal, topical, and parenteral (including subcutaneous, intramuscular, and intravenous) administration, although the most suitable route in any given case will depend on the particular host, and nature and severity of the conditions for which the active ingredient is being administered. The pharmaceutical compositions can be conveniently presented in unit dosage form and prepared by any of the methods well known in the art of pharmacy.
- Techniques and compositions for making dosage forms useful for materials and methods described herein are described, for example, in the following references: Modern Pharmaceutics, Chapters 9 and 10 (Banker & Rhodes, Editors, 1979); Pharmaceutical Dosage Forms: Tablets (Lieberman et al., 1981); Ansel, Introduction to Pharmaceutical Dosage Forms 2nd Edition (1976); Remington's Pharmaceutical Sciences, 17th ed. (Mack Publishing Company, Easton, Pa., 1985); Advances in Pharmaceutical Sciences (David Ganderton, Trevor Jones, Eds., 1992); Advances in Pharmaceutical Sciences Vol 7. (David Ganderton, Trevor Jones, James McGinity, Eds., 1995); Aqueous Polymeric Coatings for Pharmaceutical Dosage Forms (Drugs and the Pharmaceutical Sciences, Series 36 (James McGinity, Ed., 1989); Pharmaceutical Particulate Carriers: Therapeutic Applications: Drugs and the Pharmaceutical Sciences, Vol 61 (Alain Rolland, Ed., 1993); Drug Delivery to the Gastrointestinal Tract (Ellis Horwood Books in the Biological Sciences. Series in Pharmaceutical Technology; J. G. Hardy, S. S. Davis, Clive G. Wilson, Eds.); Modern Pharmaceutics Drugs and the Pharmaceutical Sciences, Vol 40 (Gilbert S. Banker, Christopher T. Rhodes, Eds.).
- The compounds described herein are typically to be administered in admixture with suitable pharmaceutical diluents, excipients, extenders, or carriers (termed herein as a pharmaceutically acceptable carrier, or a carrier) suitably selected with respect to the intended form of administration and as consistent with conventional pharmaceutical practices. The deliverable compound will be in a form suitable for oral, rectal, topical, intravenous injection or parenteral administration. Carriers include solids or liquids, and the type of carrier is chosen based on the type of administration being used. The compounds may be administered as a dosage that has a known quantity of the compound.
- Because of the ease in administration, oral administration can be a preferred dosage form, and tablets and capsules represent the most advantageous oral dosage unit forms in which case solid pharmaceutical carriers are obviously employed. However, other dosage forms may be suitable depending upon clinical population (e.g., age and severity of clinical condition), solubility properties of the specific disclosed compound used, and the like. Accordingly, the disclosed compounds can be used in oral dosage forms such as pills, powders, granules, elixirs, tinctures, suspensions, syrups, and emulsions. In preparing the compositions for oral dosage form, any convenient pharmaceutical media can be employed. For example, water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents and the like can be used to form oral liquid preparations such as suspensions, elixirs and solutions; while carriers such as starches, sugars, microcrystalline cellulose, diluents, granulating agents, lubricants, binders, disintegrating agents, and the like can be used to form oral solid preparations such as powders, capsules and tablets. Because of their ease of administration, tablets and capsules are the preferred oral dosage units whereby solid pharmaceutical carriers are employed. Optionally, tablets can be coated by standard aqueous or nonaqueous techniques.
- The disclosed pharmaceutical compositions in an oral dosage form can comprise one or more pharmaceutical excipient and/or additive. Non-limiting examples of suitable excipients and additives include gelatin, natural sugars such as raw sugar or lactose, lecithin, pectin, starches (for example corn starch or amylose), dextran, polyvinyl pyrrolidone, polyvinyl acetate, gum arabic, alginic acid, tylose, talcum, lycopodium, silica gel (for example colloidal), cellulose, cellulose derivatives (for example cellulose ethers in which the cellulose hydroxy groups are partially etherified with lower saturated aliphatic alcohols and/or lower saturated, aliphatic oxyalcohols, for example methyl oxypropyl cellulose, methyl cellulose, hydroxypropyl methyl cellulose, hydroxypropyl methyl cellulose phthalate), fatty acids as well as magnesium, calcium or aluminum salts of fatty acids with 12 to 22 carbon atoms, in particular saturated (for example stearates), emulsifiers, oils and fats, in particular vegetable (for example, peanut oil, castor oil, olive oil, sesame oil, cottonseed oil, corn oil, wheat germ oil, sunflower seed oil, cod liver oil, in each case also optionally hydrated); glycerol esters and polyglycerol esters of saturated fatty acids C12H24O2 to C18H36O2 and their mixtures, it being possible for the glycerol hydroxy groups to be totally or also only partly esterified (for example mono-, di- and triglycerides); pharmaceutically acceptable mono- or multivalent alcohols and polyglycols such as polyethylene glycol and derivatives thereof, esters of aliphatic saturated or unsaturated fatty acids (2 to 22 carbon atoms, in particular 10-18 carbon atoms) with monovalent aliphatic alcohols (1 to 20 carbon atoms) or multivalent alcohols such as glycols, glycerol, diethylene glycol, pentacrythritol, sorbitol, mannitol and the like, which may optionally also be etherified, esters of citric acid with primary alcohols, acetic acid, urea, benzyl benzoate, dioxolanes, glyceroformals, tetrahydrofurfuryl alcohol, polyglycol ethers with C1-C12-alcohols, dimethylacetamide, lactamides, lactates, ethylcarbonates, silicones (in particular medium-viscous polydimethyl siloxanes), calcium carbonate, sodium carbonate, calcium phosphate, sodium phosphate, magnesium carbonate and the like.
- Other auxiliary substances useful in preparing an oral dosage form are those which cause disintegration (so-called disintegrants), such as: cross-linked polyvinyl pyrrolidone, sodium carboxymethyl starch, sodium carboxymethyl cellulose or microcrystalline cellulose. Conventional coating substances may also be used to produce the oral dosage form. Those that may for example be considered are: polymerizates as well as copolymerizates of acrylic acid and/or methacrylic acid and/or their esters; copolymerizates of acrylic and methacrylic acid esters with a lower ammonium group content (for example EudragitR RS), copolymerizates of acrylic and methacrylic acid esters and trimethyl ammonium methacrylate (for example EudragitR RL); polyvinyl acetate; fats, oils, waxes, fatty alcohols; hydroxypropyl methyl cellulose phthalate or acetate succinate; cellulose acetate phthalate, starch acetate phthalate as well as polyvinyl acetate phthalate, carboxy methyl cellulose; methyl cellulose phthalate, methyl cellulose succinate, -phthalate succinate as well as methyl cellulose phthalic acid half ester; zein; ethyl cellulose as well as ethyl cellulose succinate; shellac, gluten; ethylcarboxyethyl cellulose; ethacrylate-maleic acid anhydride copolymer; maleic acid anhydride-vinyl methyl ether copolymer; styrol-maleic acid copolymerizate; 2-ethyl-hexyl-acrylate maleic acid anhydride; crotonic acid-vinyl acetate copolymer; glutaminic acid/glutamic acid ester copolymer; carboxymethylethylcellulose glycerol monooctanoate; cellulose acetate succinate; polyarginine.
- Plasticizing agents that may be considered as coating substances in the disclosed oral dosage forms are: citric and tartaric acid esters (acetyl-triethyl citrate, acetyl tributyl-, tributyl-, triethyl-citrate); glycerol and glycerol esters (glycerol diacetate, -triacetate, acetylated monoglycerides, castor oil); phthalic acid esters (dibutyl-, diamyl-, diethyl-, dimethyl-, dipropyl-phthalate), di-(2-methoxy- or 2-ethoxyethyl)-phthalate, ethylphthalyl glycolate, butylphthalylethyl glycolate and butylglycolate; alcohols (propylene glycol, polyethylene glycol of various chain lengths), adipates (diethyladipate, di-(2-methoxy- or 2-ethoxyethyl)-adipate; benzophenone; diethyl- and diburylsebacate, dibutylsuccinate, dibutyltartrate; diethylene glycol dipropionate; ethyleneglycol diacetate, -dibutyrate, -dipropionate; tributyl phosphate, tributyrin; polyethylene glycol sorbitan monooleate (polysorbates such as Polysorbar 50); sorbitan monooleate.
- Moreover, suitable binders, lubricants, disintegrating agents, coloring agents, flavoring agents, flow-inducing agents, and melting agents may be included as carriers. The pharmaceutical carrier employed can be, for example, a solid, liquid, or gas. Examples of solid carriers include, but are not limited to, lactose, terra alba, sucrose, glucose, methylcellulose, dicalcium phosphate, calcium sulfate, mannitol, sorbitol talc, starch, gelatin, agar, pectin, acacia, magnesium stearate, and stearic acid. Examples of liquid carriers are sugar syrup, peanut oil, olive oil, and water. Examples of gaseous carriers include carbon dioxide and nitrogen.
- In various aspects, a binder can include, for example, starch, gelatin, natural sugars such as glucose or beta-lactose, corn sweeteners, natural and synthetic gums such as acacia, tragacanth, or sodium alginate, carboxymethylcellulose, polyethylene glycol, waxes, and the like. Lubricants used in these dosage forms include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride, and the like. In a further aspect, a disintegrator can include, for example, starch, methyl cellulose, agar, bentonite, xanthan gum, and the like.
- In various aspects, an oral dosage form, such as a solid dosage form, can comprise a disclosed compound that is attached to polymers as targetable drug carriers or as a prodrug. Suitable biodegradable polymers useful in achieving controlled release of a drug include, for example, polylactic acid, polyglycolic acid, copolymers of polylactic and polyglycolic acid, caprolactones, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacylates, and hydrogels, preferably covalently crosslinked hydrogels.
- Tablets may contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets. These excipients may be, for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example starch, gelatin or acacia, and lubricating agents, for example magnesium stearate, stearic acid or talc. The tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period.
- A tablet containing a disclosed compound can be prepared by compression or molding, optionally with one or more accessory ingredients or adjuvants. Compressed tablets can be prepared by compressing, in a suitable machine, the active ingredient in a free-flowing form such as powder or granules, optionally mixed with a binder, lubricant, inert diluent, surface active or dispersing agent. Molded tablets can be made by molding in a suitable machine, a mixture of the powdered compound moistened with an inert liquid diluent.
- In various aspects, a solid oral dosage form, such as a tablet, can be coated with an enteric coating to prevent ready decomposition in the stomach. In various aspects, enteric coating agents include, but are not limited to, hydroxypropylmethylcellulose phthalate, methacrylic acid-methacrylic acid ester copolymer, polyvinyl acetate-phthalate and cellulose acetate phthalate. Akihiko Hasegawa “Application of solid dispersions of Nifedipine with enteric coating agent to prepare a sustained-release dosage form” Chem. Pharm. Bull. 33:1615-1619 (1985). Various enteric coating materials may be selected on the basis of testing to achieve an enteric coated dosage form designed ab initio to have a preferable combination of dissolution time, coating thicknesses and diametral crushing strength (e.g., see S. C. Porter et al. “The Properties of Enteric Tablet Coatings Made From Polyvinyl Acetate-phthalate and Cellulose acetate Phthalate”, J. Pharm. Pharmacol. 22:42p (1970)). In a further aspect, the enteric coating may comprise hydroxypropyl-methylcellulose phthalate, methacrylic acid-methacrylic acid ester copolymer, polyvinyl acetate-phthalate and cellulose acetate phthalate.
- In various aspects, an oral dosage form can be a solid dispersion with a water soluble or a water insoluble carrier. Examples of water soluble or water insoluble carrier include, but are not limited to, polyethylene glycol, polyvinylpyrrolidone, hydroxypropylmethyl-cellulose, phosphatidylcholine, polyoxyethylene hydrogenated castor oil, hydroxypropylmethylcellulose phthalate, carboxymethylethylcellulose, or hydroxypropylmethylcellulose, ethyl cellulose, or stearic acid.
- In various aspects, an oral dosage form can be in a liquid dosage form, including those that are ingested, or alternatively, administered as a mouth wash or gargle. For example, a liquid dosage form can include aqueous suspensions, which contain the active materials in admixture with excipients suitable for the manufacture of aqueous suspensions. In addition, oily suspensions may be formulated by suspending the active ingredient in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin. Oily suspensions may also contain various excipients. The pharmaceutical compositions of the present disclosure may also be in the form of oil-in-water emulsions, which may also contain excipients such as sweetening and flavoring agents.
- For the preparation of solutions or suspensions it is, for example, possible to use water, particularly sterile water, or physiologically acceptable organic solvents, such as alcohols (ethanol, propanol, isopropanol, 1,2-propylene glycol, polyglycols and their derivatives, fatty alcohols, partial esters of glycerol), oils (for example peanut oil, olive oil, sesame oil, almond oil, sunflower oil, soya bean oil, castor oil, bovine hoof oil), paraffins, dimethyl sulphoxide, triglycerides and the like.
- In the case of a liquid dosage form such as a drinkable solutions, the following substances may be used as stabilizers or solubilizers: lower aliphatic mono- and multivalent alcohols with 2-4 carbon atoms, such as ethanol, n-propanol, glycerol, polyethylene glycols with molecular weights between 200-600 (for example 1 to 40% aqueous solution), diethylene glycol monoethyl ether, 1,2-propylene glycol, organic amides, for example amides of aliphatic C1-06-carboxylic acids with ammonia or primary, secondary or tertiary C1-04-amines or C1-04-hydroxy amines such as urea, urethane, acetamide, N-methyl acetamide, N,N-diethyl acetamide, N,N-dimethyl acetamide, lower aliphatic amines and diamines with 2-6 carbon atoms, such as ethylene diamine, hydroxyethyl theophylline, tromethamine (for example as 0.1 to 20% aqueous solution), aliphatic amino acids.
- In preparing the disclosed liquid dosage form can comprise solubilizers and emulsifiers such as the following non-limiting examples can be used: polyvinyl pyrrolidone, sorbitan fatty acid esters such as sorbitan trioleate, phosphatides such as lecithin, acacia, tragacanth, polyoxyethylated sorbitan monooleate and other ethoxylated fatty acid esters of sorbitan, polyoxyethylated fats, polyoxyethylated oleotriglycerides, linolizated oleotriglycerides, polyethylene oxide condensation products of fatty alcohols, alkylphenols or fatty acids or also 1-methyl-3-(2-hydroxyethyl)imidazolidone-(2). In this context, polyoxyethylated means that the substances in question contain polyoxyethylene chains, the degree of polymerization of which generally lies between 2 and 40 and in particular between 10 and 20. Polyoxyethylated substances of this kind may for example be obtained by reaction of hydroxyl group-containing compounds (for example mono- or diglycerides or unsaturated compounds such as those containing oleic acid radicals) with ethylene oxide (for example 40 Mol ethylene oxide per 1 Mol glyceride). Examples of oleotriglycerides are olive oil, peanut oil, castor oil, sesame oil, cottonseed oil, corn oil. See also Dr. H. P. Fiedler “Lexikon der Hillsstoffe für Pharmazie, Kostnetik and angrenzende Gebiete” 1971, pages 191-195.
- In various aspects, a liquid dosage form can further comprise preservatives, stabilizers, buffer substances, flavor correcting agents, sweeteners, colorants, antioxidants and complex formers and the like. Complex formers which may be for example be considered are: chelate formers such as ethylene diamine retrascetic acid, nitrilotriacetic acid, diethylene triamine pentacetic acid and their salts.
- It may optionally be necessary to stabilize a liquid dosage form with physiologically acceptable bases or buffers to a pH range of approximately 6 to 9. Preference may be given to as neutral or weakly basic a pH value as possible (up to pH 8).
- In order to enhance the solubility and/or the stability of a disclosed compound in a disclosed liquid dosage form, a parenteral injection form, or an intravenous injectable form, it can be advantageous to employ α-, β- or γ-cyclodextrins or their derivatives, in particular hydroxyalkyl substituted cyclodextrins, e.g. 2-hydroxypropyl-β-cyclodextrin or sulfobutyl-β-cyclodextrin. Also co-solvents such as alcohols may improve the solubility and/or the stability of the compounds according to the present disclosure in pharmaceutical compositions.
- In various aspects, a disclosed liquid dosage form, a parenteral injection form, or an intravenous injectable form can further comprise liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles, and multilamellar vesicles. Liposomes can be formed from a variety of phospholipids, such as cholesterol, stearylamine, or phosphatidylcholines.
- Pharmaceutical compositions of the present disclosure suitable injection, such as parenteral administration, such as intravenous, intramuscular, or subcutaneous administration. Pharmaceutical compositions for injection can be prepared as solutions or suspensions of the active compounds in water. A suitable surfactant can be included such as, for example, hydroxypropylcellulose. Dispersions can also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof in oils. Further, a preservative can be included to prevent the detrimental growth of microorganisms.
- Pharmaceutical compositions of the present disclosure suitable for parenteral administration can include sterile aqueous or oleaginous solutions, suspensions, or dispersions. Furthermore, the compositions can be in the form of sterile powders for the extemporaneous preparation of such sterile injectable solutions or dispersions. In some aspects, the final injectable form is sterile and must be effectively fluid for use in a syringe. The pharmaceutical compositions should be stable under the conditions of manufacture and storage; thus, preferably should be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g., glycerol, propylene glycol and liquid polyethylene glycol), vegetable oils, and suitable mixtures thereof.
- Injectable solutions, for example, can be prepared in which the carrier comprises saline solution, glucose solution or a mixture of saline and glucose solution. Injectable suspensions may also be prepared in which case appropriate liquid carriers, suspending agents and the like may be employed. In some aspects, a disclosed parenteral formulation can comprise about 0.01-0.1 M, e.g. about 0.05 M, phosphate buffer. In a further aspect, a disclosed parenteral formulation can comprise about 0.9% saline.
- In various aspects, a disclosed parenteral pharmaceutical composition can comprise pharmaceutically acceptable carriers such as aqueous or non-aqueous solutions, suspensions, and emulsions. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate. Aqueous carriers include but not limited to water, alcoholic/aqueous solutions, emulsions or suspensions, including saline and buffered media. Parenteral vehicles can include mannitol, normal serum albumin, sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's and fixed oils. Intravenous vehicles include fluid and nutrient replenishers, electrolyte replenishers such as those based on Ringer's dextrose, and the like. Preservatives and other additives may also be present, such as, for example, antimicrobials, antioxidants, collating agents, inert gases and the like. In a further aspect, a disclosed parenteral pharmaceutical composition can comprise may contain minor amounts of additives such as substances that enhance isotonicity and chemical stability, e.g., buffers and preservatives. Also contemplated for injectable pharmaceutical compositions are solid form preparations that are intended to be converted, shortly before use, to liquid form preparations. Furthermore, other adjuvants can be included to render the formulation isotonic with the blood of the subject or patient.
- In addition to the pharmaceutical compositions described herein above, the disclosed compounds can also be formulated as a depot preparation. Such long acting formulations can be administered by implantation (e.g., subcutaneously or intramuscularly) or by intramuscular injection. Thus, for example, the compounds can be formulated with suitable polymeric or hydrophobic materials (e.g., as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, e.g., as a sparingly soluble salt.
- Pharmaceutical compositions of the present disclosure can be in a form suitable for topical administration. As used herein, the phrase “topical application” means administration onto a biological surface, whereby the biological surface includes, for example, a skin area (e.g., hands, forearms, elbows, legs, face, nails, anus and genital areas) or a mucosal membrane. By selecting the appropriate carrier and optionally other ingredients that can be included in the composition, as is detailed herein below, the compositions of the present invention may be formulated into any form typically employed for topical application. A topical pharmaceutical composition can be in a form of a cream, an ointment, a paste, a gel, a lotion, milk, a suspension, an aerosol, a spray, foam, a dusting powder, a pad, and a patch. Further, the compositions can be in a form suitable for use in transdermal devices. These formulations can be prepared, utilizing a compound of the present disclosure, or pharmaceutically acceptable salts thereof, via conventional processing methods. As an example, a cream or ointment is prepared by mixing hydrophilic material and water, together with about 5 wt % to about 10 wt % of the compound, to produce a cream or ointment having a desired consistency.
- In the compositions suitable for percutaneous administration, the carrier optionally comprises a penetration enhancing agent and/or a suitable wetting agent, optionally combined with suitable additives of any nature in minor proportions, which additives do not introduce a significant deleterious effect on the skin. Said additives may facilitate the administration to the skin and/or may be helpful for preparing the desired compositions. These compositions may be administered in various ways, e.g., as a transdermal patch, as a spot-on, as an ointment.
- Ointments are semisolid preparations, typically based on petrolatum or petroleum derivatives. The specific ointment base to be used is one that provides for optimum delivery for the active agent chosen for a given formulation, and, preferably, provides for other desired characteristics as well (e.g., emollience). As with other carriers or vehicles, an ointment base should be inert, stable, nonirritating and nonsensitizing. As explained in Remington: The Science and Practice of Pharmacy, 19th Ed., Easton, Pa.: Mack Publishing Co. (1995), pp. 1399-1404, ointment bases may be grouped in four classes: oleaginous bases; emulsifiable bases; emulsion bases; and water-soluble bases. Oleaginous ointment bases include, for example, vegetable oils, fats obtained from animals, and semisolid hydrocarbons obtained from petroleum. Emulsifiable ointment bases, also known as absorbent ointment bases, contain little or no water and include, for example, hydroxystearin sulfate, anhydrous lanolin and hydrophilic petrolatum. Emulsion ointment bases are either water-in-oil (W/O) emulsions or oil-in-water (O/W) emulsions, and include, for example, cetyl alcohol, glyceryl monostearate, lanolin and stearic acid. Preferred water-soluble ointment bases are prepared from polyethylene glycols of varying molecular weight.
- Lotions are preparations that are to be applied to the skin surface without friction. Lotions are typically liquid or semiliquid preparations in which solid particles, including the active agent, are present in a water or alcohol base. Lotions are typically preferred for treating large body areas, due to the ease of applying a more fluid composition. Lotions are typically suspensions of solids, and oftentimes comprise a liquid oily emulsion of the oil-in-water type. It is generally necessary that the insoluble matter in a lotion be finely divided. Lotions typically contain suspending agents to produce better dispersions as well as compounds useful for localizing and holding the active agent in contact with the skin, such as methylcellulose, sodium carboxymethyl-cellulose, and the like.
- Creams are viscous liquids or semisolid emulsions, either oil-in-water or water-in-oil. Cream bases are typically water-washable, and contain an oil phase, an emulsifier and an aqueous phase. The oil phase, also called the “internal” phase, is generally comprised of petrolatum and/or a fatty alcohol such as cetyl or stearyl alcohol. The aqueous phase typically, although not necessarily, exceeds the oil phase in volume, and generally contains a humectant. The emulsifier in a cream formulation is generally a nonionic, anionic, cationic or amphoteric surfactant. Reference may be made to Remington: The Science and Practice of Pharmacy, supra, for further information.
- Pastes are semisolid dosage forms in which the bioactive agent is suspended in a suitable base. Depending on the nature of the base, pastes are divided between fatty pastes or those made from a single-phase aqueous gel. The base in a fatty paste is generally petrolatum, hydrophilic petrolatum and the like. The pastes made from single-phase aqueous gels generally incorporate carboxymethylcellulose or the like as a base. Additional reference may be made to Remington: The Science and Practice of Pharmacy, for further information.
- Gel formulations are semisolid, suspension-type systems. Single-phase gels contain organic macromolecules distributed substantially uniformly throughout the carrier liquid, which is typically aqueous, but also, preferably, contain an alcohol and, optionally, an oil. Preferred organic macromolecules, i.e., gelling agents, are crosslinked acrylic acid polymers such as the family of carbomer polymers, e.g., carboxypolyalkylenes that may be obtained commercially under the trademark Carbopol™. Other types of preferred polymers in this context are hydrophilic polymers such as polyethylene oxides, polyoxyethylene-polyoxypropylene copolymers and polyvinylalcohol; modified cellulose, such as hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxypropyl methylcellulose, hydroxypropyl methylcellulose phthalate, and methyl cellulose; gums such as tragacanth and xanthan gum; sodium alginate; and gelatin. In order to prepare a uniform gel, dispersing agents such as alcohol or glycerin can be added, or the gelling agent can be dispersed by trituration, mechanical mixing or stirring, or combinations thereof.
- Sprays generally provide the active agent in an aqueous and/or alcoholic solution which can be misted onto the skin for delivery. Such sprays include those formulated to provide for concentration of the active agent solution at the site of administration following delivery, e.g., the spray solution can be primarily composed of alcohol or other like volatile liquid in which the active agent can be dissolved. Upon delivery to the skin, the carrier evaporates, leaving concentrated active agent at the site of administration.
- Foam compositions are typically formulated in a single or multiple phase liquid form and housed in a suitable container, optionally together with a propellant which facilitates the expulsion of the composition from the container, thus transforming it into a foam upon application. Other foam forming techniques include, for example the “Bag-in-a-can” formulation technique. Compositions thus formulated typically contain a low-boiling hydrocarbon, e.g., isopropane. Application and agitation of such a composition at the body temperature cause the isopropane to vaporize and generate the foam, in a manner similar to a pressurized aerosol foaming system. Foams can be water-based or aqueous alkanolic, but are typically formulated with high alcohol content which, upon application to the skin of a user, quickly evaporates, driving the active ingredient through the upper skin layers to the site of treatment.
- Skin patches typically comprise a backing, to which a reservoir containing the active agent is attached. The reservoir can be, for example, a pad in which the active agent or composition is dispersed or soaked, or a liquid reservoir. Patches typically further include a frontal water permeable adhesive, which adheres and secures the device to the treated region. Silicone rubbers with self-adhesiveness can alternatively be used. In both cases, a protective permeable layer can be used to protect the adhesive side of the patch prior to its use. Skin patches may further comprise a removable cover, which serves for protecting it upon storage.
- Examples of patch configuration which can be utilized with the present invention include a single-layer or multi-layer drug-in-adhesive systems which are characterized by the inclusion of the drug directly within the skin-contacting adhesive. In such a transdermal patch design, the adhesive not only serves to affix the patch to the skin, but also serves as the formulation foundation, containing the drug and all the excipients under a single backing film. In the multi-layer drug-in-adhesive patch a membrane is disposed between two distinct drug-in-adhesive layers or multiple drug-in-adhesive layers are incorporated under a single backing film.
- Examples of pharmaceutically acceptable carriers that are suitable for pharmaceutical compositions for topical applications include carrier materials that are well-known for use in the cosmetic and medical arts as bases for e.g., emulsions, creams, aqueous solutions, oils, ointments, pastes, gels, lotions, milks, foams, suspensions, aerosols and the like, depending on the final form of the composition. Representative examples of suitable carriers according to the present invention therefore include, without limitation, water, liquid alcohols, liquid glycols, liquid polyalkylene glycols, liquid esters, liquid amides, liquid protein hydrolysates, liquid alkylated protein hydrolysates, liquid lanolin and lanolin derivatives, and like materials commonly employed in cosmetic and medicinal compositions. Other suitable carriers according to the present invention include, without limitation, alcohols, such as, for example, monohydric and polyhydric alcohols, e.g., ethanol, isopropanol, glycerol, sorbitol, 2-methoxyethanol, diethyleneglycol, ethylene glycol, hexyleneglycol, mannitol, and propylene glycol; ethers such as diethyl or dipropyl ether; polyethylene glycols and methoxypolyoxyethylenes (carbowaxes having molecular weight ranging from 200 to 20,000); polyoxyethylene glycerols, polyoxyethylene sorbitols, stearoyl diacetin, and the like.
- Topical compositions of the present disclosure can, if desired, be presented in a pack or dispenser device, such as an FDA-approved kit, which may contain one or more unit dosage forms containing the active ingredient. The dispenser device may, for example, comprise a tube. The pack or dispenser device may be accompanied by instructions for administration. The pack or dispenser device may also be accompanied by a notice in a form prescribed by a governmental agency regulating the manufacture, use, or sale of pharmaceuticals, which notice is reflective of approval by the agency of the form of the compositions for human or veterinary administration. Such notice, for example, may include labeling approved by the U.S. Food and Drug Administration for prescription drugs or of an approved product insert. Compositions comprising the topical composition of the invention formulated in a pharmaceutically acceptable carrier may also be prepared, placed in an appropriate container, and labeled for treatment of an indicated condition.
- Another patch system configuration which can be used by the present invention is a reservoir transdermal system design which is characterized by the inclusion of a liquid compartment containing a drug solution or suspension separated from the release liner by a semi-permeable membrane and adhesive. The adhesive component of this patch system can either be incorporated as a continuous layer between the membrane and the release liner or in a concentric configuration around the membrane. Yet another patch system configuration which can be utilized by the present invention is a matrix system design which is characterized by the inclusion of a semisolid matrix containing a drug solution or suspension which is in direct contact with the release liner. The component responsible for skin adhesion is incorporated in an overlay and forms a concentric configuration around the semisolid matrix.
- Pharmaceutical compositions of the present disclosure can be in a form suitable for rectal administration wherein the carrier is a solid. It is preferable that the mixture forms unit dose suppositories. Suitable carriers include cocoa butter and other materials commonly used in the art. The suppositories can be conveniently formed by first admixing the composition with the softened or melted carrier(s) followed by chilling and shaping in molds.
- Pharmaceutical compositions containing a compound of the present disclosure, and/or pharmaceutically acceptable salts thereof, can also be prepared in powder or liquid concentrate form.
- The pharmaceutical composition (or formulation) may be packaged in a variety of ways. Generally, an article for distribution includes a container that contains the pharmaceutical composition in an appropriate form. Suitable containers are well known to those skilled in the art and include materials such as bottles (plastic and glass), sachets, foil blister packs, and the like. The container may also include a tamper proof assemblage to prevent indiscreet access to the contents of the package. In addition, the container typically has deposited thereon a label that describes the contents of the container and any appropriate warnings or instructions.
- The disclosed pharmaceutical compositions may, if desired, be presented in a pack or dispenser device which may contain one or more unit dosage forms containing the active ingredient. The pack may for example comprise metal or plastic foil, such as a blister pack. The pack or dispenser device may be accompanied by instructions for administration. The pack or dispenser may also be accompanied with a notice associated with the container in form prescribed by a governmental agency regulating the manufacture, use, or sale of pharmaceuticals, which notice is reflective of approval by the agency of the form of the drug for human or veterinary administration. Such notice, for example, may be the labeling approved by the U.S. Food and Drug Administration for prescription drugs, or the approved product insert. Pharmaceutical compositions comprising a disclosed compound formulated in a compatible pharmaceutical carrier may also be prepared, placed in an appropriate container, and labeled for treatment of an indicated condition.
- The exact dosage and frequency of administration depends on the particular disclosed lithium cholesterol composition, including, but not limited to lithium cholesterol sulfate, or derivative thereof; the particular condition being treated and the severity of the condition being treated; various factors specific to the medical history of the subject to whom the dosage is administered such as the age, weight, sex, extent of disorder and general physical condition of the particular subject, as well as other medication the individual may be taking; as is well known to those skilled in the art. Furthermore, it is evident that said effective daily amount may be lowered or increased depending on the response of the treated subject and/or depending on the evaluation of the physician prescribing the compounds of the present disclosure.
- Depending on the mode of administration, the pharmaceutical composition will comprise from 0.05 to 99% by weight, preferably from 0.1 to 70% by weight, more preferably from 0.1 to 50% by weight of the active ingredient, and, from 1 to 99.95% by weight, preferably from 30 to 99.9% by weight, more preferably from 50 to 99.9% by weight of a pharmaceutically acceptable carrier, all percentages being based on the total weight of the composition.
- For therapeutic treatments of the present disclosure, with lithium cholesterol composition, including, but not limited to lithium cholesterol sulfate, as active ingredient, in general, an appropriate dosage level will generally be about 0.01 to 1000 mg per kg patient body weight per day and can be administered in single or multiple doses. In various aspects, the dosage level will be about 0.1 to about 500 mg/kg per day, about 0.1 to 250 mg/kg per day, or about 0.5 to 100 mg/kg per day. A suitable dosage level can be about 0.01 to 1000 mg/kg per day, about 0.01 to 500 mg/kg per day, about 0.01 to 250 mg/kg per day, about 0.05 to 100 mg/kg per day, or about 0.1 to 50 mg/kg per day. Within this range the dosage can be 0.05 to 0.5, 0.5 to 5.0 or 5.0 to 50 mg/kg per day. For oral administration, the compositions are preferably provided in the form of tablets containing 1.0 to 1000 mg of the active ingredient, particularly 1.0, 5.0, 10, 15, 20, 25, 50, 75, 100, 150, 200, 250, 300, 400, 500, 600, 750, 800, 900 and 1000 mg of the active ingredient for the symptomatic adjustment of the dosage of the patient to be treated. The compound can be administered on a regimen of 1 to 4 times per day, preferably once or twice per day. This dosing regimen can be adjusted to provide the optimal therapeutic response.
- Such unit doses as described hereinabove and hereinafter can be administered more than once a day, for example, 2, 3, 4, 5 or 6 times a day. In various aspects, such unit doses can be administered 1 or 2 times per day, so that the total dosage for a 70 kg adult is in the range of 0.001 to about 500 mg per kg weight of subject per administration. In a further aspect, dosage is 0.001 to about 300 mg per kg weight of subject per administration, and such therapy can extend for a number of weeks or months, and in some cases, years. It will be understood, however, that the specific dose level for any particular patient will depend on a variety of factors including the activity of the specific compound employed; the age, body weight, general health, sex and diet of the individual being treated; the time and route of administration; the rate of excretion; other drugs that have previously been administered; and the severity of the particular disease undergoing therapy, as is well understood by those of skill in the area.
- A typical dosage can be one 1 mg to about 1000 mg tablet or 1 mg to about 300 mg taken once a day, or, multiple times per day, or one time-release capsule or tablet taken once a day and containing a proportionally higher content of active ingredient. The time-release effect can be obtained by capsule materials that dissolve at different pH values, by capsules that release slowly by osmotic pressure, or by any other known means of controlled release.
- It can be necessary to use dosages outside these ranges in some cases as will be apparent to those skilled in the art. Further, it is noted that the clinician or treating physician will know how and when to start, interrupt, adjust, or terminate therapy in conjunction with individual patient response.
- The present disclosure is further directed to a method for the manufacture of a medicament comprising an effective amount of lithium cholesterol sulfate for treating a neurological disorder (e.g., treatment of one or more neurological disorders such as neurodegenerative conditions and/or neurodevelopmental disorders, and other disorders, such as bipolar disorder or conditions caused by brain injury) in mammals (e.g., humans) comprising combining one or more disclosed lithium cholesterol compositions, including, but not limited to lithium cholesterol sulfate, products, or compositions with a pharmaceutically acceptable carrier or diluent. Thus, in one aspect, the present disclosure further relates to a method for manufacturing a medicament comprising combining at least one disclosed lithium cholesterol composition, including, but not limited to lithium cholesterol sulfate, or at least one disclosed product with a pharmaceutically acceptable carrier or diluent.
- The disclosed pharmaceutical compositions can further comprise other therapeutically active compounds, which are usually applied in the treatment of the above mentioned pathological or clinical conditions.
- It is understood that the disclosed compositions can be prepared from the disclosed compounds. It is also understood that the disclosed compositions can be employed in the disclosed methods of using.
- As already mentioned, the present disclosure relates to a pharmaceutical composition comprising a therapeutically effective amount of a disclosed lithium cholesterol composition, including, but not limited to lithium cholesterol sulfate, a product of a disclosed method of making, and a pharmaceutically acceptable carrier. Additionally, the present disclosure relates to a process for preparing such a pharmaceutical composition, characterized in that a pharmaceutically acceptable carrier is intimately mixed with a therapeutically effective amount of a disclosed lithium cholesterol composition, including, but not limited to lithium cholesterol sulfate, according to the present disclosure.
- As already mentioned, the present disclosure also relates to a pharmaceutical composition comprising a disclosed lithium cholesterol composition, including, but not limited to lithium cholesterol sulfate, a product of a disclosed method of making, or a pharmaceutically acceptable derivative thereof, and one or more other drugs in the treatment, prevention, control, amelioration, or reduction of risk of diseases or conditions for a disclosed compound or the other drugs may have utility as well as to the use of such a composition for the manufacture of a medicament. The present disclosure also relates to a combination of disclosed lithium cholesterol composition, including, but not limited to lithium cholesterol sulfate, a product of a disclosed method of making, a pharmaceutically acceptable derivative thereof, a polymorph thereof, and an additional therapeutic agent, as a combined preparation for simultaneous, separate or sequential use in the treatment or prevention of a condition in a mammal, including a human, the treatment or prevention of which is affected or facilitated by the modulatory effect of the disclosed compound and the additional therapeutic agent. The different drugs of such a combination or product may be combined in a single preparation together with pharmaceutically acceptable carriers or diluents, or they may each be present in a separate preparation together with pharmaceutically acceptable carriers or diluents.
- In certain embodiments, the present disclosure provides compounds and/or pharmaceutical compositions comprising lithium cholesterol sulfate for use as a medicament. This disclosure also provides compounds and pharmaceutical compositions comprising lithium cholesterol sulfate for use in the treatment of a neurological disorder. As discussed below, in embodiments, the neurological disorder is selected from the group consisting of: Alzheimer's disease, Autism spectrum disorder (ASD), bipolar disorder, traumatic brain injury, radiation induced brain injury and other neuropsychiatric disorders inducing, but not limited to amyotrophic laterals sclerosis (ALS), Parkinson's disease (PD), depressive disorder, suicidality, schizoaffective disorder, tic disorder (e.g., Tourette's syndrome), etc.
- Methods of Making the Compounds.
- In one aspect, the disclosure relates to methods of making compounds useful for the treatment for neurodegenerative conditions (such as Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic laterals sclerosis (ALS), and the like), neurodevelopmental disorders (such as Autism spectrum disorders, and the like), traumatic brain injury and acute brain injury (such as caused by ischemic stroke, head trauma, and the like), radiation induced brain injury, mood disorders (such as suicidal ideation, bipolar disorder, depressive disorder), and other neuropsychiatric disorders, including but not limited to schizoaffective disorder, tic disorder (e.g., Tourette's syndrome), and the like. In one aspect, the disclosure relates to the disclosed synthetic manipulations. In a further aspect, the disclosed compositions, such as lithium cholesterol compositions, including, but not limited to lithium cholesterol sulfate compositions (LiCS), comprise the products of the synthetic methods described herein.
- The compounds of this disclosure can be prepared by employing reactions as shown in the disclosed schemes, in addition to other standard manipulations that are known in the literature, exemplified in the experimental sections or clear to one skilled in the art. For clarity, examples having a fewer substituent can be shown where multiple substituents are allowed under the definitions disclosed herein. Thus, the following examples are provided so that the disclosure might be more fully understood, are illustrative only, and should not be construed as limiting.
- It is contemplated that each disclosed method can further comprise additional steps, manipulations, and/or components. It is also contemplated that any one or more step, manipulation, and/or component can be optionally omitted from the disclosure. It is understood that a disclosed method can be used to provide the disclosed compounds. It is also understood that the products of the disclosed methods can be employed in the disclosed compositions, kits, and uses.
- In one aspect, the disclosed lithium cholesterol compositions, included, but not limited to compositions comprising a lithium cholesterol sulfate compound. In one aspect, a lithium cholesterol sulfate compound of the present disclosure can be prepared under mild conditions by a dicyclohexylcarbodiimide-mediated sulfation reaction of a hydroxyl moiety as shown immediately below. This type of reaction can be carried out as described in various methods, including, but not limited to, those described by R. O. Mumma (Lipids (1966) 1: 221) and R. O. Mumma, et al. (Steroids (1969) 14(1):67-74), and the reaction conditions set forth in this exemplary method can be suitably modified by the skilled artisan with regard to reaction amounts and ratios, temperature, time, and specific methods of purification. It should be noted that in the various following reaction schemes, the preparation of a lithium salt in the last step is shown utilizing LiOH, under conditions as generally described in the indicated reference or alternatively, as described S. Natelson, et al. (J. Biol. Chem. 1934, 105:761-765). However, other suitable bases can be used such as lithium carbonate.
- Alternatively, a method of obtaining the disclosed lithium cholesterol sulfate compounds can utilize chlorosulfuric acid comprising a suitable protecting group (indicated as “PG” in the reaction scheme shown below) on the acid group, e.g., an alkyl protecting group such as isobutyl. Suitable methods such as these are described by L. S. Simpson and T. S. Widlanski (JACS (2006) 128(5):1605-1610), and the reaction conditions set forth in this exemplary method can be suitably modified by the skilled artisan with regard to reaction amounts and ratios, temperature, time, and specific methods of purification. The overall reaction is shown below.
- A further alternative sulfation method is as described by H. Noda, et al. (J. Clin. Biochem. Nutr. (1991) 10:83-91) involving reaction of excess cholesterol with sulfur trioxide-pyridine complex, followed by isolation using LiOH instead of NaOH. Preparation of lithium cholesterol sulfate from a sodium saltcan also be generally carried out as described by S. Natelson, et al. (J. Biol. Chem. 1934, 105:761-765).
- Cholesterol sulfate is commercially available as the sodium salt, and this can be converted to the lithium salt by a variety of methods, including those described by S. Natelson, et al. (J. Biol. Chem. 1934, 105:761-765). Alternatively, commercially available sodium cholesterol sulfate can be dissolved in methanol with a molar equivalent of lithium chloride and heated, followed by differential precipitation and filtration to first remove sodium chloride, then with further cooling and addition of water, pure lithium cholesterol sulfate can be crystalizeed and obtained by filtration.
- In one aspect, a lithium cholesterol oxoalkanoate compounds, i.e., wherein R is —(C═O)(CH2)n(C═O)OLi), where n is an integer having a value of 1, 2, 3, 4, 5, or 6, of the present disclosure can be prepared by reaction of cholesterol with a suitable cyclic dicarboxylic anhydride essentially as described by Y. Nie (Theranostics 2012; 2(11):1092-1103), and the reaction conditions set forth in this exemplary method can be suitably modified by the skilled artisan with regard to reaction amounts and ratios, temperature, time, and specific methods of purification. A generalized reaction approach is shown immediately below. In the following reaction scheme, as an example, when n=4, the cyclic dicarboxylic anhydride used would be succinic anhydride.
- In one aspect, a lithium cholesterol phosphate compounds of the present disclosure can be prepared by reaction of cholesterol with a suitable cyclic dicarboxylic anhydride essentially as described by S. C. Davis and F. C. Szoka, Jr. (Bioconj. Chem. (1998) 9:783-792), and the reaction conditions set forth in this exemplary method can be suitably modified by the skilled artisan with regard to reaction amounts and ratios, temperature, time, and specific methods of purification. A generalized reaction approach is shown immediately below.
- In one aspect, a lithium cholesterol carboxylate compounds, i.e., wherein R is —(CH2)n(C═O)OLi), where n is an integer having a value of 1, 2, 3, 4, 5, or 6, of the present disclosure can be prepared as generally described in U.S. Pat. Publ. No. 2015/0018436 for acids of general formula IX therein. For example, the lithium cholesterol carboxylate compounds, i.e., wherein R is —(CH2)n(C═O)OLi), where n is an integer having a value of 1, 2, 3, 4, 5, or 6, of the present disclosure can be prepared base catalyzed alkylation of cholesterol by tert-butylester of ω-bromoalkane acids having C2-C13 carbon atoms in an aprotic solvent followed by acidic cleavage (preferably using formic acid in diethylether) of the obtained tert-butylesters. Alternatively; the lithium cholesterol carboxylate compounds, i.e., wherein R is —(CH2)n(C═O)OLi), where n is an integer having a value of 1, 2, 3, 4, 5, or 6, of the present disclosure can be prepared by O-tosylation of cholesterol using standard techniques, followed by reaction w-hydroxyalkanenitriles having C2-C6 carbon atoms in a nonpolar aprotic solvent at increased temperature (prefer-ably in boiling toluene) followed by basic hydrolysis (preferably in a mixture of toluene and aqueous solution of NaOH at elevated temperature) of the intermediary O-[(3β)-cholest-5-en-3-yl]-ω-hydroxyalkanenitrile.
- Methods of Using the Compounds.
- In a further aspect, the present disclosure provides methods of treatment comprising administration of a therapeutically effective amount of a disclosed lithium cholesterol composition, including, but not limited to lithium cholesterol sulfate, or pharmaceutical composition as disclosed herein above to a subject in need thereof. A subject in need of treatment with the lithium cholesterol composition, including, but not limited to lithium cholesterol sulfate, or pharmaceutical compositions of the present disclosure can include, but are not necessarily limited to, subjects in need of treatment for neurodegenerative conditions (such as Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic laterals sclerosis (ALS), and the like), neurodevelopmental disorders (such as Autism spectrum disorders, and the like), traumatic brain injury and acute brain injury (such as caused by ischemic stroke, head trauma, and the like), radiation induced brain injury, mood disorders (such as suicidal ideation, bipolar disorder, depressive disorder), and other neuropsychiatric disorders, including but not limited to schizoaffective disorder, tic disorder (e.g., Tourette's syndrome), and the like. In particular, methods of the present disclosure include treatment of a patient in need of treatment for Alzheimer's disease, bipolar disorder, or autism spectrum disorder with a therapeutically effective amount of a lithium cholesterol composition, including, but not limited to lithium cholesterol sulfate, or lithium cholesterol composition, including, but not limited to lithium cholesterol sulfate, pharmaceutical composition of the present disclosure.
- In embodiments, methods of the present disclosure also include increasing levels of inhibitory phosphorylation of GSK3β in cells or in a subject by exposing the cells or subject to an effective amount of a lithium cholesterol composition, including, but not limited to lithium cholesterol sulfate, or a lithium cholesterol composition, including, but not limited to lithium cholesterol sulfate, pharmaceutical composition of the present disclosure. In embodiments, methods of the present disclosure include decreasing levels of phosphorylation of tau in cells or in a subject by exposing the cells or subject to an effective amount of a lithium cholesterol composition, including, but not limited to lithium cholesterol sulfate, or a lithium cholesterol composition, including, but not limited to lithium cholesterol sulfate, pharmaceutical composition of the present disclosure. In embodiments, methods of the present disclosure include decreasing levels of LPS-induced TNFα in cells or in a subject by exposing the cells or subject to an effective amount of a lithium cholesterol composition, including, but not limited to lithium cholesterol sulfate, or a lithium cholesterol composition, including, but not limited to lithium cholesterol sulfate, pharmaceutical composition of the present disclosure. Embodiments of the present disclosure also include a combination of one or more of increasing levels of inhibitory phosphorylation of GSK3β, decreasing levels of phosphorylation of tau, and/or decreasing levels of LPS-induced TNFα in cells or in a subject by exposing the cells or subject to an effective amount of a lithium cholesterol composition, including, but not limited to lithium cholesterol sulfate, or lithium cholesterol composition, including, but not limited to lithium cholesterol sulfate, pharmaceutical composition of the present disclosure.
- In embodiments of the methods of the present disclosure, administration of the pharmaceutical compositions including lithium cholesterol sulfate increases the lithium levels in the brain such that a subject has a greater brain to blood lithium level ratio than the brain to blood lithium level in a subject administered lithium chloride. Also, in methods of the present disclosure, administration of the pharmaceutical compositions including lithium cholesterol sulfate does not substantially increase lithium levels in the liver or kidney of the subject.
- The methods of the present disclosure may further comprise administering an additional therapeutic and/or active agent for treating the neurological disorder before, during, or after the administration of the lithium cholesterol composition. The additional agent may be administered to the subject in the same composition as the lithium cholesterol composition or in separate compositions administered by the same or different anatomical routes. Accordingly, the compositions of the disclosure discussed above may include one or more such additional agents as well.
- In some embodiments, the additional agent is an anti-depressant, anti-convulsant, or mood stabilizer, or a combination of two or more of the foregoing. In some embodiments, the additional agent is a selective serotonin reuptake inhibitor (SSRI), serotonin-noroepinephrine reuptake inhibitor (SNRI), serotonin antagonist and reuptake inhibitor (SARI), monamine oxidase inhibitor (MAOI), carboxamide, fructose derivative, triazine, or a combination of two or more of the foregoing. In some embodiments, the disorder is a neurodegenerative disease such as Alzheimer's disease, and the additional agent is selected from the group consisting of a cholinesterase inhibitor (e.g., donepezil, rivastigmine, galantamine), N-methyl D-aspartate antagonist (e.g., memantine), or vitamin E, or a combination. In some embodiments, the additional agent is donepezil, rivastigmine, galantamine, memantine, or a combination of two or more of the foregoing.
- Kits.
- In a further aspect, the present disclosure relates to kits comprising a disclosed lithium cholesterol sulfate compound, or a pharmaceutically composition comprising lithium cholesterol composition, including, but not limited to lithium cholesterol sulfate, and instructions for administering the compound to treat a neurological disorder. In embodiment, the kit may further contain additional instructions for combining the pharmaceutical composition comprising lithium cholesterol composition, including, but not limited to lithium cholesterol sulfate, with additional components and/or additional therapeutic agents and administration of the composition to a subject to treat a neurological disorder.
- The disclosed compounds and/or pharmaceutical compositions comprising the disclosed compounds can conveniently be presented as a kit, whereby two or more components, which may be active or inactive ingredients, carriers, diluents, and the like, are provided with instructions for preparation of the actual dosage form by the patient or person administering the drug to the patient. Such kits may be provided with all necessary materials and ingredients contained therein, or they may contain instructions for using or making materials or components that must be obtained independently by the patient or person administering the drug to the patient. In further aspects, a kit can include optional components that aid in the administration of the unit dose to patients, such as vials for reconstituting powder forms, syringes for injection, customized IV delivery systems, inhalers, etc. Additionally, a kit can contain instructions for preparation and administration of the compositions. The kit can be manufactured as a single use unit dose for one patient, multiple uses for a particular patient (at a constant dose or in which the individual compounds may vary in potency as therapy progresses); or the kit may contain multiple doses suitable for administration to multiple patients (“bulk packaging”). The kit components may be assembled in cartons, blister packs, bottles, tubes, and the like. In a further aspect, the disclosed kits can be packaged in a daily dosing regimen (e.g., packaged on cards, packaged with dosing cards, packaged on blisters or blow-molded plastics, etc.). Such packaging promotes products and increases patient compliance with drug regimens. Such packaging can also reduce patient confusion. The present invention also features such kits further containing instructions for use.
- In a further aspect, the present disclosure also provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the pharmaceutical compositions of the invention. Associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration.
- In various aspects, the disclosed kits can also comprise compounds and/or products co-packaged, co-formulated, and/or co-delivered with other components. For example, a drug manufacturer, a drug reseller, a physician, a compounding shop, or a pharmacist can provide a kit comprising a disclosed compound and/or product and another component for delivery to a patient.
- Thus, in embodiments, the kit further includes at least one additional therapeutic agent for treatment of the neurological disorder. In embodiments, the neurological disorder can include neurodegenerative conditions, such as, but not limited to Alzheimer's disease, Parkinson's disease, and myotrophic laterals sclerosis (ALS); neurodevelopmental disorders, such as, but not limited to Autism spectrum disorders; traumatic brain injury, radiation induced brain injury, and acute brain injury, such as but not limited to, neurological injury caused by ischemic stroke, head trauma, and the like; mood disorders, such as but not limited to suicidal ideation, bipolar disorder, and depressive disorder; and other neuropsychiatric disorders, including but not limited to schizoaffective disorder, tic disorder (e.g., Tourette's syndrome).
- In some embodiments, the additional agent is an anti-depressant, anti-convulsant, or mood stabilizer, or a combination of two or more of the foregoing. In some embodiments, the additional agent is a selective serotonin reuptake inhibitor (SSRI), serotonin-noroepinephrine reuptake inhibitor (SNRI), serotonin antagonist and reuptake inhibitor (SARI), monamine oxidase inhibitor (MAOI), carboxamide, fructose derivative, triazine, or a combination of two or more of the foregoing. In some embodiments, the disorder is a neurodegenerative disease such as Alzheimer's disease, and the additional agent is selected from the group consisting of a cholinesterase inhibitor (e.g., donepezil, rivastigmine, galantamine), N-methyl D-aspartate antagonist (e.g., memantine), or vitamin E, or a combination. In some embodiments, the additional agent is donepezil, rivastigmine, galantamine, memantine, or a combination of two or more of the foregoing.
- It is contemplated that the disclosed kits can be used in connection with the disclosed methods of making, the disclosed methods of using or treating, and/or the disclosed compositions.
- Research Tools.
- The disclosed compounds and pharmaceutical compositions have activity as activators/inhibitors of biomarkers associated with various neurological disorders. For instance, the lithium cholesterol sulfate compounds and pharmaceutical compositions of the present disclosure have activity as activating/increasing levels of inhibitory phosphorylation of GSK3β, as inhibiting/decreasing levels of phosphorylation of tau, and inhibiting/decreasing levels of LPS-induced TNFα. The examples below demonstrate these effects in particular as compared to the levels of said compounds in a subject not receiving treatment with the lithium cholesterol composition, including, but not limited to lithium cholesterol sulfate, and/or pharmaceutical compositions or as compared to a subject or cells receiving treatment with a different lithium salt compounds, such as LiCl. As such, the disclosed compounds are also useful as research tools. Accordingly, one aspect of the present disclosure relates to a method of using a lithium cholesterol composition, including, but not limited to lithium cholesterol sulfate, of the disclosure as a research tool, the method comprising conducting a biological assay using a lithium cholesterol composition, including, but not limited to lithium cholesterol sulfate, of the invention. Compounds of the invention can also be used to evaluate new chemical compounds. Thus another aspect of the invention relates to a method of evaluating a test compound in a biological assay, comprising: (a) conducting a biological assay with a test compound to provide a first assay value; (b) conducting the biological assay with a compound of the invention to provide a second assay value; wherein step (a) is conducted either before, after or concurrently with step (b); and (c) comparing the first assay value from step (a) with the second assay value from step (b). Exemplary biological assays include, but are not limited to, a GSK3β activator assay, a tau phosphorylation inhibitor assay, and/or a LPS-induced TNFα inhibitor assay that can be conducted in vitro or in a cell culture system. Still another aspect of the invention relates to a method of studying a biological system, e.g., a model animal for a clinical condition, or biological sample.
- Additional details regarding the methods, compositions, and organisms of the present disclosure are provided in the Examples below. The specific examples below are to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever. Without further elaboration, it is believed that one skilled in the art can, based on the description herein, utilize the present disclosure to its fullest extent. All publications recited herein are hereby incorporated by reference in their entirety.
- It should be emphasized that the embodiments of the present disclosure, particularly, any “preferred” embodiments, are merely possible examples of the implementations, merely set forth for a clear understanding of the principles of the disclosure. Many variations and modifications may be made to the above-described embodiment(s) of the disclosure without departing substantially from the spirit and principles of the disclosure. All such modifications and variations are intended to be included herein within the scope of this disclosure and protected by the following claims.
- The following examples are put forth so as to provide those of ordinary skill in the art with a complete disclosure and description of how to perform the methods and use the compositions and compounds disclosed herein. Efforts have been made to ensure accuracy with respect to numbers (e.g., amounts, temperature, etc.), but some errors and deviations should be accounted for. Unless indicated otherwise, parts are parts by weight, temperature is in ° C., and pressure is at or near atmospheric. Standard temperature and pressure are defined as 20° C. and 1 atmosphere.
- It should be noted that ratios, concentrations, amounts, and other numerical data may be expressed herein in a range format. It is to be understood that such a range format is used for convenience and brevity, and thus, should be interpreted in a flexible manner to include not only the numerical values explicitly recited as the limits of the range, but also to include all the individual numerical values or sub-ranges encompassed within that range as if each numerical value and sub-range is explicitly recited. To illustrate, a concentration range of “about 0.1% to about 5%” should be interpreted to include not only the explicitly recited concentration of about 0.1 wt % to about 5 wt %, but also include individual concentrations (e.g., 1%, 2%, 3%, and 4%) and the sub-ranges (e.g., 0.5%, 1.1%, 2.2%, 3.3%, and 4.4%) within the indicated range. In an embodiment, the term “about” can include traditional rounding according to significant figures of the numerical value. In addition, the phrase “about ‘x’ to ‘y’” includes “about ‘x’ to about ‘y’”.
- Now having described the embodiments of the disclosure, in general, the examples describe some additional embodiments. While embodiments of the present disclosure are described in connection with the example and the corresponding text and figures, there is no intent to limit embodiments of the disclosure to these descriptions. On the contrary, the intent is to cover all alternatives, modifications, and equivalents included within the spirit and scope of embodiments of the present disclosure.
- Recent studies have shown that lithium treatment can reduce symptoms of Alzheimer's disease (AD) and Autism Spectrum Disorder (ASD). However, the presently available lithium salts have serious short- and long-term side effects, meaning that the use of these lithium salts requires frequent monitoring of blood chemistry and plasma lithium levels so as to avoid toxicity. Consequently, there is a demand for a safer and more effective lithium formulation to treat these diseases. The present example describes the synthesis of a disclosed lithium salt, lithium cholesterol sulfate (LiCS) (
FIG. 1 ) and its therapeutic potential. This example also provides a comparison of the pharmacological effects of LiCS with that of lithium chloride (LiCl) and sodium cholesterol sulfate (NaCS) on markers of neurodegenerative disease in cell cultures. - This example examined the pharmacological effect of LiCS on inhibitory GSK and tau phosphorylation as well as TNFα levels, important biomarkers associated with the pathogenesis of both AD and ASD. As will be described in greater detail in the results below, LiCS proved more potent than LiCl in increasing inhibitory GSK3β (Ser9) phosphorylation (pGSK3β) in both CHO and SH-SY5Y cells. These agents dose-dependently increased pGSK3β, starting at 10 μM for LiCS and 60 μM for LiCl and maximally by approximately 100% at 60 μM for LiCS and 1.25 mM for LiCl, without altering total GSK3β levels. In HEK293/tau cells, LiCS reduced tau (Thr231) phosphorylation (ptau) starting at 10 μM and maximally by 63% at 40 μM without altering total tau levels, but ptau levels were not altered by LiCl at any dose between 60 μM and 1.25 mM. In BV2 cells, LiCS and LiCl decreased LPS-induced TNFα levels, starting at 20 μM for LiCS and 5 mM for LiCl, and maximally by approximately 30% at 80 μM for LiCS and 20 mM for LiCl. NaCS at any dose between 5 and 90 μM did not alter pGSK3β, ptau or LPS-induced TNFα. Thus, LiCS represents a new pharmaceutical compound with potent pharmacodynamics for treatment of AD and ASD.
- Materials and Methods
- Reagents
- Lithium cholesterol sulfate (LiCS, 96%) was synthetized by New England Discovery Partners (USF) using variations of procedures for sulfating molecules (22, 23, incorporated by reference herein). Specifically, LiCS was synthesized as generally described in
FIG. 1A . - LiCS and lithium chloride (LiCl, ≥99%, Millipore Sigma, St Louis, Mo.) were dissolved in methanol at 250 mM, and sodium cholesterol sulfate (NaCS, ≥98.0%, Millipore Sigma) was dissolved in methanol at 100 mM. LPS (Millipore Sigma) was diluted in Dulbecco's Modified Eagle's Medium (DMEM) at 10 μg/ml. Mouse TNFα uncoated ELISA Kit was purchased from Thermo Fisher Scientific (Waltham, Mass.). Primary antibodies include anti-pGSK3β (Ser9) and anti-total GSK3β (Thermo Fisher Scientific), anti-p-tau (Thr231) and anti-total tau (tau12, Millipore Sigma). The secondary antibodies used were anti-rabbit Ig G and anti-mouse Ig G, respectively (Millipore Sigma).
- Cell Culture
- Human neuroblastoma SH-SY5Y cells (ATCC, Manassas, Va.) were cultured in DMEM/Nutrient Mixture F-12 (DMEM/F-12), 10% fetal bovine serum (FBS) and 15 mM HEPES. Chinese Hamster Ovary cells (CHO, Millipore Sigma), human embryonic kidney 293 cells expressing wild-type tau (HEK293/tau cells, ATCC) and mouse BV2 microglial cells (Creative Bioarray, Shirley, N.Y.) were cultured in DMEM with 10% FBS. SH-SY5Y cells and CHO cells were cultured in 24-well plates at a density of 2.5×105 cells/well. HEK293/tau cells were cultured in 24-well plates at a density of 3.5×105 cells/well, after being treated with Tetracycline (1:1000) for about 24 h to create high and stable cells lines (24).
- Western Blot Analysis for GSK and Tau Phosphorylation
- Cells were treated with LiCS or NaCS at 0, 5, 10, 20, 40, 60 or 90 μM or LiCl at 0, 0.06, 0.15, 0.3, 0.6, 1.2 and 2.5 mM for 18 hours, followed by washing with ice-
cold PBS 3×, lysis with cell lysis buffer and centrifugation at 1.4×104 rpm for 20 minutes. The supernatants were then used for analysis of GSK3β (Ser9) and tau (Thr231) phosphorylation by Western Blot (WB) and WB bands were calculated by Image J software (Java 1.6.0_20, NIH, USA). - Microglial Inflammatory Activity Analysis
- Microglial cells (3.5×105/well) were treated with LPS at 100 ng/mL in the presence of LiCS, NaCS or LiCl at increasing concentrations for 3 hours, followed by analysis of TNFα levels in conditioned media by ELISA according to the manufacturer's instructions.
- Statistical Analysis
- All statistical analyses were conducted using Student' t-test and One-way ANOVA with SPSS 13.0. Data were presented as mean±standard deviation from at least three separate experiments. P value less than 0.05 was considered statistically significant.
- Results and Discussion
- Effects of LiCS, LiCl and NaCS on Inhibitory pGSK3β (Ser9) Phosphorylation in SH-SY5Y Cells and CHO Cells:
- In order to discover a potentially more effective and safer lithium formulation for treating AD and ASD, LiCS was synthesized, and its pharmacological effects on three biomarkers of the conditions—(GSK3β (Ser9) phosphorylation, tau (Thr231) phosphorylation, and LPS-induced TNFα production)—were determined and compared with that of LiCl and NaCS in cell cultures. LiCS and LiCl dose-dependently increased inhibitory GSK3β (Ser9) phosphorylation (pGSK3β) in both CHO and SH-SY5Y cells. For CHO cells, LiCS increased pGSK3β starting at 10 μM and maximally by 92% at 60 μM. In comparison, LiCl increased pGSK3β starting at 160 μM and maximally by 91% at 1.25 mM (
FIGS. 2A, 2B & 2E ). - Similarly, for SH-SY5Y cells, LiCS increased pGSK3β starting at 10 μM and maximally by 90% at 90 μM, while LiCl increased pGSK3β starting at 60 μM and maximally by 119% at 2.5 mM (
FIGS. 2C, 2D & 2F ). Notably, NaCS at 5-90 μM did not alter pGSK3β, and neither LiCS, LiCl nor NaCS altered total GSK3β at any dose. Taken together, these findings indicate that LiCS is approximately 21-28 fold more potent than LiCl in increasing inhibitory GSK3β (Ser9) phosphorylation. At 60 μM, LiCS maximally while LiCl minimally increased pGSK3β levels. - Effects of LiCS, LiCl and NaCS Treatment on Tau Phosphorylation in HEK293/Tau Cells:
- In addition to increasing GSK3β phosphorylation, LiCS dose-dependently decreased tau (Thr231) phosphorylation (ptau) in HEK293/tau cells. LiCS decreased ptau starting at 10 μM and maximally by 63% at 40 μM (
FIGS. 3A & 3D ). However, neither LiCl at any dose between 60 μM and 1.25 mM nor NaCS at any dose between 5 and 60 μM altered ptau, and neither LiCS, NaCS nor LiCl at any dose altered total tau (FIGS. 3B & 3C ). Thus, LiCS reduces tau phosphorylation at micromolar levels, while LiCl is ineffective even at millimolar levels. - Effects of LiCS, LiCl and NaCS Treatment on Microglial LPS-Mediated TNFα Production:
- In order to determine the effect of LiCS on microglial inflammation, mouse microglial cells (BV2) were treated with lipopolysaccharides (LPS, 100 ng/ml) together with LiCS, LiCl or NaCS for 3 hours, followed by TNFα analysis by ELISA. Cell morphology was not altered by any treatment. Both LiCS and LiCl dose-dependently decreased TNFα (
FIG. 4 ). LiCS decreased TNFα starting at 20 μM and maximally by 28% at 80 μM, while LiCl decreased TNFα starting at 5 mM and maximally by 34% at 20 mM. However, TNFα level was not altered by NaCS at any concentration between 20 and 80 μM. Thus, LiCS was approximately 250-fold more potent than LiCl for reducing LPS-induced TNFα production. - In order to develop a new, more effective lithium formulation for the potential treatment of AD and ASD, the pharmacological effects of LiCS were determined in comparison with LiCl and NaCS on markers of neurodegenerative disease in cell cultures. It was found that while both LiCS and LiCl increased inhibitory GSK3β (Ser9) phosphorylation (pGSK3β) in a dose-dependent fashion in CHO and SH-SY5Y cells, LiCS increased pGSK3β at low micromolar levels while LiCl required high micromolar and low millimolar levels (
FIGS. 2A-2F ). Thus, LiCS was 21-28 fold more potent than LiCl. In addition, LiCS reduced tau (Thr231) phosphorylation at micromolar levels (FIGS. 3A and 3D ), while LiCl failed to alter tau phosphorylation at even millimolar levels (FIG. 3C ), in HEK293/tau cells. In microglial cultures, LiCS was approximately 250 fold more potent than LiCl for reducing LPS-induced TNFα production (FIG. 4 ). Notably, NaCS at any dose between 5 and 90 μM failed to alter pGSK3β (FIGS. 2A and 2C ), ptau (FIG. 3B ), or LPS-induced TNFα (FIG. 4 ). Thus, LiCS modulates important markers of AD and ASD and thus provides a novel and effective treatment for AD, ASD and other related neurodegenerative diseases. - Lithium as a mood stabilizer has been used in the standard pharmacological treatment of bipolar disorder (BD) for more than 60 years (11, 12). It remains to be recommended by many treatment guidelines as the first-line treatment for acute mania, and prophylactically for recurrent manic and depressive episodes. Lithium can help prevent suicide and is associated with a lower risk for all-cause mortality in patients with mood disorders (11, 12). In recent years, there have appeared many experimental studies describing new effects of lithium for treatment of neurodegenerative diseases such as AD (13, 14), ASD (7, 15, 16), Parkinson's disease (PD) (25, 26), stroke and spinal cord injury (27, 28). Regarding PD, studies have found that lithium treatment of hNT neurons increases tyrosine hydroxylase (TH) activity, the rate limiting enzyme in the synthesis of dopamine (25). Moreover, brief exposure of hNT neurons to lithium increases cell survival, TH expression and fibre outgrowth after transplantation into the striatum of hemiparkinsonian rats. Interestingly, recent studies suggest that lithium treatment may also be effective for peripheral disorders such as atherosclerosis and ischemic coronary disease, which may be mediated in part by suppression of MMP-9 gene expression in macrophages (29, 30). Inhibition of MMP-9 by lithium may help maintain the BBB, since toxic free radicals can disrupt the BBB via increased activity of MMP (31, 32). In addition, lithium has been suggested to be beneficial for treatment of granulocytopenia resulting from radiation and chemotherapy, to boost immunoglobulins after vaccination and enhance natural killer cell activity (27). Lithium may also increase gut microbial richness and diversity, which can play an important role in its therapeutic effectiveness for neurodegenerative diseases (33). Therefore, lithium salts represent potential drugs for the treatment of diverse central and peripheral diseases.
- As an ion, lithium is formulated in lithium salts. Lithium carbonate is usually applied in the clinic, but other lithium salts such as lithium citrate, lithium sulfate, lithium orotate and lithium chloride, are also sometimes used as alternatives. All conventional lithium salt treatments require frequent monitoring of blood chemistry and plasma lithium levels so as to avoid toxicity, which may discourage patients from choosing these drugs. For this reason, some novel lithium salts such as lithium carbonate sustained-release tablets or controlled-release tablets have been developed. Remarkably, recent studies from our laboratory have also found that different lithium salts can have profoundly different pharmacokinetic effects depending on the associated anion. For example, treatment with lithium salicylate produced longer elevated plasma lithium levels with a slower elimination process compared with lithium lactate treatment in rats (34). In addition, LISPRO, a novel ionic co-crystal of lithium salicylate and L-proline, produced significantly higher brain lithium levels and more steady plasma lithium levels compared with lithium carbonate or lithium salicylate in mice (35) and rats (36). Long term oral administration of LISPRO reduced AD pathology, including β-amyloid plaques, tau hyperphosphorylation, neuroninflammation, neuronal and synaptic protein loss and GSK3β activity, without eliciting renal inflammation, in Tg2576 and 3XTg AD mice models (35). Thus, LISPRO might be a superior form of lithium with improved safety and efficacy as a potentially new disease modifying therapeutic for AD. However, continued exploration of ways to improve lithium's therapeutic profile lent to the surprising discovery of the improved potency and safety of the novel lithium salts of the present disclosure.
- Cholesterol sulfate was first isolated from human plasma in 1965 and found to be present in a concentration of 300 μg/100 ml (37), thus being one of the most abundant sterol sulfates in the plasma. In addition, cholesterol sulfate is a normal constituent in a variety of human tissues including cell membranes, platelets and red blood cells (18). The sulfate moiety of cholesterol sulfate has a pKa of 3.3, indicating that it is normally ionized under physiologic conditions (18). Thus, the sulfoconjugation of cholesterol results in the conversion of a rather rigid hydrophobic molecule into a very amphiphilic compound containing a highly charged subgroup. The hydrophobic/hydrophilic property of cholesterol sulfate represents an important characteristic underlying its biologic action and making it better suited for interactions with membrane constituents. The rate of intermembrane exchange for cholesterol sulfate was found to be approximately 10-fold faster than for cholesterol in all liposomes tested (38). In addition, cholesterol sulfate can be considered to be a potent thermosensitizer, which enhances the selectivity of biological drug carriers (39). In the present study, cholesterol sulfate was tested as a carrier for lithium in the development of a novel lithium salt, LiCS. It was discovered that the use of LiCS may allow lithium to more easily pass through the cell membrane as well as intestinal and blood brain barriers after peripheral or oral administration, thereby allowing it to more readily target intracellular pathological processes than clinically available lithium chloride.
- In the United States, Alzheimer's disease (AD) is the most common cause of dementia, accompanied by substantial economic and emotional costs. During 2015, more than 15 million family members who provided care to AD patients had an estimated total cost of 221 billion dollars. Autism spectrum disorder (ASD), another neurodegenerative disease, currently afflicts around 20 per 1,000 children between the ages of 6 and 17. LiCS represents a new treatment option with good pharmacological potential for treatment of neurodegenerative disorders such as AD and ASD by allowing lithium to more readily access intracellular pathological processes. Additional studies described in the examples below using animal models further explore its pharmacokinetic, pharmacodynamics and therapeutic potential.
- In a recent study, we found that a lithium cocrystal (LISPRO), composed of lithium salicylate and proline, reduced AD pathology in two AD mouse models, Tg2576 and 3XTg-AD. In addition, LISPRO reduced AD-related behavioral impairment (Habib et al., Journal of Neuroscience Research, revised, 2019). Since long term salicylate treatment can be harmful to the elderly, investigation of another approach was desired, and lithium cholesterol sulfate was identified as a possible candidate. Cholesterol is present in all cellular membranes, where its supports proper structure and function. The brain contains about 25% of the body's cholesterol and is essential for synaptic function. Cholesterol sulfate a quantitatively important sterol sulfate in human plasma. Cholesterol sulfate is also a normal constituent in a variety of human tissues including skin, hair, nails, aorta, adrenal, liver, and kidney. The highest level of cholesterol sulfate in the rat brain occurred in subcellular fraction rich in nerve endings. It stabilizes cell membranes, regulates the activity of serine proteases and protein kinase C, such as those involved in blood clotting, fibrinolysis, epidermal cell adhesion and barrier formation, and is a substrate for the synthesis of neurosteroids, such as pregnenolone, DHEA, estrogen and testosterone sulfate. Sulfoconjugation of cholesterol results in the conversion of a rather rigid hydrophobic molecule into a very amphiphilic compound containing a highly charged subgroup. The hydrophobic/hydrophilic property of cholesterol sulfate represents an important characteristic in its biologic action. This aspect of the structure of cholesterol sulfate makes it a candidate for interactions with membrane constituents as well as absorption and transport freely into the blood stream and across the blood brain barrier.
- Materials and Methods:
- Chemistry: LiCS was first synthesized by collaboration with New England Discovery Partners (NEDP) as described above in Example 1 (
FIG. 1 ). The preparations and purity of the final product were confirmed by mass spectrometry. - Mouse protocol: C57BL/6J male mice at 4 months of age were treated with LiCl or LiCS at 0.04 mmol lithium/mouse p.o by gavage, followed by determination of lithium levels in blood plasma, brain, kidney and liver at 0.5, 1, 2, 3, 5 and 24 h after gavage by ELISA (N=2 mice/time point).
- Blood and tissue lithium ELISA: At 0.5, 1, 2, 3, 5 and 24 h after treating mice with LiCl or LiCS p.o. by gavage, mice were anesthetized with isoflourane (50 mg/kg) (Sigma-Aldrich), euthanized by bilateral thoracotomy, and blood was collected. Brain, kidney, and liver were harvested, homogenized in 400 μL ddH2O with Minilys tissue homogenizer (Bertin Technologies, Montigny-le-Bretonneux, France), and centrifuged for 30 min. Lithium levels in plasma and supernatants from brain, kidney, and liver homogenates were determined by ELISA (Biovision, Milpitas, Calif.) following the manufacturer's instructions. Plasma, brain, kidney and liver homogenates from control mice were used to generate standard curve.
- Results:
- As illustrated in
FIG. 5A , Lithium levels in the blood increased between 0.5 and 5 h after LiCl and between 0.5 and 24 h after LiCS treatment. In addition, lithium levels in the brain increased at 5 h after LiCl and at 0.5 and 5 h after LiCS treatment (FIG. 5B ), and lithium levels in the kidney increased at 0.5 and 5 h after LiCl but failed to increase at any time after LiCS treatment (FIG. 5B ). Lithium levels in the liver failed to increase at any time after LiCl or LiCS treatment (FIG. 5B ). There was no detectable lithium in plasma, brain, kidney or liver before treatment (0 time, data not shown). All mice received normal drinking water ad libitum during the treatment period. Lithium ELISA results are presented as the mean (±s.d.). Asterisk indicates P<0.05 versus LiCl treatment as determined by ANOVA. - These in vivo results suggest that lithium blood levels are more stable and last longer after LiCS compared with LiCl oral treatment and that LiCS more readily crosses the blood-brain barrier. In addition, LiCl but not LiCS treatment markedly increases lithium levels in the kidneys. These results are important, since lithium chronic treatment has been associated with several forms of kidney injury (40, 41). It is estimated that impaired urinary concentrating ability is present in at least 50% of individuals on chronic lithium therapy, a condition called lithium-induced nephrogenic diabetes insipidus. Continued use of lithium can lead to more serious kidney damage in an aggravated form of diabetes insipidus and chronic kidney failure. Indeed, chronic kidney disease is found in about one-third of people undergoing long-term lithium treatment, according to one study. Some forms of lithium-caused kidney damage may be progressive and lead to end-stage kidney failure.
- These data demonstrate that this novel compound (LiCS) would allow lithium to more readily cross the intestinal and blood-brain barriers for oral treatment of bipolar affective disorder. Lithium salts have been used in psychiatry to treat bipolar disorder for many years and are now still considered as a first-line therapy for acute and long-term treatment of bipolar disorder. In recent years, lithium has also been shown to be a potential therapeutic for other neurodegenerative diseases, such as Alzheimer's disease (AD) and autism (ASD). CS has a hydrophobic/hydrophilic property which is well-suited for interaction with membrane constituents and present results demonstrate CS as a suitable carrier for the delivery of drugs across the intestinal and blood brain barriers. In addition CS, a normal constituent of a variety of human tissues, may also be beneficial in the treatment of AD and ASD, as well as other diseases potentially resulting from sulfur shortage, including eczema and asthma. The results from the present examples demonstrate that LiCS appears particularly beneficial for treating neurodegenerative disease.
-
- 1. Scheltens P, Blennow K, Breteler M M, de Strooper B, Frisoni G B, Salloway S, Van der Flier W M. Alzheimer's disease. Lancet (London, England). 2016; 388(10043):505-17. Epub 2016/02/28. doi: 10.1016/s0140-6736(15)01124-1. PubMed PMID: 26921134.
- 2. Wang J, Gu B J, Masters C L, Wang Y J. A systemic view of Alzheimer disease—insights from amyloid-beta metabolism beyond the brain. Nature reviews Neurology. 2017; 13(11):703. Epub 2017/10/14. doi: 10.1038/nrneuro1.2017.147. PubMed PMID: 29027541.
- 3. Clayton K A, Van Enoo A A, Ikezu T. Alzheimer's Disease: The Role of Microglia in Brain Homeostasis and Proteopathy. Frontiers in neuroscience. 2017; 11:680. Epub 2018/01/10. doi: 10.3389/fnins.2017.00680. PubMed PMID: 29311768; PMCID: PMC5733046.
- 4. Matsunaga S, Kishi T, Annas P, Basun H, Hampel H, Iwata N. Lithium as a Treatment for Alzheimer's Disease: A Systematic Review and Meta-Analysis. Journal of Alzheimer's disease: JAD. 2015; 48(2):403-10. Epub 2015/09/25. doi: 10.3233/jad-150437. PubMed PMID: 26402004.
- 5. Fitzpatrick S E, Srivorakiat L, Wink L K, Pedapati E V, Erickson C A. Aggression in autism spectrum disorder: presentation and treatment options. Neuropsychiatric disease and treatment. 2016; 12:1525-38. Epub 2016/07/07. doi: 10.2147/ndt.S84585. PubMed PMID: 27382295; PMCID: PMC4922773.
- 6. Siegel M, Beresford C A, Bunker M, Verdi M, Vishnevetsky D, Karlsson C, Teer O, Stedman A, Smith K A. Preliminary investigation of lithium for mood disorder symptoms in children and adolescents with autism spectrum disorder. Journal of child and adolescent psychopharmacology. 2014; 24(7):399-402. Epub 2014/08/06. doi: 10.1089/cap.2014.0019. PubMed PMID: 25093602.
- 7. Canitano R. Mood Stabilizers in Children and Adolescents With Autism Spectrum Disorders. Clinical neuropharmacology. 2015; 38(5):177-82. Epub 2015/09/15. doi: 10.1097/wnf.0000000000000096. PubMed PMID: 26366961.
- 8. Blumberg S J, Bramlett M D, Kogan M D, Schieve L A, Jones J R, Lu M C. Changes in prevalence of parent-reported autism spectrum disorder in school-aged U.S. children: 2007 to 2011-2012. National health statistics reports. 2013(65):1-11, 1 p following Epub 2013/03/20. PubMed PMID: 24988818.
- 9. Theoharides T C,
Tsilioni 1, Patel A B, Doyle R. Atopic diseases and inflammation of the brain in the pathogenesis of autism spectrum disorders. Translational psychiatry. 2016; 6(6):e844. Epub 2016/06/29. doi: 10.1038/tp.2016.77. PubMed PMID: 27351598; PMCID: PMC4931610. - 10. Gassowska M, Baranowska-
Bosiacka 1, Moczydlowska J, Tarnowski M, Pilutin A,Gutowska 1, Struzynska L, Chlubek D, Adamczyk A. Perinatal exposure to lead (Pb) promotes Tau phosphorylation in the rat brain in a GSK-3beta and CDKS dependent manner: Relevance to neurological disorders. Toxicology. 2016; 347-349:17-28. Epub 2016/03/26. doi: 10.1016/j.tox.2016.03.002. PubMed PMID: 27012722. - 11. Richardson T, Macaluso M. Clinically relevant treatment considerations regarding lithium use in bipolar disorder. Expert opinion on drug metabolism & toxicology. 2017; 13(11):1105-13. Epub 2017/10/03. doi: 10.1080/17425255.2017.1386653. PubMed PMID: 28965429.
- 12. Oruch R, Elderbi M A, Khattab H A, Pryme I F, Lund A. Lithium: a review of pharmacology, clinical uses, and toxicity. European journal of pharmacology. 2014; 740:464-73. Epub 2014/07/06. doi: 10.1016/j.ejphar.2014.06.042. PubMed PMID: 24991789.
- 13. Devanand D P, Strickler J G, Huey E D, Crocco E, Forester B P, Husain M M, Vahia I V, Andrews H, Wall M M, Pelton G H. Lithium Treatment for Agitation in Alzheimer's disease (Lit-AD): Clinical rationale and study design. Contemporary clinical trials. 2018; 71:33-9. Epub 2018/06/04. doi: 10.1016/j.cct.2018.05.019. PubMed PMID: 29859917; PMCID: PMC6082137.
- 14. Devanand D P, Pelton G H, D'Antonio K, Strickler J G, Kreisl W C, Noble J, Marder K, Skomorowsky A, Huey E D. Low-dose Lithium Treatment for Agitation and Psychosis in Alzheimer Disease and Frontotemporal Dementia: A Case Series. Alzheimer disease and associated disorders. 2017; 31(1):73-5. Epub 2016/11/08. doi: 10.1097/wad.0000000000000161. PubMed PMID: 27819842; PMCID: PMC5322244.
- 15. Wu X, Bai Y, Tan T, Li H, Xia S, Chang X, Zhou Z, Zhou W, Li T, Wang Y T, Dong Z. Lithium ameliorates autistic-like behaviors induced by neonatal isolation in rats. Frontiers in behavioral neuroscience. 2014; 8:234. Epub 2014/07/16. doi: 10.3389/fnbeh.2014.00234. PubMed PMID: 25018711; PMCID: PMC4071979.
- 16. Serret S, Thummler S, Dor E, Vesperini S, Santos A, Askenazy F. Lithium as a rescue therapy for regression and catatonia features in two SHANK3 patients with autism spectrum disorder: case reports. BMC psychiatry. 2015; 15:107. Epub 2015/05/08. doi: 10.1186/s12888-015-0490-1. PubMed PMID: 25947967; PMCID: PMC4428105.
- 17. Foglia F, Rogers S E, Webster J R, Akeroyd F A, Gascoyne K F, Lawrence M J, Barlow D J. Neutron Scattering Studies of the Effects of Formulating Amphotericin B with Cholesteryl Sulfate on the Drug's Interactions with Phospholipid and Phospholipid-Sterol Membranes. Langmuir: the ACS journal of surfaces and colloids. 2015; 31(29):8042-51. Epub 2015/07/04. doi: 10.1021/acs.langmuir.5b01365. PubMed PMID: 26139630.
- 18. Strott C A, Higashi Y. Cholesterol sulfate in human physiology: what's it all about? J Lipid Res. 2003; 44(7):1268-78. Epub 2003/05/06. doi: 10.1194/jlr.R300005-JLR200. PubMed PMID: 12730293.
- 19. Merten M, Dong J F, Lopez J A, Thiagarajan P. Cholesterol sulfate: a new adhesive molecule for platelets. Circulation. 2001; 103(16):2032-4. Epub 2001/04/25. PubMed PMID: 11319189.
- 20. Seneff S, Davidson R, Mascitelli L. Might cholesterol sulfate deficiency contribute to the development of autistic spectrum disorder? Medical hypotheses. 2012; 78(2):213-7. Epub 2011/11/22. doi: 10.1016/j.mehy.2011.10.026. PubMed PMID: 22098722.
- 21. Beel A J, Sakakura M, Barrett P J, Sanders C R. Direct binding of cholesterol to the amyloid precursor protein: An important interaction in lipid-Alzheimer's disease relationships? Biochimica et biophysica acta. 2010; 1801(8):975-82. Epub 2010/03/23. doi: 10.1016/j.bbalip.2010.03.008. PubMed PMID: 20304095; PMCID: PMC2886191.
- 22. Al-Horani R A, Desai U R. Chemical Sulfation of Small Molecules—Advances and Challenges. Tetrahedron. 2010; 66(16):2907-18. Epub 2010/08/07. doi: 10.1016/j.tet.2010.02.015. PubMed PMID: 20689724; PMCID: PMC2913517.
- 23. Donazzolo E, Gucciardi A, Mazzier D, Peggion C, Pirillo P, Naturale M, Moretto A, Giordano G. Improved synthesis of glycine, taurine and sulfate conjugated bile acids as reference compounds and internal standards for ESI-MS/MS urinary profiling of inborn errors of bile acid synthesis. Chemistry and physics of lipids. 2017; 204:43-56. Epub 2017/03/17. doi: 10.1016/j.chemphyslip.2017.03.004. PubMed PMID: 28300538.
- 24. Bandyopadhyay B, Li G, Yin H, Kuret J. Tau aggregation and toxicity in a cell culture model of tauopathy. The Journal of biological chemistry. 2007; 282(22):16454-64. Epub 2007/04/13. doi: 10.1074/jbc.M700192200. PubMed PMID: 17428800.
- 25. Willing A E, Zigova T, Milliken M, Poulos S, Saporta S, McGrogan M, Snable G, Sanberg P R. Lithium exposure enhances survival of NT2N cells (hNT neurons) in the hemiparkinsonian rat. The European journal of neuroscience. 2002; 16(12):2271-8. Epub 2002/12/21. PubMed PMID: 12492421.
- 26. Zigova T, Wiling A E, Tedesco E M, Borlongan C V, Saporta S, Snable G L, Sanberg P R. Lithium chloride induces the expression of tyrosine hydroxylase in hNT neurons. Experimental neurology. 1999; 157(2):251-8. Epub 1999/06/12. doi: 10.1006/exnr.1999.7054. PubMed PMID: 10364437.
- 27. Young W. Review of lithium effects on brain and blood. Cell transplantation. 2009; 18(9):951-75. Epub 2009/06/16. doi: 10.3727/096368909x471251. PubMed PMID: 19523343.
- 28. Zhu H, Poon W, Liu Y, Leung G K, Wong Y, Feng Y, Ng S C P, Tsang K S, Sun D T F, Yeung D K, Shen C, Niu F, Xu Z, Tan P, Tang S, Gao H, Cha Y, So K F, Fleischaker R, Sun D, Chen J, Lai J, Cheng W, Young W. Phase I-II Clinical Trial Assessing Safety and Efficacy of Umbilical Cord Blood Mononuclear Cell Transplant Therapy of Chronic Complete Spinal Cord Injury. Cell transplantation. 2016; 25(11):1925-43. Epub 2016/04/15. doi: 10.3727/096368916x691411. PubMed PMID: 27075659.
- 29. Choi S E, Jang H J, Kang Y, Jung J G, Han S J, Kim H J, Kim D J, Lee K W. Atherosclerosis induced by a high-fat diet is alleviated by lithium chloride via reduction of VCAM expression in ApoE-deficient mice. Vascular pharmacology. 2010; 53(5-6):264-72. Epub 2010/10/05. doi: 10.1016/j.vph.2010.09.004. PubMed PMID: 20888430.
- 30. Kim S, Bong N, Kim O S, Jin J, Kim D E, Lee D K. Lithium chloride suppresses LPS-mediated matrix metalloproteinase-9 expression in macrophages through phosphorylation of GSK-3beta. Cell biology international. 2015; 39(2):177-84. Epub 2014/07/24. doi: 10.1002/cbin.10352. PubMed PMID: 25053111.
- 31. Yang Y, Rosenberg G A. Matrix metalloproteinases as therapeutic targets for stroke. Brain research. 2015; 1623:30-8. Epub 2015/04/29. doi: 10.1016/j.brainres.2015.04.024. PubMed PMID: 25916577; PMCID: PMC4569515.
- 32. Ralay Ranaivo H, Hodge J N, Choi N, Wainwright M S. Albumin induces upregulation of matrix metalloproteinase-9 in astrocytes via MAPK and reactive oxygen species-dependent pathways. Journal of neuroinflammation. 2012; 9:68. Epub 2012/04/18. doi: 10.1186/1742-2094-9-68. PubMed PMID: 22507553; PMCID: PMC3419618.
- 33. Cussotto S, Strain C R, Fouhy F, Strain R G, Peterson V L, Clarke G, Stanton C, Dinan T G, Cryan J F. Differential effects of psychotropic drugs on microbiome composition and gastrointestinal function. Psychopharmacology. 2018. Epub 2018/08/30. doi: 10.1007/s00213-018-5006-5. PubMed PMID: 30155748.
- 34. Smith A J, Kim S H, Tan J, Sneed K B, Sanberg P R, Borlongan C V, Shytle R D. Plasma and Brain Pharmacokinetics of Previously Unexplored Lithium Salts. RSC advances. 2014; 4(24):12362-5. Epub 2014/07/22. doi: 10.1039/c3ra46962j. PubMed PMID: 25045517; PMCID: PMC4100714.
- 35. Habib A, Sawmiller D, Li S, Xiang Y, Rongo D, Tian J, Hou H, Zeng J, Smith A, Fan S, Giunta B, Mori T, Currier G, Shytle D R, Tan J. LISPRO mitigates beta-amyloid and associated pathologies in Alzheimer's mice. Cell death & disease. 2017; 8(6):e2880. Epub 2017/06/16. doi: 10.1038/cddis.2017.279. PubMed PMID: 28617434; PMCID: PMC5520933.
- 36. Smith A J, Kim S H, Duggirala N K, Jin J, Wojtas L, Ehrhart J, Giunta B, Tan J, Zaworotko M J, Shytle R D. Improving lithium therapeutics by crystal engineering of novel ionic cocrystals. Mol Pharm. 2013; 10(12):4728-38. Epub 2013/11/07. doi: 10.1021/mp400571a. PubMed PMID: 24191685; PMCID: PMC3850245.
- 37. Drayer N M, Lieberman S. ISOLATION OF CHOLESTEROL SULFATE FROM HUMAN BLOOD AND GALLSTONES. Biochemical and biophysical research communications. 1965; 18:126-30. Epub 1965/01/04. PubMed PMID: 14265744.
- 38. Rodrigueza W V, Wheeler J J, Klimuk S K, Kitson C N, Hope M J. Transbilayer movement and net flux of cholesterol and cholesterol sulfate between liposomal membranes. Biochemistry. 1995; 34(18):6208-17. Epub 1995/05/09. PubMed PMID: 7742326.
- 39. Przybylska M, Faber M, Zaborowski A, Bryszewska M. Cholesterol sulfate induces changes in human erythrocyte thermostability. Biochemistry and molecular biology international. 1998; 46(2):399-410. Epub 1998/11/05. PubMed PMID: 9801808.
- 40. Nielsen J, Kwon T H, Christensen B M, Frokiaer J, Nielsen S. Dysregulation of renal aquaporins and epithelial sodium channel in lithium-induced nephrogenic diabetes insipidus. Semin Nephrol. 2008; 28(3):227-44. doi: 10.1016/j.semnephro1.2008.03.002.
- 41. Alexander M P, Farag Y M, Mittal B V, Rennke H G, Singh A K. Lithium toxicity: a double-edged sword. Kidney Int. 2008; 73(2):233-7. Epub 2007 Oct. 17. PMID: 17943083.
Claims (18)
1. A method of treatment for a neurological disorder, the method comprising:
administering to a subject in need of treatment for a neurological disorder a therapeutically effective amount of a pharmaceutical composition consisting essentially of a therapeutically effective amount of a lithium cholesterol, and one or more pharmaceutically acceptable carriers; wherein the lithium cholesterol has a structure having the formula:
where R is selected from —SO3Li, —PO3(Li)2, —(CH2)n(C═O)OLi, or —(C═O)(CH2)n(C═O)OLi, where n is integer selected from 1, 2, 3, 4, 5, and 6
4. The method of claim 1 , wherein the one or more solid pharmaceutically acceptable carriers is selected from the group consisting of: diluents, excipients, extenders, preservatives, antioxidants, solubilizers, emulsifiers, coloring agents, releasing agents, coating agents, sweetening agents, flavoring agents, perfuming agents, and adjuvants.
5. The method of claim 1 , wherein the pharmaceutical composition is administered orally.
6. The method of claim 1 , wherein the pharmaceutical composition is an oral dosage formulation.
7. The method of claim 1 , wherein the pharmaceutical composition is a solid, oral dosage form and the one or more pharmaceutically acceptable carriers comprise a solid pharmaceutical carrier.
8. The method of claim 1 , wherein the neurological disorder is selected from: a neurodegenerative condition, a neurodevelopment disorder, a brain injury, and other neuropsychiatric disorders.
9. The method of claim 1 , wherein the neurological disorder is selected from the group consisting of: Alzheimer's disease, autism spectrum disorder (ASD), Parkinson's disease, suicidal ideation, bipolar disorder, mood disorders, traumatic brain injury, radiation induced brain injury, amyotrophic laterals sclerosis, schizoaffective disorder, and tic disorder.
10. The method of claim 8 , wherein the neurodegenerative condition is Alzheimer's disease.
11. The method of claim 8 , wherein the neurodevelopmental disorder is Autism Spectrum disorder (ASD).
12. The method of claim 1 , wherein the neurological disorder is bipolar disorder.
13. The method of claim 1 , wherein administration of the pharmaceutical composition produces one or more of the following effects in the subject: increasing levels of inhibitory phosphorylation of GSK3β, decreasing levels of phosphorylation of tau, and decreasing levels of LPS-induced TNFα, as compared to the levels of said compounds in a subject not receiving treatment with the pharmaceutical composition.
14. The method of claim 1 , wherein administration of the pharmaceutical composition produces a greater brain to blood lithium level ratio in the subject than administration of lithium chloride.
15. The method of claim 1 , wherein administration of the pharmaceutical composition does not substantially increase lithium levels in the liver or kidney of the subject.
18. The method of claim 1 , further comprising separately administering the pharmaceutical composition with a second, separate pharmaceutical composition comprising at least one other therapeutic agent for treatment of the neurological disorder.
19. The method of claim 18 , wherein the other therapeutic agent is selected from the group consisting of: an anti-depressant, an anti-convulsant, a mood stabilizer, and a combination of two or more of the foregoing.
20. The method of claim 19 , wherein the other therapeutic agent is selected from the group consisting of: a selective serotonin reuptake inhibitor (SSRI), serotonin-noroepinephrine reuptake inhibitor (SNRI), serotonin antagonist and reuptake inhibitor (SARI), monamine oxidase inhibitor (MAOI), carboxamide, fructose derivative, triazine, a cholinesterase inhibitor, a N-methyl D-aspartate antagonist, a vitamin E, donepezil, rivastigmine, galantamine, memantine, and a combination of two or more of the foregoing.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/076,081 US20210030770A1 (en) | 2018-10-29 | 2020-10-21 | Lithium cholesterol compositions, including, but not limited to lithium cholesterol sulfate compositions, and methods of treatment for alzheimer's disease and neurological disorders |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862752251P | 2018-10-29 | 2018-10-29 | |
US16/432,367 US10828312B2 (en) | 2018-10-29 | 2019-06-05 | Lithium cholesterol compositions, including, but not limited to lithium cholesterol sulfate compositions, and methods of treatment for Alzheimer's disease and neurological disorders |
US17/076,081 US20210030770A1 (en) | 2018-10-29 | 2020-10-21 | Lithium cholesterol compositions, including, but not limited to lithium cholesterol sulfate compositions, and methods of treatment for alzheimer's disease and neurological disorders |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/432,367 Division US10828312B2 (en) | 2018-10-29 | 2019-06-05 | Lithium cholesterol compositions, including, but not limited to lithium cholesterol sulfate compositions, and methods of treatment for Alzheimer's disease and neurological disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
US20210030770A1 true US20210030770A1 (en) | 2021-02-04 |
Family
ID=70328121
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/432,367 Active US10828312B2 (en) | 2018-10-29 | 2019-06-05 | Lithium cholesterol compositions, including, but not limited to lithium cholesterol sulfate compositions, and methods of treatment for Alzheimer's disease and neurological disorders |
US17/076,081 Abandoned US20210030770A1 (en) | 2018-10-29 | 2020-10-21 | Lithium cholesterol compositions, including, but not limited to lithium cholesterol sulfate compositions, and methods of treatment for alzheimer's disease and neurological disorders |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/432,367 Active US10828312B2 (en) | 2018-10-29 | 2019-06-05 | Lithium cholesterol compositions, including, but not limited to lithium cholesterol sulfate compositions, and methods of treatment for Alzheimer's disease and neurological disorders |
Country Status (2)
Country | Link |
---|---|
US (2) | US10828312B2 (en) |
WO (1) | WO2020091845A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112472697A (en) * | 2020-12-09 | 2021-03-12 | 安域生物制药(杭州)有限公司 | Preparation process of organic acid lithium-L-proline salt |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5043165A (en) * | 1988-12-14 | 1991-08-27 | Liposome Technology, Inc. | Novel liposome composition for sustained release of steroidal drugs |
DE69737791D1 (en) * | 1996-04-09 | 2007-07-19 | Univ Edinburgh | USE OF 7-ALPHA SUBSTITUTED STEROIDS FOR THE TREATMENT OF NEUROPSYCHIATRICAL DISEASES |
WO2010119455A2 (en) | 2009-04-15 | 2010-10-21 | Sun Pharma Advanced Research Company Ltd. | An injectable sustained release pharmaceutical composition |
US20130245253A1 (en) * | 2010-03-26 | 2013-09-19 | Department Of Veterans Affairs | Conjugated Neuroactive Steroid Compositions And Methods Of Use |
AU2018255327A1 (en) * | 2017-04-18 | 2019-11-07 | Marinus Pharmaceuticals, Inc. | Sustained release injectable neurosteroid formulations |
-
2019
- 2019-06-05 WO PCT/US2019/035546 patent/WO2020091845A1/en active Application Filing
- 2019-06-05 US US16/432,367 patent/US10828312B2/en active Active
-
2020
- 2020-10-21 US US17/076,081 patent/US20210030770A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US10828312B2 (en) | 2020-11-10 |
WO2020091845A1 (en) | 2020-05-07 |
US20200129527A1 (en) | 2020-04-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10561650B2 (en) | Method for treating a protozoal infection | |
JP6080312B2 (en) | Improved parenteral formulations of lipophilic pharmaceutical agents and methods for preparing and using the same | |
CN105050593B (en) | For improving the composition of cell viability and using the method for the composition | |
JP7066627B2 (en) | Compositions containing tannic acid and their use | |
KR20220084418A (en) | Neuroactive steroids, compositions, and uses thereof | |
US8841346B2 (en) | Use of CI-994 and dinaline for the treatment of memory/cognition and anxiety disorders | |
CA2591889A1 (en) | Treatment for severe melancholic depression with epa | |
JP2017036341A (en) | Method and use of inducing apoptosis in cancer cells | |
JP2017501975A (en) | Application of ginsenoside Rg3 in the preparation of a medicament for preventing and / or treating dementia, and a medicament for treating dementia | |
CN110520124A (en) | For treating the Compounds and methods for of primary biliary cholangitis | |
CN107207403A (en) | Composition and method for treating multiple sclerosis | |
US20210030770A1 (en) | Lithium cholesterol compositions, including, but not limited to lithium cholesterol sulfate compositions, and methods of treatment for alzheimer's disease and neurological disorders | |
WO2008143551A1 (en) | Active ingredient of a medicinal agent, a medicinal agent, a pharmaceutical composition and method for treating dementia syndrome patients | |
Kazakova et al. | From marine metabolites to the drugs of the future: Squalamine, trodusquemine, their steroid and triterpene analogues | |
KR102396113B1 (en) | Pharmaceutical composition for improving cognitive ability or memory | |
CN105612155A (en) | Compositions and methods for the treatment of local pain | |
KR20210061349A (en) | Use of roluperidone to treat negative symptoms and disorders, increase neuroplasticity, and promote neuroprotection | |
EP3102227A1 (en) | Combination of creatine, an omega-3 fatty acid, and citicoline | |
TW201902470A (en) | Use of Lithium Benzoate for Treating Central Nervous System Disorders | |
US20160113900A1 (en) | Inhibitors of mitochondrial stat3 and uses thereof in modulation of mast cell exocytosis | |
TWI460168B (en) | Pharmaceutical composition for inhibiting autophagy of motor neurons and uses of the same | |
Guseva et al. | Synthetic activators of autophagy | |
CA3225749A1 (en) | Cannabichromene derivatives and methods for making and using the same | |
RU2780450C2 (en) | Use of benzoate for treatment of disorders of central nervous system | |
WO2024102999A2 (en) | Small molecule inhibitors for the treatment and prevention of coronavirus infections |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: APPLICATION DISPATCHED FROM PREEXAM, NOT YET DOCKETED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |